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 Zusammenfassung V 
Zusammenfassung 
Das Neuroblastom (NB) ist ein von migrierenden Neuralleistenzellen abgeleiteter, embryonaler 
Tumor, der im gesamten sich entwickelnden sympathischen Nervensystem auftreten kann. 
Kürzlich haben mehrere umfangreiche Sequenzierungsstudien im NB ein heterogenes 
Mutationsspektrum und eine geringe Mutationsfrequenz beschrieben. Es gibt viele Hinweise, 
dass im NB epigenetische Deregulation eine wichtige Rolle spielt. Dies verdeutlicht den 
dringenden Bedarf, epigenetische Profile für entitätsspezifische Regulatoren wie „enhancer“ und 
„super-enhancer“ (SE) zu lokalisieren, da diese regulatorischen Elemente zellspezifische 
Genexpression und dadurch Zellidentität bestimmen oder Onkogene in Tumoren regulieren. 
Durch diesen Ansatz könnten wichtige Krebsgene für eine zielgerichtete Tumortherapie 
identifiziert werden. Im Rahmen dieser Studie wurden mittels Sequenzierung des gesamten 
Genoms (WGS) einer NB Kohorte, bestehend aus 60 Tumoren, wiederkehrende Umlagerungen 
in der Nähe des TERT Gens in 24% aller Hochrisiko-Patienten mit schlechter klinischer 
Prognose gefunden. Chromatin-Immunpräzipitation mit anschließender Sequenzierungs (ChIP-
seq) Analyse zeigte, dass Umlagerungen von starken „enhancer“ Regulatoren hin zum TERT Gen 
stattfinden und die RNA- und Protein-Expression sowie die Aktivität des Genprodukts 
Telomerase fördern. Zusätzlich wurden weitere wiederkehrende Umlagerungen von 
regulatorischen „SE“ Elementen hin zu Onkogenen wie MYC und MYCN in NB Zelllinien 
identifiziert, was in den spezifischen Fällen eine Erklärung für deren bisher unerklärbar hohe 
Expression lieferte. Mittels Integration von WGS Daten sowie auf RNS Sequenzierung basierten 
Expressionsdaten einer Kohorte, bestehend aus 111 NB Tumoren, konnte nach weiteren 
hochregulierten Genen in der Nähe von Bruchpunkten gesucht werden. Anhand dieses 
Vorgehens wurden weitere „enhancer-hijacking“ Kandidaten wie IGF2BP1 und ATOH1 in NB 
Tumoren und Zelllinien identifiziert. Durch anschließende ChIP-seq Analysen der betroffenen 
Tumoren und Zelllinien konnten hoch aktive „SE“ Bereiche, die durch Umlagerung in die Nähe 
der Onkogene gebracht wurden, und deren Expression sie höchstwahrscheinlich regulieren, 
identifiziert werden. Schließlich wurden mittels Chromatin Interaktionsanalyse mit 
anschließender Sequenzierung (4C-seq) physikalische Interaktionen zwischen regulatorischen 
„enhancer“ Elementen und durch Umlagerung in deren Einflussbereich geratenen 
Onkogenpromotoren in Zelllinien bestätigt. Zusätzlich wurde eine für die Entität spezifische 
regulatorische SE Region identifiziert, welche zwischen den Genen HAND2 und FBXO8 gelegen 
ist und die wiederkehrend in Umlagerungen mit den zuvor genannten Onkogenen involviert ist.  
Des Weiteren wurden in dieser Studie mittels ChIP-seq Analysen der Azetylierung von Histon 3 
Lysin 27 (H3K27ac) in einer NB Kohorte aus 60 Tumoren und 23 Zelllinien gewebespezifische 
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„SE“ inklusive ihrer assoziierten Zielgene identifiziert. Durch bioinformatische Analysen der 
„enhancer“ Daten konnten drei Gensignaturen definiert werden welche mit unterschiedlichen 
klinischen Subtypen assoziiert sind. Diese den Gensignaturen zugewiesenen Subtypen waren 
solche mit (i) amplifiziertem MYCN-Onkogen,  sowie (ii) Niedrigrisiko- und (iii) Hochrisiko-
Patienten  ohne amplifiziertes MYCN-Onkogen. Bemerkenswerterweise konnte eine vierte 
Gensignatur gefunden werden, die mit mesenchymalen Attributen assoziiert war. Diese „SE“ 
definierte Subgruppe konnte, basierend auf einem großen Satz an RNA-seq-Daten, auf 
Expressionsebene, reproduziert werden und zeigt innerhalb der vier Signaturen höchste 
Stabilität zwischen Zelllinien und Tumoren. Die mesenchymale Signatur wies starke 
Assoziationen mit dem Auftreten von Rezidiv-Tumoren auf  sowie mit erhöhter Expression des 
RAS und JUN/FOS Signalweges. Durch die erstmalige Integration von epigenetischen „SE“ und 
Genexpressionsdaten von Tumoren wurde ein NB-spezifisches Regulom sowie ein Subgruppen-
spezifischer Satz an essentiellen Haupttranskriptionsfaktoren definiert, die im Weiteren 
funktionell validiert wurden.  
Zusammenfassend wurde in dieser Studie mit der Entdeckung von wiederkehrenden 
Umlagerungen von regulatorischen SE Elementen, welche in der Folge das TERT Gen aktivieren, 
ein erstmaliger Beweis für „enhancer-hijacking“ in NB Primärtumoren geliefert. Durch die 
Identifizierung weiterer wiederkehrender Onkogen-Umlagerungen, welche wesentliche 
Onkogene wie MYC, MYCN, IGF2BP1 und ATOH1 betreffen, wurde bewiesen, dass 
wiederkehrende „enhancer-hijacking“ Ereignisse in vivo nicht nur auf das TERT Gen beschränkt 
sind. Basierend auf ChIP-seq Analysen einer großen Tumorkohorte identifizierte diese Studie 
erstmalig spezifische dem NB sowie den NB Subgruppen zugrundeliegende spezifische „SE“-
Landschaften, deren assoziierten Zielgene sowie die zugehörigen Sätze an essentiellen 
Haupttranskriptionsfaktoren. Die Studie identifizierte zudem viele für das NB essentielle 
deregulierte Gene, welche durch selektive Inhibition ihrer abnormalen Funktion potentiell die 
Möglichkeit für eine gezielte und personalisierte Therapie bieten können. 
 
 
 
 
 
 
 Summary VII 
Summary 
Neuroblastoma (NB) is an embryonal tumor derived from migrating neural crest cells and can 
occur within the whole developing sympathetic nervous system. Recently, several 
comprehensive sequencing studies in NB revealed a comparatively low mutation frequency and 
a heterogeneous mutation spectrum. Evidence accumulates that epigenetic deregulation play a 
prominent role in NB. Therefore, there is an urgent need to define entity-specific enhancer and 
super-enhancer (SE) profiles as regulatory elements control cell identity or oncogenes in a 
cancer context through cell type-specific gene expression. This will identify critical oncogenic 
driver genes essential for NB and help to devise a targeted therapy strategy. In the present 
study, whole genome sequencing (WGS) analysis of a 60 NB tumor cohort identified recurrent 
rearrangements in close proximity to the TERT gene in up to 24% of high-risk NB cases with 
poor clinical outcome. ChIP-sequencing analyses revealed that strong enhancers were 
juxtaposed to the TERT gene by these rearrangements likely driving increased TERT expression 
and TERT activity in the respective cases. In addition to TERT, discovery of recurrent 
repositioning of SE elements explained remarkably high expression levels of MYCN, MYC 
oncogenes in NB cell lines. Integrative analysis of WGS-based rearrangement data and RNA-seq 
based expression data in a cohort of 111 NB tumors allowed to identify highly upregulated genes 
in proximity to breakpoints. This approach located several other enhancer-hijacking candidate 
oncogenes including IGF2BP1 and ATOH1 in NB tumors and cell lines. Subsequent ChIP-seq 
analysis of the affected tumors and cell lines confirmed that highly active SE regions were 
juxtaposed to the oncogenes, which likely drives their high expression. Finally, physical 
interactions of juxtaposed enhancer elements with the oncogene promoters were confirmed by 
chromatin interaction analyses (4C-seq) in cell lines. Intriguingly, a lineage-specific SE region 
downstream of HAND2 and upstream of the FBXO8 gene locus was recurrently involved in the 
above mentioned rearrangements.  
In a set of 60 NB tumor specimen and 23 NB cell lines, the present study identified groups of 
tissue-specific SEs and associated target genes based on histone mark H3K27ac ChIP-seq data. In 
depth bioinformatic analysis of the enhancer data retrieved three gene signatures, associated 
with previously established clinico-biological association, namely MYCN-amplified, high-risk- 
and low-risk MYCN non-amplified. Intriguingly, a fourth SE-defined NB subgroup was resolved, 
as defined by a gene signature highly associated with mesenchymal (Mes) gene ontology terms. 
This subgroup was reproducibly recovered by an analogue and extended approach based on 
RNA-seq expression of SEs assigned signature genes and further proved its stability by its 
consistent presence in NB cell lines and tumors. Importantly, the Mes signature was associated 
 Summary VIII 
with relapsed NB cases as well as with increased RAS and JUN/FOS signature expression. For the 
first time, integration of SE and expression data of primary tumors enabled the establishment of 
an NB entity and NB subgroup-specific regulome resulting in the definition and subsequent 
functional validation of subgroup-specific core-regulatory networks. Taken together, with the 
discovery of recurrent rearrangements of SE elements activating the TERT gene, the present 
study provides initial evidence for “enhancer hijacking” in NB tumors. The identification of 
further recurrent oncogene rearrangements involving known NB oncogenes MYC and MYCN in 
cell lines and as well as new candidates IGF2BP1 and ATOH1 in NB tumors demonstrates that 
recurrence of enhancer hijacking in vivo is not restricted to TERT. Importantly, the present 
study reveals the first entity and subgroup-specific SE landscape including assigned target genes 
and downstream core transcription factor networks based on ChIP-seq analyses in a large 
cohort of tumors. This study identifies several critical NB cancer genes, which may open a 
therapeutic window for selective inhibition of those dysregulated key genes. 
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 Introduction 1 
1. Introduction 
1.1   Neuroblastoma 
Neuroblastoma (NB) is an embryonal tumor deriving from migrating neural crest cells and 
affects the whole developing sympathetic nervous system including the adrenal medulla, 
sympathetic ganglia and paraganglia (Johnsen et al. 2009). NB accounts for 7 – 10 % of 
paediatric malignancies and approximately 15 % of all deaths of childhood tumors (Castleberry 
1997; Castleberry 1997; Brodeur 2003). The clinical behaviour of this pediatric tumor is quite 
heterogeneous, with localized cases and excellent outcome, including spontaneous regression 
even without any therapy (Maris et al. 2007). Indeed, NB exhibits the highest spontaneous 
regression rate of all malignant neoplasms, which is 10 – 100-fold higher than for any other 
human entity (Pritchard and Hickman 1994; Castleberry 1997). On the other hand, in face of an 
intensive therapy for high-risk and metastatic diseases, which account for almost 50 % of the 
cases, long-term survival is still less than 40 % (Westermann and Schwab 2002; Oldridge et al. 
2015). Comparison of world-wide results, in this clinical and biological extremely heterogeneous 
cancer, with regards to stage assignment and treatment strategy is still challenging. By 
establishing the international NB staging system (INSS) (Figure 1), this problem was 
approached and paved the way for a consistent assignment strategy (Brodeur et al. 1993). 
According to the INSS and irrespective of minimal residual disease or affected lymph nodes, 
gross resected, localized tumors of stage 1 are associated with a favourable outcome (Matthay et 
al. 1989; Hata et al. 1990).  
Both, INSS stage 2A and 2B, represent 10-15 % of NB cases, which are described as localized 
tumors without metastases. The event-free survival (EFS) for patients classified stage 1 is with 
92 % (n=209) significantly higher than EFS of 78 % (n=103) for patients classified stage 2A and 
2B (Monclair et al. 2009). Patients with low risk tumors with the best outcome are classified 
INSS stage 4S, which are younger than one year, have in addition the ability of spontaneous 
regression and less than 1 % tumor cells in the bone marrow (Hayes et al. 1983). INSS stage 3 
tumors are described as intermediate risk with EFS of 75 % (Monclair et al. 2009). Advanced 
stage 4 tumors are considered as high-risk NB tumors that are already metastatic (Jiang et al. 
2011).  
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Figure 1: The international staging system for NB tumors (INSS). 
(modified from Castleberry et al., 1997 – licence obtained.) 
 
1.1.1 The molecular principles of Neuroblastoma for targeted therapy 
A detailed understanding of the molecular principles of a cancer cell, regardless of its origin, is 
indispensable for the development of a targeted therapy approach. In the future this will pave 
the way from nonspecific therapy towards personalized approaches. Conventional approaches 
(i.e. cytotoxic chemotherapeutics) come with non-specific toxicity and troubling side effects. 
Therefore, identification of novel and specific targets, which represent molecular drivers of a 
particular malignancy, will increase the impact of treatment, whereas side effects should 
decrease (Sawyers 2004). 
Stage 1 
Localized tumor confined to the area of origin; complete gross resection, with or without 
microscopic residual disease; identifiable ipsilateral and contralateral lymph node negative 
for tumor. 
Stage 2A 
Unilateral with incomplete gross resection; identifiable ipsilateral and contralateral lymph 
node negative for tumor. 
Stage 2B 
Unilateral with complete or incomplete gross resection; with ipsilateral lymph node positive 
for tumor; identifiable contralateral lymph node negative for tumor. 
Stage 3 
Tumor infiltration across midline with or without regional lymph node involvement; or 
unilateral tumor with contralateral lymph node involvement; or midline tumor with bilateral 
lymph node involvement. 
Stage 4 
Dissemination of tumor to distant lymph nodes, bone marrow, liver, or other organs except 
as defined in 4s. 
Stage 4s 
Localized primary tumor as defined for stage 1 or 2 with dissemination limited to liver, skin 
or bone marrow (< 10% of nucleated marrow cells are tumor cells). 
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Retrospectively, applying a targeted therapeutic approach to NB, led to various challenges 
caused by the molecular nature and genetic complexity of this disease. 
Genomic aberrations 
Analysis of karyotypes of cancer cells, in the early 70s, already revealed genomic aberrations i.e. 
the rearrangement of chromosome 9 to chromosome 22, the notorious “Philadelphia 
translocation” in chronic myeloid leukaemia (CML). This results in a fusion protein BCR-ABL1, 
which is a highly active protein involved in tyrosine kinase signalling, driving the progression in 
this type of cancer (Rowley 1973). In the beginning of 1980, first cytogenetic studies in NB 
revealed genetic aberrations like ploidy changes, deletions, allelic losses and gains of recurrent 
locations as well as amplifications. All of these genomic aberrations correlate with the clinical 
outcome of the patient and are of prognostic relevance (Bown 2001). 
1p deletion 
In 1977, recurrent deletions of the short arm of chromosome 1 (1p) have been described in NB 
tumors and cell lines (Brodeur et al. 1977). Later on it was confirmed that this genetic 
aberration is the most frequent one occurring in NB. 1p deletion correlates with amplified MYCN 
(62 % of 1p loss of heterozygosity (LOH) tumors) and is associated with unfavourable clinical 
outcome (Fong et al. 1989). The recurrent deleted region of 1p is known to contain important 
genes for NB tumorigenesis but also tumor suppressors, like the calmodulin binding 
transcription activator 1 (CAMTA1), essential for neuronal differentiation of NB cells (Henrich et 
al. 2006; Henrich et al. 2011). 
Ploidy 
New methods to detect the cellular DNA content by flow cytometry (Look et al. 1984) or the 
level of ploidy changes by cytogenetic approaches (Kaneko et al. 1987; Hayashi et al. 1989) 
revealed findings of prognostic relevance. Tumors with hyperdiploid cellular DNA content or 
near triploidy are associated with a more favourable clinical course. In contrast to this, tumors 
with normal DNA content and diploid or tetraploid tumors are associated with a reduced 
survival probability. 
17q gain 
The genetic aberration of up to five copies of chromosome arm 17q and in addition translocation 
events of 17q was detected by multicolour fluorescence in situ hybridisation (mFISH) 
(Savelyeva et al. 1994; Meddeb et al. 1996). For NB tumors and cell lines, the most recurring 
event besides 1p loss is an unbalanced translocation with 17q. Both events are associated with 
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poor patient survival, while 17q gain reflects a more favourable clinical outcome (Van Roy et al. 
1994; Bown et al. 1999). 
Amplified MYCN  
An amplified domain on the short arm of chromosome 2 was first described by Schwab and 
colleagues in 1983 (Schwab et al. 1983). The size of this amplified domain, with limited 
homology to the MYC oncogene, is varying in size and includes different co-amplified genes like 
e.g. DDX1 (DEAD-Box Helicase 1). The MYCN oncogene was found to be amplified in the shape of 
hsrs (homogenously staining regions) integrated at different chromosomes or in primary NB 
tumors mainly in form of circular extra-chromosomal dmins (double minutes chromosomes) 
(Cox et al. 1965; Kohl et al. 1983; Schwab et al. 1984; Emanuel et al. 1985). These crucial 
amplification events very frequently co-occur with either 1p loss or 17q gain (Abel et al. 1999). 
Lab tools for detecting the MYCN status for clinical evaluation as a biomarker for high-risk 
disease include southern blotting, genomic PCR or interphase MYCN FISH (Squire et al. 1996; 
Gallego et al. 1998).  
Amplified MYCN occurs in half of all high-risk tumors of stage 3-4 with advanced stage disease 
and in 20% of all NBs (Brodeur et al. 1984). This association of amplified MYCN and increasing 
MYCN copy numbers with increased risk, reduced survival probability and poor clinical outcome 
was confirmed later (Seeger et al. 1985). 
Recurrent somatic mutations in NB 
Recurrent mutations of the RAS (N-RAS, H-RAS, and K-RAS) genes play a key role in many 
human cancer types and serve as a prognostic marker. First evidence that a single point 
mutation (G into T) leads to an amino acid substitution (valine instead of glycine) and thereby 
HRAS oncogene activation and cancer cell conversion into human bladder carcinoma cells was 
described in the early 80s (Reddy et al. 1982). Approximately 20-30% of non–small cell lung 
carcinomas and large fraction of colon cancers harbor a K-RAS mutation (Forrester et al. 1987; 
Aviel-Ronen et al. 2006). In NB primary tumors and cell lines, only few RAS mutations have been 
described, including NB cell line SK-N-SH, harboring a point mutation in one N-RAS allele (Moley 
et al. 1991; Iolascon et al. 1993). A whole-genome sequencing (WGS) study from 2015 identified 
an enrichment of RAS-MAPK (mitogen-activated protein kinase) pathway gene mutations, in 
relapsed NBs as compared to the matched primary samples. In 78% of the relapsed NBs, 
activating RAS-MAPK pathway gene mutations were detected, which is in 38% exclusive for the 
relapsed samples (Eleveld et al. 2015). 
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The most prominent and intensively studied gene being affected by inactivating mutation 
events, is the tumor suppressor gene TP53. While TP53 mutations are, with a high mutation 
rate, one of the most common mutations in human cancer entities, they are rarely detected in 
primary NBs (Imamura et al. 1993; Vogan et al. 1993; Muller and Vousden 2014). 
The first NB predisposing gene, the paired–like homeo-box 2B gene (PHOX2B), that harbors 
germ line mutations, has been identified by locus-specific sequencing (Trochet et al. 2004). In a 
study from 2007, 6.4% of supposedly hereditary NBs had a germ line mutation within the 
PHOX2B gene. This did not occur in sporadic neuroblastomas (Raabe et al. 2008). In addition, 
mutations of the PHOX2B gene were identified as the cause of congenital central hypoventilation 
syndrome (CCHS) or Hirschsprung disease (HSCR), which is another disorder of neural crest 
cells (Amiel et al. 2003). 
Another predisposition gene, harboring germ line mutations, which is held responsible for most 
familial cases is the anaplastic lymphoma kinase (ALK) gene. A sequencing approach of 194 
high-risk NB samples detected in approximately 10% of all tumors a mutation in the tyrosine 
kinase domain, resulting in ALK overexpression and a constitutively active kinase. In addition, 
comparative genomic hybridization arrays (CGH) of 592 NB samples identified increased copy 
numbers or even amplification of the ALK gene locus (Mosse et al. 2004; Chen et al. 2008; 
George et al. 2008; Janoueix-Lerosey et al. 2008). 
Whole genome sequencing (WGS) NB studies 
The first WGS study of 87 NB tumors without focus on any risk group confirmed the already 
suspected small number of recurrent amino-acid-changing mutations (Molenaar et al. 2012). 
Besides recurrent structural aberrations of genes involved in neuronal growth cone 
stabilization, point mutations in the ATRX (5.7%), TIAM1 (T-cell lymphoma invasion and 
metastasis 1) (3.4%) and RAC/RHO (Rho family members of G proteins) pathway genes were 
identified. In addition, 18% of high-risk NBs revealed tremendous alterations called 
chromotripsis, which is defined as shredding of whole chromosomes (Molenaar et al. 2012). 
NB-specific low median exonic mutation frequency was confirmed by a sequencing study of 240 
NB samples. Here, whole-exome, genome and transcriptome sequencing were combined within 
the TARGET (therapeutically applicable research to generate effective treatments) initiative 
(Pugh et al. 2013). Several additional genes with significant recurrent somatic mutations like 
ALK (9.2%), PTPN11 (tyrosine-protein phosphatase non-receptor type 11) (2.9%), ATRX 
(2.5%) and NRAS (0.83%) were identified. Further studies, like the genome-wide association 
study (GWAS), a combined cohort of four case series counting more than 2000 patients, 
identified additional putative oncogenes in NB, including the LMO1 gene (Wang et al. 2011).  
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In summary, novel technologies, such as WGS and RNA-sequencing helped to identify additional 
putative NB-specific oncogenes and potential candidates for therapy, i.e. ALK (Wang et al. 2016). 
Despite of comprehensive and extensive sequencing studies in NB, the number of recurrent 
somatic coding mutations is rare and the mutation spectrum is heterogeneous, which will hinder 
the development of rational therapeutics. It is assumed that additional structural aberrations 
and epigenetic alterations contribute to the differential clinical heterogeneity of NB. This would 
help further defining the high-risk NB tumors, with the worst prognosis and outcome, at the 
molecular level. 
Epigenetic alterations in paediatric cancer like NB and future perspectives 
The fact that cancer is described equally as an epigenetic disease as well as genetic disease 
supports the fact that epigenetic changes serve as precursors of genetic transformations 
(Iacobuzio-Donahue 2009). One of the first epigenetic alterations described in cancer is the 
reduction of DNA methylation of colon cancer cells in contrast to normal tissue, like 
hypomethylation of the RAS oncogenes (Feinberg and Vogelstein 1983; Feinberg and Vogelstein 
1983). The first study of DNA-methylation in NB primary tumors revealed methylation of 
caspase-8 as well as hypermethylation of promoter CpGs of the RAS-association domain family 1 
isoform A (RASSF1A) (Teitz et al. 2000; Astuti et al. 2001). This recurrent hypermethylation of 
CASP8 apoptosis gene is associated with relapse susceptibility (Grau et al. 2011), whereas 
hypermethylation of the putative tumor suppressor gene RASSF1A is correlated with survival 
(Decock et al. 2011). In addition, promoter hypermethylation in NB leading to inactivation of 
further putative tumor suppressor genes was reported for PTEN (Phosphatase and tensin 
homolog) and CDH1 (Cadherin-1), which are both associated with reduced event-free survival 
(Hoebeeck et al. 2009). A genome wide methylation analysis of 105 primary NB samples, 
combining 450K methylation arrays, transcriptome and low copy WGS, revealed two distinct 
patient clusters (Henrich et al. 2016). Here, cluster 2, enriched for MNA (MYCN-non amplified) 
samples, was further subdivided in subgroup 2s, being enriched for low risk tumors with rare 
chromosomal aberrations. Cluster 1 consists of MYCN-amplified tumors, classified as high-risk 
cases and patients with a higher age at diagnosis. 
There are several events, like chromosomal translocations, promoter methylations or deletions 
that cause monoallelic expression (MAE), which significantly more often affects oncogenes, 
including hTERT (Telomerase reverse transcriptase), than tumor suppressors in tumors 
(Walker et al. 2012). 
 
 
 Introduction 7 
Mutations lead to altered transcription factor binding within enhancer elements 
A polymorphism within a super-enhancer region assigned to LMO1 (LIM domain 1) alters a 
GATA to a TATA binding motif in NB. This causes disruption of transcription factor binding like 
GATA3, decreases LMO1 expression and thereby leads to tumorigenesis (Oldridge et al. 2015). 
Another example is a mutation of HOXB13 (homeobox B13) binding site within a regulatory 
enhancer, which causes increased HOXB13 binding and leads to upregulation of RFX6 
(regulatory factor X6) gene expression in prostate cancer. RFX6 gene expression is associated 
with prostate cancer cell proliferation, metastasis and relapse (Huang et al. 2014). 
Deletions within enhancer elements 
Deletions within enhancer elements of tumor suppressor genes can lead to tumor development. 
In prostate cancer, a deletion within enhancer regions that are bound by members of the 
activator protein 1 (AP-1) complex, like c-JUN transcription factors, has been described. HiC 
interaction data indicates a possible interaction of this enhancer region with several genes that 
act protective against prostate cancer (Demichelis et al. 2012). 
De novo enhancer and transcription factor binding site creation  
Oncogene regulation and activation by regulatory elements including enhancers, is a common 
event in many human cancers (Mansour et al. 2014). One of these oncogene drivers is TAL1 (T-
cell acute leukemia 1) in T cell acute lymphoblastic leukemia (T-ALL), which is regulated by an 
upstream super-enhancer (SE) established by a somatic mutation. Insertions of 2 – 18 bps 
create the MYB (myeloblastosis) binding motif, which leads to acetylation of H4K27 by CBP 
(CREB-binding protein) and formation of the transcription factor complex (Mansour et al. 
2014). 
Focal amplification or duplication of enhancer elements 
There are many human tumors harboring focal amplifications and copy number gains, which 
affect enhancer elements that are driving oncogene expression. Many of these focal 
amplifications affect the MYC gene, which is independent of the tumor entity and reveals an 
important role for the MYC enhancer and MYC gene in tumorigenesis (Herz 2016). This is in line 
with MYC focal amplifications that affect a 500 kb region upstream of MYC in 5% of chronic 
lymphocytic leukemia (CLL), a 400 kb region downstream of MYC in 2% of lung adenocarcinoma 
and a 800 kb region downstream of MYC in 4% of uterine corpus endometrial carcinoma. In 
addition, 5% of T-ALL and 3-5% of adult acute myeloid leukemia (AML) are characterized by a 
duplication of an enhancer element 1,7 Mb downstream of MYC (Edelmann et al. 2012; Shi et al. 
2013; Herranz et al. 2014; Zhang et al. 2016). 
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Structural rearrangements leading to enhancer hijacking events 
The principle of alternative oncogene activation by enhancer rearrangements (enhancer 
hijacking) is defined as a process placing an enhancer into the proximity of an oncogene 
consequently resulting in ectopic oncogene activation. The phenomenon of enhancer hijacking, 
firstly described in 1982 in Burkitt’s lymphoma, revealed immunoglobulin H (IgH) enhancer 
rearrangement juxtaposing the MYC gene and causing increased MYC expression (Taub et al. 
1982). Subsequently, several translocation events were identified, like translocation of the IgH 
assigned enhancer into the proximity of the BCL2 (B-cell lymphoma 2) gene, which leads to 
increased expression of the anti-apoptotic BCL2 gene in follicular lymphoma (Bakhshi et al. 
1987). In AML, rearrangements of the GATA2 (GATA-binding factor 2) enhancer juxtaposing 
EVI1 (ecotropic virus integration site 1) activate its expression ectopically, resulting in a haplo-
insufficient GATA2 functionality. In addition, enhancer excision or BET (bromodomain and 
extra-terminal) inhibitor treatment reversed this process and led to tumor growth inhibition 
(Groschel et al. 2014). Another way of oncogene activation in paediatric cancers has been 
reported by Northcott and colleagues in 2014 (Northcott et al. 2014). Medulloblastoma 
represents a heterogeneous entity with four distinct subgroups. While WNTs and SHH (sonic 
hedgehog) are well known oncogenic drivers of subgroup 1 and 2, in the remaining subgroups 
central genes driving tumorigenesis are still unknown. However, these subgroups reveal an 
exclusive way of alternative GFI1 or GFI1B (growth factor independent 1 family proto-
oncogenes) oncogene activation. In this enhancer hijacking events, genomic rearrangements 
frequently juxtapose active enhancer and super enhancer elements to the GFI1 or GFI1B gene 
locus (Northcott et al. 2014). 
Deletion or inversion of a topologically associating domain (TAD) 
Deletion of one of these conserved TAD regions (described more in detail in 1.2.3 and Figure 8) 
can alter gene expression by changing the interaction capability of regulatory elements (Valton 
and Dekker 2016). Two types of TAD disruptions are found in cancer cells. First, deletion of a 
TAD is leading to a TAD fusion, creating an enlarged interaction context of regulator elements, 
like increased PDGFRA (platelet-derived growth factor receptor A) expression in gliomas 
(Flavahan et al. 2016). Second, a rearrangement event that is creating new TADs and a new 
interaction context of regulatory elements as described for the GATA2 enhancer juxtaposing and 
subsequently upregulating the EVI1 gene (Groschel et al. 2014). 
In contrast to this, inhibition of super-enhancers (SE) using chromatin modifying enzymes or 
BET-bromodomain inhibitors, like JQ1, causes loss of BRD4 (Bromodomain Containing 4) at 
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regulatory elements and disrupts regulation of oncogenic drivers like MYC in multiple myeloma 
(Filippakopoulos et al. 2010; Loven et al. 2013). 
Taken together, it could be hypothesized that there is a strong epigenetic involvement in NB 
tumorigenesis. This is supported by a sequencing study in paediatric cancers, including NB, 
which revealed that almost 20% of mutations are found in epigenetic regulator genes (Huether 
et al. 2014). A better understanding of the epigenetic landscape could pave the way for the 
development of specific epigenetic drugs and personalized therapies as well as epigenetic 
marker screens as a basic diagnostic analysis tool for paediatric cancer, including NB. 
 
1.2   Epigenetics 
Various definitions of the term “epigenetics” exist firstly described by Conrad Waddington in 
1942 as the phenotypical result of the interplay of genes and their products - or basically, acts 
that could not be explained simply by genetic processes (Goldberg et al. 2007). Epigenetics 
connect the genotype and phenotype as all cells in an organism share the same genetic 
information and only different regulation of gene expression generates the tremendous diversity 
of cell types and cellular functions (Figure 2). A more recent definition describes epigenetics as a 
stable heritable phenotype that results from alterations in a chromosome without changing the 
DNA sequence (Berger et al. 2009). 
  
Figure 2: Epigenetic landscape involved in cell fate.  
(A) Conrad Waddingtons epigenetic landscape – concept of developmental decision making of a 
cell results in different cell fates (adapted from Waddington, 1952 and (Goldberg et al. 2007) – 
licence obtained.). (B) Model of dendritic cell fate in a more recent interpretation, which is based 
on Conrad Waddingtons epigenetic landscape (Paul and Amit 2014) – licence obtained. 
 
A B 
 Introduction 10 
Nowadays, investigating epigenetic mechanisms are focused on modifications of DNA and 
histone proteins that influence the chromatin status. Disruption of this epigenetic balance is an 
essential cause for cancer development (Egger et al. 2004). New therapeutic strategies that 
restore the epigenetic balance will pave the way for more specific epigenetic drugs to fight 
cancer. 
 
1.2.1 DNA methylation 
DNA methylation is the first characterized epigenetic and probably best characterized chemical 
modification of chromatin (Holliday and Pugh 1975; Riggs 1975; Goldberg et al. 2007). Already 
in 1975, de novo DNA methylation by enzymatic reactions that is inherited from one cell to 
another and involved in gene silencing has been reported. DNA methylation was described in 
plants and fungi but at least in mammals shown to occur at the pyrimidine ring of cytosine 
residues of CpG dinucleotides (Figure 3). Regions of CpG dinucleotide accumulation are called 
CpG islands and their methylation at the transcriptional start site (TSS) is associated with 
transcriptional repression (Goll and Bestor 2005). In vertebrates, at least half of the genome 
contains CpG regions of approximately 1 kb length (Jones 2012). 
 
Figure 3: DNA methylation and CpG sites.  
CpG sites within the genome have different functions in respect to transcriptional regulation. 
Low methylated regions (LMRs) at enhancers and nucleosome-depleted regions (NDRs) are 
 Introduction 11 
demethylated and associated with the presence of ten-eleven translocation (TET) proteins. 
Contrary, presence of 5‑methylcytosine (5mC) is blocking CCCTC-binding factor (CTCF) binding 
and influences the process of splicing. DNA methylation is catalyzed and maintained by DNA 
methyltransferases. Adapted from (Jones 2012) – licence obtained. 
 
The region up to 2 kb surrounding CpG islands are defined as “shores” (Irizarry et al. 2009). 
Initially, methylation of the gene body was shown to be associated with actively transcribed 
genes (Wolf et al. 1984). Nowadays, this dogma gets more and more dynamic as gene body 
methylation is tissue- and cell-specific and might have more diverse functions. Regulatory 
elements like enhancers are mostly CpG poor and have variable methylation, calling them low 
methylated regions (LMRs) (Stadler et al. 2011). In T cells, methylation of CpG sites within 
differentially methylated regions (DMRs) of enhancers leads to reduced enhancer activity 
(Schmidl et al. 2009). DNA binding enzymes with binding sites at enhancers like glucocorticoid 
receptors might foster CpG demethylation and thereby restore enhancer activity (Wiench et al. 
2011). Methylation at insulators like CTCF biding-sites, which prevent promoter-enhancer 
interactions, might be involved in splicing (Shukla et al. 2011). Methylation of CTCF binding sites 
prohibit CTCF binding and thereby regulate gene expression of this locus (Bell and Felsenfeld 
2000). 
The enzymatic process of DNA methylation is maintained by three different DNA 
methyltransferases (DNMTs) (Figure 4). DNMT1 is the essential enzyme maintains DNA 
methylation patterns after DNA replication (Hermann et al. 2004). Therefore, it mainly binds 
hemi-methylated DNA target sites, which are defined by one of the strands methylated. De novo 
DNA methylation, which is necessary to establish DNA methylation patterns during early 
mammalian development, is catalyzed by DNMT3A and DNMT3B (Okano et al. 1999). A 
mutation of DNMT3B in humans leads to hypomethylation of pericentromeric regions, which are 
causing defects during human development (ICF syndrome).  
Demethylation of DNA is catalyzed by three enzymes of the TET (ten-eleven translocation) 
protein family members, which are named after a frequently occuring translocation in cancer of 
chromosome 10 and 11 (Huang and Rao 2012). 
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Figure 4: Cytosine methylation and demethylation.  
DNA methyltransferases (DNMTs) and TET proteins act on Cytosine methylation and 
demethylation. Adapted from (Huang and Rao 2012) – licence obtained. 
 
The first enzymatic step is the oxidation of 5-methylcytosine (5mC) and to 5-
hydroxymethylcytosine (5hmC). The next oxidation leads to formation of 5-formylcytosine (5fC) 
and finally to 5-carboxylcytosine (5caC) (Tahiliani et al. 2009; Ito et al. 2011). Finally, 
restoration of unmodified cytosine is catalyzed by the DNA repair enzyme thymine DNA 
glycosylase (TDG) (He et al. 2011). In embryonic stem (ES) cells, enrichment of 5hmC at TSS, 
exonic sequences and enhancers were reported. At the TSS, 5hmC was strongly enriched with 
bivalent histone marks such as H3K4me3 and H3K27me3 (He et al. 2011). 
 
1.2.2 Histone modifications 
Posttranscriptional modified histones, like histone acetylation or methylation, have been firstly 
described by Vincent Allfrey in 1964. Besides DNA methylation, histone modifications represent 
another level of epigenetic regulation by modulating nucleosome dynamics during transcription 
(Allfrey et al. 1964; Allfrey and Mirsky 1964).  
One feature of nucleosomes is packaging of 147 bps of DNA around a nucleosome that allows 
regulation of DNA accessibility for transcription, DNA repair mechanisms and replication 
(Figure 5) (Venkatesh and Workman 2015). A nucleosome itself consists of an octamer, 
subdivided into two copies of the histones H3, H4, H2A and H2B (Kornberg 1974; Kornberg and 
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Thomas 1974). Modification of specific amino acids of the histone amino-terminal-tail 
extensions are predominantly lysines (K) or arginines (R). 
 
  
Figure 5: Posttranscriptional histone modifications.  
(A) DNA-Nucleosome complex including two copies of the histones H3, H4, H2A and H2B as well 
as the outward facing amino-tails. (B) Histone modifications of lysine residues of H3 with a focus 
on methylation of K4 (K4me1 and K4me3), K9 (K9me3), K27 (K27me3) and K36 (K36me3) as 
well as acetylation of K27 (K27ac). Adapted from (Tsankova et al. 2007) – licence obtained. 
 
Possible modifications that have an impact on chromatin structure and gene regulation range 
from methylations, acetylations and phosphorylations to ubiquitinilations or SUMOylations 
(Bannister and Kouzarides 2011). Acetylation reaction is conducted by histone acetyl 
transferases (HATs) and inverted by histone deacetylases (HDACs). Histone methyltransferases 
(HMTs) and histone demethylases (HDMs) catalyze methylation and demethylation, 
respectively (Tsankova et al. 2007). The chromatin is organized in functional inactive, compact 
(heterochromatin) and active, less dense chromatin packaging (euchromatin). These domains 
are crucial for genome organization and epigenetic regulation of gene expression (Foret et al. 
2014). Further identification of histone modifications at distinct genomic locations, like 
promoters and enhancers, via ChIP-seq links epigenetic information to transcriptional 
regulatory activity (Figure 6) (Heintzman et al. 2007). One of the most studied histone 
modifications are those of histone H3 and especially trimethylated H3K4 (H3K4me3), which can 
be found at transcription start sites (TSS) and are associated with actively transcribed protein-
coding promoters (Kim et al. 2005; Hon et al. 2009).  
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Figure 6: Histone modifications define chromatin conformation.  
Chromatin accessibility changes rendered by histone modifications are essential for 
transcription factor binding, enhancer activity and transcription. Chromatin signature of 
repressive histone marks H3K9me3 together with H3K27me3 is associated with condensed 
chromatin, which prevents binding of transcription factors or RNA polymerase II. In contrast, 
enrichment of histone modifications H3K4me3, H3K4me1 or H3K27ac at the TSS leads to RNA 
polymerase II binding and active transcription. Chromatin signature of H3K36me3 at the gene 
body is likewise associated with elongation and active transcription. Enrichment of H3K4me1 in 
combination with H3K27me3 is associated with closed or poised enhancers. An active enhancer, 
accessible for transcription factor binding, is enriched for H3K4me1 and H3K27ac in the absence 
of H3K4me3. Adapted from (Shlyueva et al. 2014) – licence obtained. 
 
Likewise, the chromatin signature of trimethylated H3K36 (H3K36me3) is enriched at the gene 
body of active genes. The accumulation of H3K36me3 is not randomly distributed throughout 
the gene body but significantly higher in exons than introns (Guenther et al. 2007; Kolasinska-
Zwierz et al. 2009). Enhancer- and promoter-specific chromatin features are enriched for 
acetyltransferases, like p300 as well as monomethylated H3K4 (H3K4me1), while enhancers are 
lacking H3K4me3 marks (Hatzis and Talianidis 2002; Heintzman et al. 2007). Enhancers are 
usually defined as the sequences with binding motifs for transcription factors (approximately 
1700) that release condensed chromatin structure and enable binding of the transcription 
machinery at the TSS (Heintzman and Ren 2009; Vaquerizas et al. 2009). The promoter and TSS 
itself can be located a long way off the cis-regulatory enhancer elements and therefore 
enhancers act independently of orientation or distance (Creyghton et al. 2010). Definition of 
enhancers only by H3K4me1 mark leads to a significant ratio of inactive genomic regions. Based 
on this, Jeanisch and colleagues suggested acetylated H3K27 as an additional histone 
modification that defines active in contrast to poised enhancers, without a H3K27ac mark 
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(Creyghton et al. 2010). H3K27ac mark is set by P300 and CREB binding protein (CBP), which 
have both a histone acetyltransferase (HAT) activity. In addition, an active TSS shows enriched 
H3K27ac mark, which can be used in the presence of H3K4me1 at enhancer sites to assess 
enhancer activity according the level of enrichment (Tie et al. 2009; Wang et al. 2011). 
In contrast to transcriptional activation, gene silencing and repression are another important 
mechanism to establish and maintain tissue- und cell-specific expression patterns (Foret et al. 
2014). Post-transcriptional modifications of histones, like trimethylation of H3K27 (H3K27me), 
are associated with gene silencing and repressive function, which goes along with chromatin 
compaction. The trimethylation of H3K27 is polycomb mediated by the polycomb repressive 
complex 2 (PRC2), which is enzymatically catalyzed by the histone-lysine N-methyltransferase 
subunits EZH1 and EZH2 (Enhancer of zeste homolog 1 and 2) (Schuettengruber and Cavalli 
2009; Simon and Kingston 2009; Margueron and Reinberg 2011). Genomic locations with 
enriched trimethylation of H3K4 and H3K27 histone mark have a bivalent promoter that is 
characteristic e.g. for the pluripotent status of an embryonal stem cell (Bernstein et al. 2006). 
Another negative regulation of transcription can be achieved by trimethylation of histone H3K9 
(H3K9me3), which is crucial for heterochromatin formation and epigenetic repression. This 
modification is catalyzed by site-specific histone methyltransferase (HMT) SUV39H. H3K9me3 
acts as specific binding site for heterochromatin protein 1 (HP1α), a main component of 
heterochromatin (Peters et al. 2002; Stewart et al. 2005). The repressive marks, H3K27me and 
H3K9me3, both are hallmarks of constitutive and facultative heterochromatin, regularly co-
localize at the same genomic region (Boros et al. 2014). Co-localization of H3K27me3 and 
H3K9me3 at silent gene promoters was detected at the deleted in colon cancer gene (DCC) and 
defines bivalent gene promoters (Derks et al. 2009). 
 
1.2.3 Enhancer and super-enhancer 
In a mammalian cell, thousands of active enhancer elements are defined as DNA regulatory units 
that are bound by transcription factors and control cell type-specific gene expression (Bulger 
and Groudine 2011; Thurman et al. 2012). The term super-enhancer (SE) was first introduced 
by Hnisz and colleagues to describe a large cluster of transcriptional enhancers that drive gene 
expression, thus defining cell identity (Hnisz et al. 2013). SEs differ from normal enhancer in 
size, enrichment for binding of transcription factors and their ability for transcriptional 
activation (Whyte et al. 2013). In a cancer context, SEs are located close to key driver oncogenes 
like MYC in multiple myeloma. This might offer an opportunity for epigenetics-based therapeutic 
approaches, i.e. using the BET-bromodomain inhibitor, JQ1 (Loven et al. 2013). 
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SEs are defined in a three step procedure (Figure 7). First, normal enhancers are defined by 
enrichment of H3K27ac ChIP-seq peaks. Second, H3K27ac ChIP-seq peaks within 12.5 kb of each 
other are combined to form one single enhancer unit. Third, all enhancers and combined 
enhancer units are ranked according to their H3K27ac signal within the genomic region. 
Enhancers with the highest H3K27ac signal above the cut-off where the slope of the curve is one 
are considered as super-enhancers (Hnisz et al. 2013; Pott and Lieb 2015). 
 
Figure 7: Enhancer and SE definition.  
Step-to-step procedure of SE definition. 1. Enhancer definition by peak calling of H3K27ac ChIP-
seq data. 2. Combining/concatenating enhancers within 12.5 kb of each other. 3. Super-enhancer 
definition. All enhancers (combined and single enhancers) are ranked according to their 
H3K27ac signal. Enhancers with higher H3K27ac signal from the inflection point are considered 
as super-enhancer. Adapted from (Pott and Lieb 2015) – licence obtained. 
 
Instead of using H3K27ac as surrogates for SE identification, master transcription factor binding, 
such as OCT4 (octamer-binding transcription factor 4), SOX2 (SRY (sex determining region Y)-
box 2) and Nanog (Whyte et al. 2013) as well as MED1 (Mediator of RNA polymerase II 
transcription subunit 1) can serve for SE prediction (Loven et al. 2013). In any case, defining a 
SE by surrogate enrichment (H3K27ac, MED1 or master transcription factors) is solely a 
prediction and does not evaluate enhancer-promoter interactions and thereby functional 
enhancer activity resulting in active transcription. 
 
1.2.4 Chromatin organization – interaction and insulation 
The mechanism of differential transcriptional regulation is based on (promoting and 
preventing) physical interactions between regulatory elements of distant enhancers and 
promoters. New methods, like locus-specific 4C-seq (circularized chromosome conformation 
capture with high-throughput sequencing) or a genome wide chromatin immunoprecipitation 
conformation method (HiChIP) improved the understanding of genomes architecture (van de 
Werken et al. 2012; Mumbach et al. 2016). This essential process of facilitating enhancer looping 
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of interacting elements requires on the contrary as well shielding functions of neighboring 
domains that are blocking enhancer activity (Figure 8) (Ali et al. 2016). Those regions, which 
allow interactions within domains but prevent interactions between neighboring domains, are 
called topologically associating domains (TAD) or bordering insulators (Ong and Corces 2014). 
Essential for this 3D organization are the architectural proteins CTCF (CCCTC-binding factor) 
and SMC1A and SMC3 (structural maintenance of chromosomes protein 1A and 3) as core 
subunits of the cohesion complex (Peters et al. 2008).  
 
Figure 8: Chromatin conformation influences enhancer-promoter interaction. 
(A) Coinciding CTCF binding sites together with transcription factor complex TFIIIC and 
architectural cohesin proteins lead to TAD border formation. These insulator regions prevent 
interaction across such borders and block enhancer function. (B) CTCF binding and recruitment 
of cohesin within TAD regions supports physical enhancer-promoter interactions by enhancer 
looping. (C) Virtual HiC matrix represents interaction frequency within the TAD. CTCF peaks in 
red are involved in binding TAD boundaries in contrast to pale red peaks. Interactions in grey 
represent active enhancer-promoter looping. Adapted from (Ong and Corces 2014; Ali et al. 
2016) – licence obtained. 
  
1.2.5 Motivation and aim of the thesis 
Several structural aberrations of specific chromosomes as well as the amplification of the 
oncogene MYCN in subsets of high-risk neuroblastomas (NBs) are known till today, which are 
associated with poor NB outcome and are likely driver events. However, exome sequencing 
studies have shown that NBs harbor a low overall mutation rate with only few recurrently 
mutated genes leaving the molecular etiology of a large proportion of NBs elusive. (Molenaar et 
al. 2012; Pugh et al. 2013). Recent studies in NB and other pediatric cancer entities revealed that 
epigenetic deregulation may be a significant driver component in these cancer types (Northcott 
et al. 2014; Henrich et al. 2016). The present study is based on the hypothesis that deregulated 
B A C 
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enhancer networks may be responsible for NB development, progression and heterogeneity. A 
deeper understanding of underlying mechanisms will offer the perspective for targeted 
molecular therapies based on epigenetic drugs.   
 
1. Do structural rearrangements contribute to NB pathogenesis by generating activating de novo 
interactions between enhancers and oncogenes? 
Regulatory elements, like SEs that recruit and build up transcription factor networks and 
thereby regulate gene expression play an essential role in cell specificity and identity as well 
as aberrant function in human cancers (Demichelis et al. 2012; Huang et al. 2014; Mansour 
et al. 2014; Oldridge et al. 2015). The principle of alternative oncogene activation by locating 
enhancers in the proximity of oncogenes was described for several cancer entities and is 
referred to as enhancer-hijacking (Taub et al. 1982; Bakhshi et al. 1987; Groschel et al. 2014; 
Northcott et al. 2014). The present study aims at discovering single and especially recurrent 
structural rearrangement events leading to oncogene activation by enhancer hijacking. 
Candidate rearrangements and enhancer gene couples will be validated via expression 
analyses, chromatin interaction analyses and functional testing in cell line models.  
 
2. What are NB- or NB subtype-specific SEs and their innate transcription factor network? SEs 
are the regulatory units of core regulatory circuitries, which consist of small, auto-regulatory 
sets of cell type-specific master TFs determining identity and fate of cells. Evidence 
accumulates that differential SE landscapes have the potential to discriminate between 
cancer entities and subgroups. Furthermore, elucidating the networks of entity- and 
subtype-specific SEs and their downstream targets promises to unravel specific vulnerability 
nodes in view of potential targeted therapy (Wong et al. 2017). This subproject aims to 
define the SE landscape of NB, resolve epigenetically defined subgroups and functionally test 
vulnerabilities e.g. by knockdown of specific core regulators derived from these networks. 
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2. Materials and methods 
2.1 Materials 
2.1.1 Chemicals and consumables 
Product Supplier 
Acrylamid/ Bis 40% Bio-Rad, München 
Agarose NEEO Ultra quality Roth, Mannheim 
Agencourt AMPure XP Beckman Coulter, Sinsheim 
AlamarBlue MorphoSys AbD, Düsseldorf 
Ammonium persulfate (APS)                                      Merck, Darmstadt 
BFGF Invitrogen, Carlsbad, USA 
Bioruptor Pico 1.5 ml microtubes with caps Diagenode, Liège, Belgium 
Bovine serum albumin (BSA)        Sigma Aldrich, Munich 
Bradford Reagent Biorad, München 
Bromphenol blue  Serva, Heidelberg 
Cell culte well plates TPP, Trasadingen 
Cell culte well plates  Nunc, Wiesbaden 
Cell culture cryotubes Nunc, Wiesbaden 
Cell culture flasks TPP, Trasadingen 
Cell culture plates TPP, Trasadingen 
Chloroform Sigma Aldrich, Munich 
Citrat Monohydrat Riedel DeHaën, Seelze 
Cover slips                                                                                        Menzel, Braunschweig 
DEPC  Roth, Mannheim 
Dimethylformamide Serva, München 
Dimethylsulfoxide  Sigma Aldrich, Munich 
Disodiumhydrogenphosphate  Merck, Darmstadt 
Dithiothreitol  AppliChem, Darmstadt  
DMEM PAA, Pasching 
dNTPs Amersham-Pharmacia, Freiburg 
DTT                                                                            Roth, Mannheim 
ECL Plus Western Blotting Detection Reagent GE Healthcare, Freiburg 
ECL Prime Western Blotting Detection Reagent GE Healthcare, Freiburg 
EDTA Roth, Mannheim 
EGF Genaxxon, Ulm 
Electroporation cuvettes (1 mm gap width) Biorad, München 
Ethanol abs. Sigma Aldrich, Munich 
FBS Biochrom, Berlin 
Filter tips, graduated (10, 100, 200, 1000 µl)  Star Lab, Hamburg 
Formaldehyde Sigma Aldrich, Munich 
GelRed Genaxxon, Ulm 
GeneRuler™ 100bp DNA Ladder MBI-Fementas, St.Leon-Rot 
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GeneRuler™ 1kb DNA Ladder MBI-Fementas, St.Leon-Rot 
Giemsa’s Azure Eosin Methylene Blue solution  Merck, Darmstadt 
Glass slides                                                                Thermo Fisher Scientific, Waltham, USA 
Glycerol Roth, Mannheim 
Glycine Biorad, München 
Glycogen Roche Diagnostics, Mannheim 
Harnstoff Merck, Darmstadt 
Heparin Sigma Aldrich, Munich 
HEPES                                                            Sigma Aldrich, Munich 
Isopropanol Sigma Aldrich, Munich 
KCl Roth, Mannheim 
KH2PO4 Merck, Darmstadt 
L-Glutamin Lonza, Basel 
Lipofectamine RNAiMAX Thermo Fisher Scientific, Waltham, USA 
Luna Cell Counter Slides                                               Logos Biosystems, Annandale, USA 
Manganese (II) chloride solution Sigma Aldrich, Munich 
Methanol Sigma Aldrich, Munich 
MgCl2 Roth, Mannheim 
Milk powder  Sigma Aldrich, Munich 
Na- Citrat Roth, Mannheim 
Na2HPO4 Sigma Aldrich, Munich 
NaCl Sigma Aldrich, Munich 
NaHCO3 Merck, Darmstadt 
Natriumacetat Roth, Mannheim 
NH4Cl Merck, Darmstadt 
Nitrocellulose membranes, 0.2 mm Whatman, Dassel 
Nitrocellulose membranes, 0.45 µm                            GE Healthcare, Munich           
PCR plate 96 twin-tec, skirted, colorless Eppendorf, Hamburg 
Phenol/ chloroform/ isoamylalcohol                          Roth, Mannheim 
Pipette tips Starlab, Hamburg 
Plastic pipettes (5, 10, 25, 50 ml)                                Corning, Tewksbury, USA  
Plastic plates (black)  Greiner bio-one, Frickenhausen 
Plastic reaction tubes (0.1-2ml) Eppendorf, Hamburg 
Plastic reaction tubes (15-50ml) Greiner bio-one, Frickenhausen 
Polyacrylamide                                                            Serva Electrophoresis, Heidelberg 
Ponceau-S Sigma Aldrich, Munich 
Potassium chloride                                                     Roth, Mannheim 
Powdered milk (blotting grade) Roth, Mannheim 
Proteinase inhibitor cocktail, EDTA Roche Diagnostics, Mannheim 
RPMI-1640 PAA, Pasching 
Sodium dodecyl sulfate (SDS)  Gerbu, Heidelberg 
Sodium hydrogen carbonate                                       Merck, Darmstadt 
TEMED BioRad, München 
Tris Base Sigma Aldrich, Munich 
Tris HCl AppliChem, Darmstadt  
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Triton X-100  Serva, Heidelberg 
Trypan Blue                                                                AppliChem, Darmstadt 
Trypton AppliChem, Darmstadt  
Tween 20  Merck-Schuchardt, München 
Whatman 3MM Paper Whatman, Dassel 
β-mercaptoethanol Merck, Darmstadt 
 
2.1.2 Laboratory equipment 
Product Supplier 
CCD-cameras: 
 
CH250 Photometrics, München 
SenSys 1400 Photometrics, München 
Centrifuges: 
 
5417R Eppendorf, Wesseling-Berzdorf  
Allegra X-12 Beckman Instr., München 
Avanti J-25 I Beckman Instr., München 
Biofuge fresco 17 Heraeus, Osterode 
J 2-21 M/E  Beckman Instr., München 
Minifuge RF Heraeus, Osterode 
Varifuge 3.2RS Heraeus, Osterode 
Rotors: 
 
5310 Heraeus, Osterode 
JA 10  Beckman Instr., München 
JA 20 Beckman Instr., München 
JS 13.1 Beckman Instr., München 
Thermo incubators: 
 
Cell culture incubator Hepa Class 100 Thermoelectron Corp., Waltham, USA 
Setri-Cult Thermo Fisher Scientific, Waltham, USA 
Termicon T Heraeus, Osterode  
2100 BioAnalyzer Agilent Technologies, Santa Clara, USA 
Analytical Balances PM 4600                         Mettler, Gießen 
Axiovert 10, Imager Z1 Zeiss, Oberkochen 
Beckmann Coulter Z2  Beckman Instr., München 
Bioruptor Pico Diagenode, Liège, Begium 
Cat RM5 (Membrane roller) Neolab, Heidelberg 
Cellgard Class 2 INTEGRA Biosciences, Biebertal 
Covaris LE220  Covaris, Woburn, USA 
Covaris S-Series Covaris, Woburn, USA 
Fluoroscan Ascent FL  Thermo Electron, Dreieich 
Gel documentation system Geldoc BioRad, München 
Horizontal mini-gel systems GIBCO/BRL, Darmstadt 
Light cycler 480 II Roche, Mannheim 
Luna automated cell count Logos Biosystems, Annandale, USA 
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Magnetic Mixers Heidolph, Schwabach 
Mini trans-blot cell BioRad, München 
Mini-PROTEAN 3 electrophoresis system  BioRad, München 
Mini-PROTEAN 3 multi-casting chamber BioRad, München 
MS3 Vortexer IKA, Staufen 
Nano-Drop 1000 Peq-Lab, Erlangen 
pH-Meter pMX 2000 WTW, Weilheim 
Photometer GeneQuant 1300 General Electric, Boston, USA 
Pipetboy Integra Bioscience, Fernwald 
Platereader FLUOstar OPTIMA                                   BMG Labtech, Ortenberg 
Polymax 2040 Heidolph, Schwabach 
Power supply units, PHEROlab  Fisher Scientific, Schwerte 
Qubit 2.0 Fuorometer Invitrogen, Carlsbad, USA 
Safe 2020 Thermo Fisher Scientific, Waltham, USA 
Shacking platform, IKA KS250 Janke & Kunkel, Staufen 
Tank-transfer unit Biorad, München 
Thermo Block Biometra Trio Biometra, Goettingen 
Thermo water bads GFL, Mannheim 
Thermocycler DNA-Engine PTC200 BioRad, München 
Thermocycler Tetrad 2 BioRad, München 
Thermo-shakers G25, G24 New Brunswick Scientific, Offenbach 
Vacuum concentrator  Bachofer, Reutlingen 
 
2.1.3 Kits 
Product Supplier 
NEBNext Ultra DNA Library Prep Kit for Illumina NEB, Ipswich, USA 
BM Chemiluminescence Blotting Substrate kit            Roche, Basel, Switzerland 
CellTiter-Blue® Cell Viability Assay                          Promega, Madison, USA 
NEBNext Ultra Directional RNA Library Prep Kit for Illumina NEB, Ipswich, USA 
Ribo-Zero rRNA Removal Kit Illumina, San Diego, USA 
TRIZOL Reagent Invitrogen, Carlsbad, USA 
Effectene transfection Reagent Qiagen, Hilden 
First Strand cDNA Synthesis Kit for RT-PCR Roche, Basel, Switzerland 
High pure PCR template preparation kit Roche, Basel, Switzerland 
QIAquick Gel Extraction kit Qiagen, Hilden 
QIAquick PCR purification kit Qiagen, Hilden 
RNeasy mini kit Qiagen, Hilden 
NucleoSpin Kit for RNA  Macherey-Nagel 
NEBNext End Repair Module NEB, Ipswich, USA 
NEBNext Quick Ligation Module NEB, Ipswich, USA 
NEBNext dA-Tailing Module NEB, Ipswich, USA 
NEBNext High-Fidelity 2X PCR Master Mix NEB, Ipswich, USA 
NEBNext Multiplex Oligos for Illumina (Index Primers Set 1) NEB, Ipswich, USA 
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NEBNext Multiplex Oligos for Illumina (Index Primers Set 2) NEB, Ipswich, USA 
Nextera DNA Library Prep Kit Illumina, San Diego, USA 
Nextera Index Kit (24 Indexes) Illumina, San Diego, USA 
KAPA library Amp Illumina with primers KAPA Biosystems, Wilmington, USA 
Expand Long Template PCR System Roche, Basel, Switzerland 
Agilent DNA 12000 Kit Agilent, Santa Clara, USA 
Agilent High Sensitivity DNA Kit Agilent, Santa Clara, USA 
Agilent DNA 1000 Kit Agilent, Santa Clara, USA 
Agilent RNA 6000 Nano Kit Guide Agilent, Santa Clara, USA 
 
2.1.4 Antibiotics 
Product Stock concentration Supplier 
Ampicillin  (50 mg/ml) Serva, Heidelberg 
Kanamycin  (25 mg/ml) Serva, Heidelberg 
Blasticidin  (41,25 mg/ml)  MP Biomedicals, Illkirch, France 
Penicillin/Streptomycin  (10000 U/ml) Serva, Heidelberg 
G418 Sulfate  (200 mg/ml) Sigma, München  
Zeocin  (100 mg/mL) Invitrogen, Karlsruhe 
Tetracycline  (10 mg/ml) Sigma, München 
 
2.1.5 Cell lines 
MNA = MYCN non-amplified 
Neuroblastoma cell line MYCN status Reference/Established 
CHLA15 MNA (Keshelava et al., 1998) 
CHLA20 MNA (Keshelava et al., 1998) 
CHLA90 MNA (Keshelava et al., 1998) 
CLB-GA MNA (Combaret et al., 1995) 
GI-M-EN MNA (Donti et al., 1988) 
LAN6 MNA (Wada et al., 1993) 
NB69 MNA (Mena et al., 1989) 
NBL-S MNA (Cohn et al., 1990) 
SH-EP MNA (Ross et al., 1983) 
SH-SY5Y MNA (Biedler et al., 1978) 
SK-N-AS MNA (El-Badry et al., 1989) 
SK-N-FI MNA (Suigimoto et al., 1984) 
HD-N-33 MYCN-amplified (Schwab, unpublished) 
IMR-32 MYCN-amplified (Tumilowicz et al., 1970) 
IMR5/75 MYCN-amplified (Tumilowicz et al., 1970) 
KELLY MYCN-amplified (Schwab et al., 1983) 
LAN2 MYCN-amplified  (Seeger et al., 1977) 
LS MYCN-amplified (Rudolph et al. 1991) 
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NGP MYCN-amplified (Brodeur et al., 1977) 
NMB MYCN-amplified (Brodeur et al., 1977) 
P4 neural crest derived cell line (Hauser  et al.,2012) 
P5 neural crest derived cell line (Hauser et al., 2012) 
SK-N-BE-(2)-C  MYCN-amplified (Biedler and Spengler 1976) 
SK-N-DZ MYCN-amplified (Suigimoto et al., 1984) 
SMS-KCNR MYCN-amplified (Reynolds et al., 1986) 
TR14 MYCN-amplified (Cowell and Rupniak 1983) 
 
2.1.6 Enzymes 
Product Supplier 
Benzonase Merck, Darmstadt 
BglII Fermentas, Waltham, USA 
EcoRI NEB, Ipswich, USA 
HindIII Fermentas, Waltham, USA 
Pfu Turbo DNA polymerase Applied Biosystems, Foster City, USA 
Proteinase K  Gerbu, Heidelberg 
RNAse A Sigma, München 
T4 DNA ligase NEB, Ipswich, USA 
DPNII NEB, Ipswich, USA 
Csp6I Thermo Fisher Scientific, Waltham, USA 
 
2.1.7 Antibodies 
Antigen Application Supplier Cat.nr.: 
H3K4me3 ChIP-seq abcam, Cambridge, UK ab8580 
H3K36me3 ChIP-seq abcam, Cambridge, UK ab9050 
H3K9me3 ChIP-seq abcam, Cambridge, UK ab8898 
H3K27me3 ChIP-seq Active Motif, Carlsbad, USA 39155 
H3K27ac ChIP-seq/HiChIP abcam, Cambridge, UK ab4729 
H3K4me1 ChIP-seq abcam, Cambridge, UK ab8895 
H3K79me3 ChIP-seq abcam, Cambridge, UK ab2621 
CTCF ChIP-seq Diagenode, Liège, Belgium C15410210 
SMC1A HIChIP Bethyl, Montgomery, USA A300-055A9 
ETS1 western blot Santa Cruz, Dallas, USA sc-55581 
SMAD3 western blot abcam, Cambridge, UK ab40854 
RARB western blot Santa Cruz, Dallas, USA sc-56864 
HAND2 western blot Santa Cruz, Dallas, USA sc-398167 
IGF2BP1 western blot abcam, Cambridge, UK ab82968 
MYC western blot abcam, Cambridge, UK ab32072 
MYCN western blot (Wenzel et al. 1991) 
a-tubulin western blot Santa Cruz, Dallas, USA sc-5286 
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β-actin western blot Sigma-Aldrich, St. Louis, USA A-5441 
 
2.1.8 Secondary antibodies and ladder 
Antigen/description Host Supplier Cat.nr.: 
Anti mouse (rabbit)-HRP goat  Dianova, Hamburg 115-035-003 
Anti rabbit-TxRed goat  Dianova, Hamburg 111-075-003 
Anti goat igG-HRP donkey  Santa Cruz, Dallas, USA sc-2020 
GeneRuler 100bp (0.1 µg/µl) 
 
Thermo Scientific, Waltham, USA #SM0243 
Quick-Load 1 kb DNA ladder 
 
NEB, Ipswich, USA #N0552S 
BenchMark, prestained protein ladder 
 
Invitrogen, Carlsbad, USA 10748-010 
PageRuler, prestained protein ladder   Fermentas, Waltham, USA 26616 
 
2.1.9 Primer 
Primer name Sequence 5’-3’ Appl. 
HAND2 P300_1_f aatgatacggcgaccaccgaacactctttccctacacgacgctcttccgatctagtatgatgttttcaggatc 4C-seq 
HAND2 P300_1_r caagcagaagacggcatacgatagtttctgttctgaagccc 4C-seq 
HAND2 P300_2_f aatgatacggcgaccaccgaacactctttccctacacgacgctcttccgatcttccattgttccaatctgatc 4C-seq 
HAND2 P300_2_r caagcagaagacggcatacgatccaaatactgagccatgat 4C-seq 
HAND2 P300_3_f aatgatacggcgaccaccgaacactctttccctacacgacgctcttccgatctcaagtctaactagccagatc 4C-seq 
HAND2 P300_3_r caagcagaagacggcatacgatagcttcaattactgcccat 4C-seq 
HAND2 TSS_f aatgatacggcgaccaccgaacactctttccctacacgacgctcttccgatctctcccgtgtggtaagggatc 4C-seq 
HAND2 TSS_r caagcagaagacggcatacgacagtgaaccagagaggaaag 4C-seq 
IGF2BP1 TSS_f aatgatacggcgaccaccgaacactctttccctacacgacgctcttccgatctgggagaacacataaaagatc 4C-seq 
IGF2BP1 TSS_r caagcagaagacggcatacgaggggaaatcaaacaaaagat 4C-seq 
MYC endo_f aatgatacggcgaccaccgaacactctttccctacacgacgctcttccgatctgccaacttcttaaaaggatc 4C-seq 
MYC endo_r caagcagaagacggcatacgacttgtatttatggaggggtg 4C-seq 
MYCN endo_f aatgatacggcgaccaccgaacactctttccctacacgacgctcttccgatctgaaggcatcgtttgaggatc 4C-seq 
MYCN endo_r caagcagaagacggcatacgactggggaacatttctgtaaa 4C-seq 
TERT TSS_f aatgatacggcgaccaccgaacactctttccctacacgacgctcttccgatctctaaagatgggaccaggatc 4C-seq 
TERT TSS_r caagcagaagacggcatacgaaggagggtgaccttcttg 4C-seq 
Primer1 aatgatacggcgaccaccgagatctacactcgtcggcagcgtcagatgtg 
ATAC-
seq 
P2.1_TAAGGCGA caagcagaagacggcatacgagattcgccttagtctcgtgggctcggagatgt 
ATAC-
seq 
P2.2_CGTACTAG caagcagaagacggcatacgagatctagtacggtctcgtgggctcggagatgt 
ATAC-
seq 
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2.1.10 Puffer and solutions 
10x Amresco 1x 1 l 
Tris Base 25 mM 30.3 g 
Glycin 192 mM 144 g 
SDS 0.1% 50 ml of 20% SDS 
H2O   up to 1 l 
   
Annealing buffer 1x 100ml 
Potassium acetate 100 mM 1 g 
HEPES-potassium hydroxide 30 mM 0.83 g 
Magnesium acetate 2 mM 0.043 g 
   
DNA lysis buffer   100 ml 
NH4Cl   0.83 g 
KHCO3   0.1 g 
EDTA   0.037 g 
H2O   up to 100 ml 
autoclave     
   
Laemmli buffer 1x 50 ml 
Tris 0.5 M  4 g 
SDS 4% 10 mL of 20% SDS 
Glycerol 20% 10 ml 
β- Mercaptoethanol   5 ml 
H2O   25 ml 
Bromphenolblue   small amount 
   
Protein lysis buffer   50 ml 
Tris Base 1 M 1 ml 
Triton X-100   500 µl 
Harnstoff   21 g 
DTT 1 M 5 ml 
MgCl2 1 M 2 ml 
Protease inhibitors   2 tablets 
H2O   42 ml 
   
Separating gel buffer (pH 8.8) 1x 1 l 
Tris Base 1.5 M  182.1 g 
SDS 0.4% 20 mL of 20% SDS 
H2O   up to 1 l 
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Stacking gel buffer (pH 6.8) 1x 1 l 
Tris Base 0.5 M  60.1 g 
SDS 0.4% 30 mL of 20% SDS 
H2O   up to 1 l 
      
10x PBS (pH 7,4) (1x) 1 l 
NaCl 137 mM  8 g 
KCl 2,68 mM  0,2 g 
Na2HPO4 10 mM  1,42 g 
KH2PO4 1,76 mM  0,24 g 
H2O   up to 1 l 
   
10x TBE (pH 8.3) 1x 1 l 
Tris Base 89 mM 108.9 g 
Boric acid 89 mM 55 g 
EDTA 2 mM 7.4 g 
H2O   up to 1 l 
   
10x TBS (pH 7.6) 1x 1 l 
Tris 50 mM  6 g 
NaCl 150 mM 8.8 g 
H2O   up to 1 l 
   
Transfer buffer 1x 1 l 
Tris Base 25 mM 3 g 
Glycin 192 mM 14.4 g 
Methanol 20% 200 ml 
H2O   up to 1 l 
   
Versene (pH 7.0)   1 l 
EDTA 10 mM 0.3 g 
1x PBS   up to 1 l 
autoclave     
   
4C lysis buffer   10 ml 
TRIS pH 7.5 50 mM 500 µl of 1 M  
NaCl 150 mM 300 µl of 5 M  
EDTA 5 mM 1300 µl of 0.5 M  
NP-40 0.5% 500 µl of 10%  
Triton X-100 1% 100 µl 
H2O   8.5 ml 
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4C ligation buffer 10x 10 ml 
TRIS pH 7.5 660 mM 6.6 ml of 1 M  
DTT 50 mM 500 µl of 1 M  
MgCl2 50 mM 500 µl of 1 M  
ATP 10 mM 500 µl of 0.2 M  
H2O   1.9 ml 
   
TE  1x 0.1 l 
TRIS pH 8.0 10 mM 1 ml of 1 M  
EDTA pH 8.0 1 mM 1 ml of 0.1 M  
H2O   98 ml 
   
Na-deoxycholate (DOC) 5% 0.1 l 
Na-deoxycholate (DOC) 5% (w/v) 5 g 
H2O   0.1 l 
   
Glycine 2.5 M 0.1 l 
Glycine   18.76 g 
H2O   0.1 l 
   
RIPA buffer 1x 0.1 l 
Tris-HCl pH 8.0 10 mM 1 ml of 1 M  
EDTA, pH 8.0 1 mM 1 ml of 100 mM 
NaCl 140 mM 2.8 ml of 5 M  
Triton x-100 1% 10 ml of 10%  
SDS 0.1% 0.5 ml of 20%  
DOC 0.1% 2 ml of 5%  
H2O   82.7 ml 
   
Binding/ blocking buffer 1x 0.1 l 
BSA 0.5% 0.5 g 
Tween-20 0.5% 0.5 ml 
1x PBS   99.5 ml 
   
RIPA I buffer 1x  0.1 l 
Tris-HCl pH 8.0 10 mM 1 ml of 1 M  
EDTA, pH 8.0 1 mM 1 ml of 100 mM 
NaCl 140 mM 2.8 ml of 5 M  
SDS 0.2% 1 ml of 20%  
DOC 0.1% 2 ml of 5%  
H2O   92.2 ml 
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RIPA-500 buffer 1x  0.1 l 
Tris-HCl pH 8.0 10 mM 1 ml of 1 M  
EDTA, pH 8.0 1 mM 1 ml of 100 mM 
5 M NaCl 500 mM 10 ml 
Triton x-100 1% 10 ml of 10%  
SDS 0.1% 500 µl of 20%  
5% DOC 0.1% 2 ml of 5%  
H2O     
   
LiCl wash-buffer (ChIP-seq) 1x 0.1 l 
Tris-HCl pH 8.0 10 mM 1 ml of 1 M  
EDTA, pH 8.0 1 mM 1 ml of 100 mM 
5 M LiCl 250 mM 5 ml 
Triton x-100 1% 10 ml of 10%  
NP-40 0.5% 5 ml of 10%  
5% DOC 0.5% 10 ml of 5%  
H2O     
   
Direct elution buffer 1x 0.1 l 
Tris-HCl pH 8.0 10 mM 1 ml of 1 M  
EDTA, pH 8.0 5 mM 5 ml of 100 mM 
5 M NaCl 300 mM 5.5 ml 
20% SDS 0.5% 2.5 ml of 20%  
H2O     
   
HiChIP lysis buffer 1x 10 ml 
Tris-HCl pH 8.0 10 mM 100 µl of 1 M 
NaCl 10 mM 20 µl of 5 M 
   
Nuclear lysis buffer 1x  10 ml 
Tris-HCl pH 7.5 50 mM 500 µl of 1 M  
EDTA, pH 8.0 10 mM 200 µl of 500 mM 
SDS 1% 1 ml of 20% 
Protease Inhibitor  (50x, 1 ml) 1x 200 µl 
H2O   8.3 ml 
   
ChIP dilution buffer 1x  10 ml 
Tris-HCl pH 7.5 16.7 mM 167 µl of 1 M 
EDTA 1.2 mM 24 µl of 500 mM 
5 M NaCl 167 mM 334 µl of 5 M 
Triton x-100 1.1% 1.1 ml of 10% 
SDS 0.01% 5 µl of 20% 
H2O   8.37 ml 
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Low salt wash buffer 1x  10 ml 
Tris-HCl pH 7.5 20 mM 200 µl of 1 M 
EDTA 2 mM 40 µl of 500 mM 
NaCl 150 mM 300 µl of 5 M 
Triton x-100 1% 1 ml of 10% 
SDS 0.1% 50 µl of 20% 
H2O   8.86 ml 
   
High salt wash buffer 1x  10 ml 
Tris-HCl pH 7.5 20 mM 200 µl of 1 M 
EDTA 2 mM 40 µl of 500 mM 
NaCl 500 mM 1 ml of 5 M 
Triton x-100 1% 1 ml of 10% 
SDS 0.1% 50 µl of 20% 
H2O   8.16 ml 
   
LiCl wash-buffer (HiChIP) 1x 10 ml 
Tris-HCl pH 7.5 10 mM 100 ml of 1 M  
EDTA 1 mM 20 µl of 500 mM 
LiCl 250 mM 500 µl of 5 M 
NP-40 1% 1 ml of 10% 
DOC 1% 2 ml of 5% 
H2O   6.38 ml 
   
STE buffer 1x 1 l 
NaCl 100 mM 100 ml of 1 M 
EDTA 1 mM 1 ml of 1 M 
Tris-HCl pH 8 10 mM 10 ml  of 1 M 
H2O   889 ml 
 
2.1.11 Software 
Software Company/Source 
FLUOstar Optima                                                        BMG Labtech, Ortenberg 
IGV 2.3 Broad Institute of MIT and Harvard 
IGV viewer                                                                Broad Institute, Cambridge, USA 
ImageJ version 1.47                                                Wayne Rasband 
Inkscape 0.91 
  
Microsoft Office package 2010                                 Microsoft Corp., Redmond, USA 
R2                                                                              https://hgserver1.amc.nl  
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2.2 Methods 
2.2.1 General molecular biological methods 
Agarose gel electrophoresis 
The gel electrophoretic separation of DNA was conducted in 1-4% agarose in 1x TBE buffer. 
Agarose was heated up in 1xTBE buffer until it was completely dissolved. The DNA samples 
were loaded onto the gel in the ratio of 5:1 with 6x loading dye containing 2% GelRed. The 
electrophoretic separation was performed in 1x TBE buffer at 20 - 90 V. 
 
2.2.2  General cell culture methods 
Culturing of NB cells 
NB cell lines were cultured in either RPMI1640 or DMEM supplemented with 1% 
penicillin/streptomycin and 10% FCS. Cells were incubated at 37°C, 5% CO2 and standard cell 
culturing procedures were used. Cell culture medium was replaced with pre-warmed medium 
every 2 - 4 days. Cells were split at ratios from 1/3 to 1/12 depended on confluency and cell line. 
Therefore, cells were gently detached by incubation in 1 - 5 ml versene chelating agent for 1 - 5 
min. Cell morphology was observed at least every second day by light microscopy (Zeiss 
Axiovert microscope). Cell count was performed using the Luna automated cell count (Logos 
Biosystems) according to the manufacturer´s protocol. 
Thawing of NB cells 
In liquid nitrogen or -80°C freezer preserved cells were thawed at 37°C for approximately  
1 min. Subsequently, cells were resuspended with 10 ml pre-warmed cell culture media. 
Thereafter, cells were centrifuged at 800 rpm for 5 min and supernatant was removed. Finally, 
the cell pellet was resuspended and transferred into a cell culture flask (25 cm) containing pre-
warmed cell culture media, which was replaced after 24 h. 
Cryo-preservation of NB cells 
For cryo-preservation, special freezing medium containing 70% RPMI1640 or DMEM, 10% 
sterile filtered DMSO and 20% FCS was prepared and stored on ice. Medium of cells in 
preparation for cryo-preservation was changed the previous day and cells did not exceed 
confluency higher than 80%. Approximately 2*108 cells were harvested, centrifuged at  
800 rpm for 5 min and the supernatant was removed. The cell pellet was resuspended with 
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approximately 1 ml freezing medim, split into cryo tubes and cells were cooled down using a 
freezing container.  
 
2.2.3 ATRA (all-trans retinoic acid) treatment  
The NB cell line SK-N-BE(2)-C served as a well-established in vitro model for neuronal 
differentiation (Dreidax et al. 2014). All-trans retinoic acid (ATRA) is an established element of 
high-risk NB therapy (Matthay et al. 1999). ATRA induces neuronal differentiation in some but 
not all high-risk NBs. Cells were cultured in media containing 10 μm ATRA (Sigma) (+ATRA) or 
ethanol solvent control (+EtOH). Cells were harvested at the indicated time points for 
subsequent ChIP-seq (24 h and 144 h after ATRA treatment) or as replicates for RNA-seq (0 h, 1 
h, 3 h, 6 h, 12 h, 24 h, 48 h, 96 h and 144 h after ATRA treatment) analysis.   
 
2.2.4 Quantification of proteins - SDS-PAGE/Western blot 
Total protein extraction and purification of  
For preparation and quantification of total protein cell culture samples, cells were detached by 
versene, washed with cold PBS and pelleted. Cell pellets are resuspended in 20 – 60 µl 
(depending on the pellet size) MPER lysis buffer and can be stored at -80°C or directly used for 
total protein extraction and purification. For digestion of high molecular weight DNA or RNA, 
lysed samples were treated with 1 µl benzonase (endonuclease) and incubated for 15 – 30 min 
at 37°C. To remove insoluble membranes the samples were centrifuged at 13000 for 1 min and 
the protein containing supernatants were used for protein quantification and further analysis. 
Protein quantification (Bradford 1976) 
First, 800 µl autoclaved H2O were mixed with 200 µl Bradford reagent in a cuvette. Then 1 µl of 
the protein sample was added to each cuvette and mixed thoroughly while a Bradford/H2O 
mixture served as a blank. The absorption at 595 nm was measured with a photometer and the 
total protein concentration was determined due to a corresponding serial protein dilution with 
known concentrations. The absorption switch from 470 nm to 595 nm is caused by the 
stabilization of the anionic dye bound to cationic protein side chains, which built a colored 
protein complex. 
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Protein sample preparation 
For protein denaturation, 50 µg of each sample was mixed up to 15 µl with 1x Laemmli buffer 
including ß-mercaptoethanol to generate reducing conditions. The sample mix was incubated at 
95°C for 2 min, shortly centrifuged and loaded onto a polyacrylamide gel. 
SDS-PAGE 
The SDS-polyacrylamide gel electrophoresis enables the separation of proteins under 
denaturing conditions in the presence of SDS according to their electrophoretic mobility. This 
depends on the percentage of the polyacrylamide in the separating gel matrix (12.5%) as well as 
shape and size of the denatured proteins.  
SDS-PAGE was performed in Tris-glycine buffered system (Laemmli) using a stacking and 
subjacent separation gel while all ions are moving towards the anode during gel electrophoresis. 
Due to the pH-value of 6.8 in the stacking gel buffer, glycine exists as a dipolar ion and Cl- is 
negatively charged. All denatured proteins are moving in between these two ions, were 
accelerated and concentrated due to lack of charge carrier. Additionally, the proteins are stacked 
while reaching the border to the separating gel, holding a higher percentage of polyacrylamide. 
Secondary, the pH-value shift of 6.8 to 8.8 in the separating gel buffer leads to a negatively 
charged glycine ion and a removal of the lack of charge carrier. Thereby, the denatured proteins 
are separated due to their electrophoretic mobility. 
First, for the separating gel (12.5%), 4.7 ml of 40% polyacrylamide solution, 6.4 ml H2O, 75 µl 
20% SDS solution and 3.75 ml separating gel buffer were mixed. 
Thereafter, 6 µl TEMED served as catalyst of the polymerization reaction and 150 µl 10% APS 
solution for initiation. The casted separating gels were overlaid with H2O saturated isobutyl 
alcohol for approximately 2 h until the polymerization process was completed.  
After polymerization of the separating gel, the isopropyl alcohol was removed, components for 
the stacking gel were mixed (0.375 ml 40% polyacrylamide solution, 1.2 ml stacking gel buffer, 
2.75 ml H2O, 25 µl 20% SDS solution, 6 µl TEMED and 150 µl 10% APS solution) and poured 
above the separating gel.  
For electrophoresis, two gels were assembled into the chamber. The inner chamber between the 
two assembled gels and the outer tank were filled with 1x Amresco buffer.  
The combs were removed and the cavities were thoroughly rinsed with a syringe. For each 
sample 15 µl containing 50 µg protein sample in Laemmli buffer were loaded onto the gel. As a 
marker for determination of the protein size, 10 µl of BenchMark prestained protein ladder or 5 
µl of PageRuler prestained protein ladder were used. The separation of the proteins was carried 
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out at 80 V until the samples entered the stacking gel and subsequently increased up to 110 V 
for approximately 2 h. 
Protein transfer – Western blot 
After separation of proteins via SDS-PAGE, they were electro transferred onto a 0.45 µm 
nitrocellulose membrane using the tank blotting method. The assembly for the electro blotting 
was conducted and every component was soaked in transfer buffer. The final assembly was 
rolled with a bar to remove residual air blowing. Afterwards, the electro transfer was performed 
twice for 45 min at 125 V / 440 mA at 4°C. 
After successful protein blotting, the nitrocellulose membrane was washed with 1x TBS and 
incubated in complex blocking solution or alternatively in a 1:10 dilution of ECL plus blocking 
solution at 4°C overnight. Blocking of binding sites with unspecific proteins is important to 
decrease unspecific signals during immunodetection. Afterwards, the membrane was washed 
three times with approximately 5 ml TBS. 
Immunodetection 
For immunodetection of proteins, a primary antibody was added in a concentration of 1-10 
μg/ml to 5 ml of 5% nonfat-milk in H2O (2.1.7). The common dilution of primary antibody to 
nonfat milk solution was between 1:300 - 1:5000 except of beta-actin with a ratio of 1:10000, 
which served as a loading control. Incubation was performed at 4°C overnight, anti-ß-actin had 
an incubation time of 45 - 60 min at RT. After incubation, the membrane was washed three times 
with approximately 5 ml 1x TBS and incubated with the appropriate secondary antibody 
conjugated with HRP in 5% nonfat milk solution for 2 h at 4°C. Subsequently, the membrane was 
washed three times with 1x TBS and the chemiluminescence reaction was started by adding BM 
Chemiluminescence or ECL plus reagent with extended stability according to the manufacturer´s 
protocol. The added solution served the secondary antibody conjugated horseradish peroxidase 
as substrate to catalyze the chemiluminescence reaction after 1 - 5 min of incubation. The signal 
was detected using Chemi-Capt 5000 (Vilber).  
Protein quantification 
Quantification of protein level was performed using ImageJ version 1.47. The image of the 
chemiluminescence reaction was inverted using ImageJ and bands were encircled fitting all 
bands that have to be analyzed. The mean value of the analyze/measure function was used for 
all bands and the background, which was subtracted. Protein samples after knockdown by RNA 
interference were divided by the value of the loading control (actin or tubulin). Finally, the 
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normalized value of the protein samples after knockdown (RNA-interference; RNAi) were 
divided the normalized value of the negative control to achieve the reduced protein level.  
 
2.2.5 CTB (CellTiter Blue) viability assay 
CTB viability assay (Promega, Mannheim, Germany) measures the metabolic activity and was 
performed to evaluate the effect of RNAi-induced gene silencing experiments or drug treatments 
on NB cells viability.  
The NB cell lines SH-EP (1500 cell/well), GI-ME-N (2000 cells/well) and NMB (3500 cells/well) 
were seeded in 96well plates in 100 µl medium and RNAi experiments were performed after  
24 h as described below (2.2.7). 72 h or 96 h after siRNA mediated knockdown, 10 µl of CTB 
reagent was added to the cells in 100 µl medium (ratio 1:10) and incubated for 5 h under cell 
culture conditions. Fluorescence was detected using a flouro-scan plate reader with the setting 
540 nm excitation and 580 nm emission filters. Empty medium with CTB reagent served as a 
blank for normalization of the fluorescence of the samples. The relative cell viability was 
evaluated by setting the highest fluorescence value to 1, representing viable and metabolically 
active cells. 
 
2.2.6 Colony formation assay using GIEMSA staining 
Colony formation assay was performed to evaluate the effect of RNAi-induced gene silencing 
experiments or drug treatments on NB cells colony formation capacity.  
The NB cell lines SH-EP (1500 cell/well), GI-ME-N (2000 cells/well) and NMB (3500 cells/well) 
were seeded in 96well plates in 100 µl medium and RNAi experiments were performed after  
24 h as described below (2.2.7). 72 h or 96 h after siRNA mediated knockdown, cells were fixed 
(11% glutaraldehyde) and incubated for 30 min. After removing the fixation solution, the cells 
were washed twice with 100 µl PBS.  Subsequently, the cells were stained using 100 µl of a 10% 
Giemsa Azure Eosin Methylen Blue solution in 1x PBS and incubated overnight. The stained cells 
were washed twice with 100 µl PBS, once with 100 µl water and dried afterwards.  For 
evaluation of the cells colony formation capability, the wells were scanned and analyzed by the 
ImageJ software version 1.47 and ColonyArea plugin. 
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2.2.7 RNA interference using siRNA 
For detection of the candidate gene impact on cell viability or gene expression, RNAi-induced 
gene silencing experiments were performed were preformed using siRNAs.  
NB cells were seeded 24 h before the transfection in 96-well plates or in 10/25 cm dishes to 
achieve 50% confluency at transfection. First, Lipofectamine RNAiMAX reagent was diluted 
1:100 – 1:25 (cell line depended), in Opti-MEM medium (serum- and antibiotic-free). SiRNAs 
(50 µM stock solution) were diluted in Opti-MEM medium in a ratio of 1:250. Subsequently, both 
solutions were mixed in equal amounts and incubated for 15 min at room temperature. 
Depending on the cell culture vessel (96-well plates up to 10/25 cm dishes), the siRNA-lipid 
complex were added to the cells (10 µl/96-well wells and 1 ml/10 cm dish) and incubated for 
the desired time (24 h - 72 h). 
 
2.2.8 Fluorescence in situ hybridisation (FISH) 
FISH experiments and analysis were performed by Olga Sepman and Larissa Savelyeva. The 
preparation was performed according to the published protocol (Brueckner et al. 2013) for NB 
cell lines CLB-GA, GI-ME-N, KELLY, NBL-S, NB69, SH-SY5Y, CHLA15/20 and SK-N-AS. Labeled 
BAC clones were selected by Olga Sepman with the exception of TERT and IGF2BP2 (Larissa 
Savelyeva). 
 
2.2.9 Multicolour fluorescence in situ hybridisation (mFISH) 
mFISH experiments and analysis were performed by Olga Sepman and Larissa Savelyeva. To 
generate mFISH karyotypes of cell lines CLB-GA, GI-ME-N, KELLY, NBL-S, NB69, SH-SY5Y, 
CHLA15/20 and SK-N-AS the 24xCyte multicolour FISH probe mix (MetaSystems, Altlussheim, 
Germany) was used according to the manufacturer's protocol (Brueckner et al. 2013). 
 
2.2.10 RNA isolation, purification and RNA sequencing (RNA-seq) 
RNA isolation 
For RNA isolation, approximately 3*106 cells were used. Therefore, the culture media was 
discarded and cells were detached by incubation with 3 ml versene for 1 - 5 min. The cells were 
pelleted by centrifugation at 800 rpm and the supernatant was removed. The cell pellet was 
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resuspended in 1 ml Trizol reagent and thoroughly mixed. Subsequently, the isolate was directly 
stored at -80°C to avoid RNA degradation. Afterwards, total RNA was isolated using the 
miRNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. 
RNA isolation of primary tumors 
For RNA isolation of primary tumors, the NucleoSpin Kit for RNA (Macherey-Nagel) isolation 
was used and tumor slices were prepared according to the manufacturers’ protocol. 
RNA sequencing  
RNA was depleted from ribosomal RNAs using the Ribo-Zero rRNA Removal Kit (Illumina) 
according to the manufacturer's protocol. RNA libraries were prepared using the NEBNext Ultra 
Directional RNA Library Prep Kit for Illumina (New England Bio Labs) according to the 
manufacturer's protocol with the following changes: RNA was fragmented for 20 min at 94°C 
followed by first strand cDNA synthesis for 10 min at 25°C, 50 min at 42°C and 15 min at 70°C. 
Size selection of adapter-ligated DNA was done with a bead:DNA ratio of 2/5 (AMPure XP beads, 
Beckman Coulter) removing index primer and short fragments. Quality, quantity and sizing 
(approximately 320 bp) of the RNA library were analyzed using a DNA High Sensitivity DNA chip 
run on a 2100 Bioanalyzer (Agilent Technologies). Libraries were sequenced (50 bases single-
end) on the Illumina sequencing platform (German Cancer Research Center Core facility).  
Data analysis of RNA-seq samples was performed by Naveed Ishaque. 
 
2.2.11 Chromatin immunoprecipitation sequencing (ChIP-seq) 
The tumor ChIP-seq protocol was established by modifying the previously published protocol by 
Blecher-Gonen and colleagues (Blecher-Gonen et al. 2013). A detailed step-to-step description of 
the ChIP-seq protocol is given in the appendix (5.1).  
Data analysis of ChIP-seq as follows was performed by Carl Herrmann and is described briefly. 
Single end reads were aligned to the hg19 genome using Bowtie2 (version 2.1.0). Only uniquely 
aligned reads were kept. BAM-Files of aligned reads were further processed using the deepTools 
suite (Ramirez et al. 2014). Input files were subtracted from the treatment files using the 
bamCompare tool, applying the SES method for normalization of signal to noise. Resulting 
signals were normalized to an average 1X coverage to produce signal (bigWig) files. Peaks were 
called using the MACS 1.4 tool using default parameters. 
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2.2.12 Tumor ChIP-seq 
The tumor ChIP-seq protocol was established by modifying and combining two previously 
published ChIP protocols from Dahl as well as  Blecher-Gonen and colleagues (Dahl and Collas 
2008; Blecher-Gonen et al. 2013). A detailed step-by-step description of the tumor ChIP-seq 
protocol is given in the appendix (5.2). 
The tumor ChIP-seq protocol is based on a distinct tissue disruption step, which is essential for 
high performance and reproducibility of experiments. For disruption, a standard microtome-
cryostat is used to cut a number of slices (dependent on the volume of the biopsy) of defined 
thickness from frozen biopsies. Roughly six milligrams of these slices are sufficient for six ChIP 
reactions of histone marks or two ChIP reactions of transcription factors, respectively. The slices 
are transferred to standard reaction tubes in which they can be stored or directly processed. 
SDS-based lysis of the tissue is supported by dounce homogenization with a micro-pestle and 
brief sonification in the reaction tube. Chromatin shearing via sonification is performed under 
standard ChIP-seq conditions.  After sonification, the tissue ChIP-seq protocol follows a slightly 
modified version of a previously published high-throughput ChIP-seq protocol (Blecher-Gonen 
et al. 2013) with all the downstream convenience and high-throughput compatibility.  
Data analysis of tumor ChIP-seq was performed by Carl Herrmann according to ChIP-seq 
processing described in 2.2.11. 
 
2.2.13 ChIPmentation 
The ChIPmentation protocol, which describes the tagmentation of immunoprecipitated 
chromatin, was established by modifying and combining two previously published protocols 
(Schmidl et al, 2016 (Schmidl et al. 2015), Blecher-Gonen et al., 2013 (Blecher-Gonen et al. 
2013)). A detailed step-to-step description of the tumor ChIPmentation protocol is given in the 
appendix (5.3). 
Data analysis of ChIPmentation data was performed by Carl Herrmann according to ChIP-seq 
processing described in 2.2.11. 
 
2.2.14 4C sequencing (4C-seq) 
For a better understanding of long range cis- and trans gene regulation via interaction of 
regulatory DNA elements with promoters, we applied a technique called “circularized 
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chromosome conformation capture with high-throughput sequencing” (4C-seq) (van de Werken 
et al. 2012). 4C allows the examination of the regulatory environment of a certain locus of choice 
(viewpoint) with each individual regulatory element genome wide as a high resolution 
interaction profile. This technique starts with the formaldehyde fixation of the genome 
conformation and thereby the three-dimensional proximity of regulatory elements. This is 
followed by two subsequent processes of restriction enzyme digestion and fragment ligation. A 
PCR amplification step using primers of the viewpoint of interest is followed by sequencing of 
the product. A detailed step-by-step description of the 4C-seq protocol is given in the appendix 
(5.4). 
Data analysis of 4C-seq samples was performed by Carl Herrmann and Paul Saary and is 
described briefly. Unpaired 4C reads were demultiplexed allowing zero miss-matching between 
barcodes and aligned to the hg19 ref-genome with bwa-mem v. 0.7.17. Aligned reads were then 
matched and filtered to match expected restriction fragments using FourCseq using default 
parameters (Klein et al. 2015). Far cis- and trans-interactions were detected as suggested by 
Splinter et al. (Splinter et al. 2012). Trans-interactions with more than 50 supporting reads were 
subsequently visualized using circlize (Gu et al. 2014). 4Cker was used to detect close bait, cis 
and/or trans-interactions (Raviram et al. 2016). Domainograms for whole chromosomes were 
created according to Splinter et al. and for regions of interest were computed according to the 
method published by http://compgenomics.weizmann.ac.il/tanay/?page_id=367. Using 
adaptive windows domainograms for regions of interest in close and far cis-interactions were 
computed, by comparing the signal to a localized background. 
 
2.2.15 HiChIP sequencing 
To obtain information of genome wide chromatin conformation in NB cells, we performed 
HiChIP with subsequent sequencing in two NB cell lines (SK-N-AS and KELLY). The HiChIP 
method was performed according to the previously published protocol by Mumbach and 
colleagues (Mumbach et al. 2016) with slight modifications as described briefly. 
1x106 cells were detached, pelleted and subsequently resuspended in 1 ml of 1% FA for 10 min 
crosslinking. Decrosslinking, lysis and restriction using MboI restriction enzyme, was performed 
according to the published protocol.  Incorporation of biotin-ATP was achieved using 15 µl 1 mM 
Biotin-14-dATP (NU-835-BIO14-S, Jena Bioscience) to the master mix instead of 37.5 µl of 0.4 
mM biotin-dATP (819524016, Thermo). Proximity ligation was performed according to the 
protocol with the only variation of ligation incubation over night at 16°C. 
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Sonication of the material was accomplished using the Covaris LE220 and 1 ml tubes instead of 
Covaris E220 as described in the protocol. The change of sonication device altered the sonication 
parameters as follows: 
Duty Cycle 15% 
PIP 350 W 
Cycles/Burst 200 
Time 4 min 
 
The subsequent IP reaction was performed using SMC1A (Bethyl A300-055A9) and H3K27ac 
(ab4729) antibodies. After ChIP DNA elution in 27 µl water, the obtained post ChIP DNA amount 
reached from 30ng for SMC1A to more than 150ng for H3K27ac HiChIP samples. During the 
biotin-capture step the Streptavidin C-1 beads were incubated at RT for 30 min instead of 15 
min. For the PCR reaction, Illumina Nextera i5/i7 primer (Illumina Nextera Index Kit 24 Indexes 
– 96 samples - Illumina 15055289) and Nextera PCR master mix (Illumina Nextera DNA Library 
Prep Kit 24 samples – Illumina 15028212) were used and reaction was performed for 8 cycles in 
total. Ampure XP beads (AMPure XP beads, Beckman Coulter) were used for a size selection to 
obtain fragments greater than 300 and smaller than 700 bps of the amplified libraries. For final 
quantification and fragment size distribution of libraries, a Bioanalyzer assay was performed. 
The libraries were sequenced paired-end and one per lane with 100 bps read length adding 10% 
PhiX to increase sequence complexity. 
Data analysis of HiChIP-seq samples was performed by Carl Herrmann and Paul Saary and is 
described briefly. HiChIP reads were aligned using HiC-pro with the default configuration 
(Servant et al. 2015). Valid pairs were analyzed using step 4 and 5 of a slightly modified Mango 
version (Phanstiel et al. 2015). A FDR of 0.05 was applied to all samples. 
 
2.2.16 ATAC sequencing (ATAC-seq) 
For genome-wide mapping of chromatin accessibility and to perform transcription factor 
footprinting analysis we conducted Assay for Transposase‐Accessible Chromatin with high‐
throughput sequencing (ATAC‐seq) using the protocols published by Buenrostro and colleagues 
(Buenrostro et al. 2013; Buenrostro et al. 2015) with the following changes. In total 50.000 cells 
were used for lysis and transposase reaction. After purification Nextera PCR primer (2.1.9) were 
used in a 11 cycle amplification PCR. ATAC-seq library was finally cleaned up and the 
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concentration and fragment distribution were tested. The libraries were pooled, 15% PhiX was 
added to increase sequence complexity and finally sequenced using a HiSeq 2000 V4 platform 
with 50 bp single read. 
Data analysis of ATAC-seq samples was performed by Carl Herrmann and is described briefly. 
Differential ATAC-seq analysis between SK-N-AS and Kelly cell lines was done based on the 
footprints of a collection of transcription factor binding motifs containing in particular motifs for 
all TFs identified in the CRC analysis. Footprinting was done using the PIQ method (Sherwood et 
al. 2014). For each motif, we filtered the motif occurrences for which the purity score was larger 
than 0.7 in at least one of the two cell lines and computed a paired t-test on this set of filtered 
motifs. Hence, we obtained a value of the t-statistics for each motif, indicating a tendency of 
these motifs to be more accessible in one or the other of the two cell lines. 
 
2.2.17 DNA preparation and whole genome sequencing (WGS) 
DNA isolation cell lines 
Cells were seeded into 15 cm cell culture plates until they reached a density up to 80%. 
Subsequently, cells were incubated in an appropriate volume of versene for detachment and 
were transferred into a 15 ml tube. Afterwards the cells were centrifuged at  
800 rpm for 5 min and the supernatant was removed. For the following DNA isolation, the High 
Pure PCR Template Preparation Kit (Roche) was used according to manufacturer’s protocol. 
DNA isolation primary tumors 
Tumors were sliced in small fractions while cooled with dry-ice. Subsequently, tumor fractions 
were diluted in STE buffer and 100 - 200 µl proteinase K (20 mg/ml) and 50 µl SDS (20% 
solution) were added to the resuspended cell pellet and mixed. For protein digestion, the 
mixture was incubated at 65°C for at least 2 h. The cell suspension was mixed occasionally and 
proteinase K concentration was increased if necessary. 
DNA purification 
By the time, the suspension was no longer highly viscous, the DNA was purified using a 
phenol/chloroform mixture (Kirby 1956). The removal of the proteins was carried out by 
adding an equal volume of phenol/chloroform/isoamylalcohol (25:24:1) with a pH-value of  
7.8 - 8. All further steps were performed on ice. The two phases were mixed rapidly inverting the 
tube followed by a centrifuge step at 3000 rpm for 10 min at 4°C. The aqueous phase containing 
nucleic acids was carefully transferred into a new tube. Thereby, phenol denatured proteins 
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were collected at the interphase, lipids in the organic and the DNA in the aqueous phase. This 
process was repeated and finally the aqueous phase was mixed with chloroform and centrifuged 
again at 3000 rpm for 10 min at 4°C to remove any residual phenol. Finally, the DNA-containing 
aqueous phase was transferred into a fresh tube. 
DNA precipitation 
DNA was precipitated by adding 3 ml of 3 M sodium acetate and 30 ml of ice cold 100% ethanol. 
Directly afterwards, the tube was carefully inverted until the precipitated DNA became visible. 
The DNA was coiled on a little rod and washed in ice cold 70% ethanol. Subsequently, the DNA 
was dried until all residual ethanol was evaporated and resuspended in 200 - 500 µl H2O. For 
complete solubility, the tube was incubated at 42°C for 20 min using a shaking device. The 
concentration was determined using a Nanodrop ND-1000. 
DNA quantification (tumors and cell lines) 
For DNA quantification, the Qubit Fluorometer was used according to the manufacturer´s 
protocol. The fluorometer detects highly specific dyes of dsDNA broad range and high sensitivity 
assay kit fluorescence when bound to dsDNA. First, the working solution was prepared and 
mixed in the ratio 1:20 with two provided standards and 1:200 with each sample to a final 
volume of 200 µl. After incubation for 2 min, calibration was performed by measuring the two 
standards.  
Fragmentation 
The Covaris S series was used for sample preparation and shearing of the genomic DNA to a size 
of 160 - 200 bp. The Covaris S series uses the AFA-technology (Adaptive Focused Acoustics) for 
fragmentation. Therefore, 5 µg of genomic sample DNA were transferred into a Covaris micro 
tube and filled up to 120 µl with H2O. The micro tube was load in the Covaris tube holder and 
DNA was sheared 3 times with 200 cycles per burst at 4°C for 120 sec.  
Purification 
The sheared DNA was purified using the Agencourt AMPure XP and a magnetic device. The DNA 
was eluted after purification in 30 µl H2O and transferred into a fresh tube. 
DNA library preparation and WGS 
For using the “Next Generation Sequencing” platform and especially the Illumina paired-end 
sequencing assay, the sample genomic DNA had to be prepared. All subsequent reactions were 
performed according to the NEBNext Ultra DNA Library Prep Kit for Illumina (NEB) 
manufacturer’s protocol. 
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3. Results 
3.1 Global enhancer hijacking landscape in NB 
The principle of alternative oncogene activation by locating enhancers in the proximity of 
oncogenes was described for different cancer entities and is referred to as “enhancer hijacking” 
(Taub et al. 1982; Bakhshi et al. 1987; Groschel et al. 2014; Northcott et al. 2014). Shedding light 
on the global landscape of enhancer and hijacking events for the first time in NB, was a central 
task of this work. As depicted in Figure 9 enhancer hijacking describes a rearrangement of a 
gene or oncogene joined with other chromosome segments harboring strong regulatory 
elements like super-enhancer (SE). 
 
 
Figure 9: The mechanism of enhancer hijacking.  
Structural rearrangements lead to juxtaposition of gene X locus to strong enhancer elements (A 
and B) that up regulates the transcription of gene X. Adapted from (Shlyueva et al. 2014) – 
licence obtained. 
 
3.1.1 Telomerase activation by genomic rearrangements in high-risk NB 
In a study performed together with colleagues from the university children’s hospital cologne, 
whole genome sequencing (WGS) of 56 NB primary tumors and matched normal controls (17 
low-risk and 39 high-risk patients) was performed (Peifer et al. 2015). All bioinformatics work 
of this study was performed by Martin Pfeifer. The WGS data confirmed a low overall mutation 
rate (13.3 mutations/genome) and four recurrent genomic alterations in total (Wang et al. 2011; 
Molenaar et al. 2012). Three of these alterations are established alterations in NB including 
amplified MYCN, ATRX deletion and gain of chromosome 17 (Figure 10) (Schwab et al. 1983; 
Savelyeva et al. 1994). A novel recurrent genomic aberration located at chromosome 5p15.33 
was found in 12 of 56 NB primary tumors (21%). All the 12 cases were high-risk tumors with 
Fusionpoint of translocation partners
Translocation
from Chr. A
Translocation
from Chr. B
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rearrangements that clustered upstream of the TERT gene without affecting the promoter. No 
TERT gene or promoter mutations were detected and structural aberrations were intra- (n = 7) 
as well as inter- (n = 5) chromosomal and included balanced translocations with single-copy 
gains or amplifications. In 56 primary tumors, ATRX mutations (n = 7), amplified MYCN (n=10) 
or TERT rearrangements (n = 12) were observed in a mutually exclusive fashion. 
 
 
Figure 10: WGS revealed recurrent genomic rearrangements in NB. 
WGS of 56 NB primary tumors revealed recurrent genomic rearrangements like amplified 
MYCN, ATRX deletion, gain of chromosome 17 and TERT rearrangement in high risk patients 
(recurrence in more than three tumors is marked red). Adapted from (Peifer et al. 2015). 
 
Screening for TERT genomic aberrations by fluorescent in situ hybridization (FISH) and locus-
specific targeted sequencing in an extended cohort of 217 primary NB tumors revealed a total of 
28 TERT rearrangements (13%; Figure 11A). Almost all TERT-rearranged cases were classified 
as high-risk with the exception of one intermediate-risk sample. 
 
TERT rearrangement was associated with poor survival of NB patients 
 
TERT rearrangements were associated with poor prognosis and poor clinical outcome, which 
was comparable with patients harboring amplified MYCN or remaining high-risk cases (Figure 
11B and 11C). The Kaplan-Meier survival probability diagram indicated overall survival (OS) 
probability of P = 0.056 and event-free survival (EFS) probability of P = 0.038.  
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Figure 11: TERT rearrangement is associated with poor survival in NB. 
(A) Cohort description of 217 primary NB tumors. TERT rearrangements were discovered by 
WGS or FISH and targeted sequencing. (B) Kaplan-Meier event-free survival diagram (EFS). (C) 
Kaplan-Meier overall survival probability diagram (OS). All figures are adapted from (Peifer et 
al. 2015). 
 
mRNA expression of TERT in NB tumors and cell lines 
 
TERT expression level of NB tumors harboring TERT rearrangements (TERT) were compared 
with MYCN-amplified (MYCN) as well as remaining high- (HR) and low-risk (LR) NB primary 
tumors (Figure 12A). The highest TERT expression was observed in TERT-rearranged cases, 
with a median expression of 12.3 and significantly higher than that of MYCN-amplified tumors  
(P = 0.028). High-risk tumors without amplified MYCN or TERT rearrangement expressed 
significantly lower TERT levels than MYCN-amplified tumors (P = 0.021) but higher TERT levels 
as compared to low-risk tumors. As a next step, the TERT expression level in the RNA-
sequencing (RNA-seq) dataset of 32 NB cell lines, 18 MYCN-amplified and 14 MYCN non-
amplified (MNA), was evaluated (Figure 12B). The highest TERT expression was detected in 
MYCN-amplified NGP cells (FPKM of 10.7). This was followed by two MNA cell lines CLB-GA 
(FPKM of 3.9), GI-ME-N (FPKM of 3.2) and finally by the MYCN-amplified cell line KELLY (FPKM 
of 2.6). The lowest TERT expression level in the NB cell line cohort was detected for MNA cell 
line SK-N-FI with almost no detectable TERT mRNA (FPKM of 0.01). 
A B C 
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Figure 12: TERT mRNA expression in NB. 
(A) TERT mRNA expression in tumors with TERT rearrangement (n=10, yellow), amplified 
MYCN (n = 9, red) in high-risk tumors without TERT rearrangement or amplified MYCN (n = 18, 
grey; tumors with additional ATRX mutations are shown in blue (n = 7)) and in low-risk tumors 
(n = 17, green). Adapted from (Peifer et al. 2015). (B) TERT mRNA expression in NB cell lines (n 
= 32). 
 
FISH identified structural aberrations involving TERT 
 
A technique to detect DNA sequences of genomic locations on chromosomes (2.2.9), 
fluorescence in situ hybridization (FISH), was performed with TERT locus-specific probes to 
identify structural aberrations in NB cell lines (Figure 13). Chromosomal rearrangement 
partners joining chromosome 5 including the TERT locus (green) were evaluated. 
In MNA cell line CLB-GA two chromosome 5 derivatives were detected carrying the TERT gene 
(der(5) and der(20)) with translocation events (t(5;11), t(5;20)) (Figure 13A). Derivatives 
comprise structurally rearranged chromosomes indicating the chromosome with an intact 
centromere. In the case of t(5;20), a rearrangement of chromosome 5 and 20 occurred, with the 
breakpoint on chromosome 5 located close to the TERT gene. MNA cell line GI-ME-N had six 
copies of the TERT gene (Figure 13B). Two copies were located on a derivate of chromosome 6, 
der(6), with translocation event t(5;6;19) and two copies on der(16) with the rearrangements 
including t(5;16;19). The TERT gene locus was juxtaposed to genomic regions on chromosome 
19 in der(6) as well as der(16). In MYCN-amplified KELLY cells, three copies of TERT were 
detected (Figure 13C). Two translocation events were present carrying the TERT gene joined to 
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the genomic regions on chromosome 2 (der(2) and der(5)). A large duplication event on 
chromosome 5 was identified in MYCN-amplified cell line NGP, but was not further 
characterized within this study (data not shown). Chromosome painting visualizing numerical 
and structural chromosomal aberrations also revealed evidence for a TERT rearrangement in 
LAN2 cells (data not shown). 
 
Figure 13: Structural aberrations involving TERT. 
Fluorescence in situ hybridization (FISH) of NB cell lines CLB-GA (A), GI-ME-N (B) and KELLY 
(C). TERT locus-specific probes were labelled in green. Analyses were performed by Larissa 
Savelyeva. 
 
4C-seq confirmed physical TERT promoter-enhancer interactions in rearranged cell lines 
 
Circular chromatin conformation capturing with subsequent sequencing (4C-seq) was used for 
detection of physical enhancer-promoter interactions of a specific region, which is called the 
viewpoint, with all other locations of the genome (2.2.14). Such a viewpoint matching the TERT 
promoter was designed and tested in NB cell lines CLB-GA, GI-ME-N, KELLY and LAN2 (Figure 
14 and Figure 15). In cell lines CLB-GA and GI-ME-N, interactions were confirmed between the 
TERT promoter and juxtaposed enhancers at chromosome 20 and 19, respectively (Figure 14). 
der(20)
t(5;20)
5
TERT
CLB-GA
der(5)
t(5;11)
der(6)
t(5;6;19)
5 der(16)
t(5;16;19)
TERT
GI-ME-N Kelly
der(5)
TERT
der(2) der(5)
t(2;5)
A B C 
 Results 48 
 
Figure 14: Genome-wide interactions of TERT promoter. 
Genome-wide circos plot interaction profile of the TERT promoter with regulatory elements on 
chromosome 20 in NB cell line CLB-GA (A) and elements on chromosome 19 in GI-ME-N (B) as 
determined via 4C-seq. Different viewpoints were applied (green and blue = TERT TSS) 
 
In KELLY, 4C-seq identified two SE regions on chromosome 2 close to the ALK gene as 
interaction partners of the TERT promoter (Figure 15A).  
 
 
Figure 15: Genome-wide interactions of TERT promoter. 
Genome-wide circos plot interaction profile of the TERT promoter with regulatory elements on 
chromosome X in NB cell line LAN2 (A) and elements on chromosome 2 in NB cell line KELLY 
(B) as determined via 4C-seq. Different viewpoints were applied (blue = TERT TSS) 
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B 
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Finally, in LAN2 cells, the rearranged chromosome 5 region carrying TERT was located next to 
chromosome X and enhancer regions that are physically interacting with the TERT promoter 
(Figure 15B). All TERT promoter assays provided various cis-interactions in the surrounding of 
the TERT viewpoint on chromosome 5. 
 
ChIP-seq of histone marks identified the epigenetic status  
of TERT locus in rearranged NB cell lines 
 
CLB-GA, GI-ME-N and KELLY cells showed high TERT expression level due to a TERT 
rearrangement and interaction of the TERT promoter with juxtaposed enhancer regions close to 
the breakpoint of new interacting chromosomal regions. As a next step, the epigenetic status and 
chromatin state of TERT gene acceptor region was explored by ChIP-seq of histone marks 
(H3K4me3, H3K4me1, H3K27ac, H3K36me3, H3K27me3 and H3K9me3) or ATAC-seq (Figure 
16). The cell lines SK-N-FI and LAN6 without elevated TERT genes expression or TERT 
rearrangement served as controls (Figure 17). 
TERT-rearranged CLB-GA cells demonstrated the strongest TERT expression in the cohort, 
followed by MYCN-amplified NGP cells (Figure 12B). The ATAC-seq profile, a characteristic of 
open chromatin, was enriched for peaks at the TERT locus and surroundings (Figure 16A). This 
was accompanied by enrichment of H3K27ac, H3K4me1 and H3K4me3 at the TERT TSS, which 
are all associated with actively transcribed protein-coding promoters. The TERT gene body was 
marked by H3K36me3, which is enriched at the gene body of active genes, as well as by 
H3K27me3 and some distinct peaks of H3K9me3, which are both associated with gene silencing 
and repressive function. The epigenetic status of KELLY was comparable to that of CLB-GA, 
except for additional strong enrichment of histone mark H3K27ac at the TSS of TERT, 
surrounding genes as well as at intergenic and intronic regions (Figure 16B). 
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Figure 16: Epigenetic profiling of TERT locus. 
Input normalized read counts of histone marks H3K4me3, H3K4me1, H3K27ac, H3K36me3, 
H3K27me3 and H3K9me3 and ATAC-seq peaks (only CLB-GA and KELLY) at the TERT locus. 
Peaks are shown of cell lines with rearrangements close to the TERT locus (CLB-GA (A), KELLY 
(B), GI-ME-N (C)). 
 
GI-ME-N cells, which express comparable TERT levels to CLB-GA, showed similar epigenetic 
profile of enrichment of histone modifications H3K4me3, H3K4me1, H3K27ac and H3K36me3 as 
did CLB-GA at gene body and TSS (Figure 16C). However, the patterns of H3K27me3 and 
H3K9me3 were different. While histone H3K27me3 was nearly absent at the TERT locus, 
H3K9me3 was heavily enriched upstream of the TERT gene. 
The two TERT non-rearranged and TERT non-expressing control cell lines LAN6 and SK-N-FI, 
showed a comparable epigenetic pattern (Figure 17). H3K4me3, H3K4me1, H3K27ac and 
H3K36me3 were nearly absent at TERT TSS and gene body. However, strong enrichment for 
histone modification H3K27me3 and moderate peaks for H3K9me3 were observed, which are 
associated with gene silencing and repressive function.  
 
 
Figure 17: Epigenetic profiling of TERT locus. 
Input normalized read counts of histone marks H3K4me3, H3K4me1, H3K27ac, H3K36me3, 
H3K27me3 and H3K9me3 at the TERT locus. Peaks are shown of cell lines lacking TERT 
alterations (LAN6 (A) and SK-N-FI (B)). 
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ChIP-seq of histone marks identified active enhancers  
with TERT promoter in rearranged NB tumors 
 
The epigenetic status and chromatin state of TERT gene acceptor region and donor region of the 
corresponding translocation partner was examined by ChIP-seq for histone marks H3K4me3 
and H3K27ac in three TERT-rearranged tumors (Figure 18). Two tumors had inter-
chromosomal chromosome 5 rearrangements (NB-2 and NB-3; Figure 18B and 18C) and one 
tumor harbored a translocation event of chromosome 7 and 5, close to the TERT gene (NB-1; 
Figure 18A). In all three cases, there was strong enrichment of histone mark H3K27ac in the 
translocated region adjacent to the breakpoints. For an additional tumor, a TERT translocation 
close to the HAND2 (heart and neural crest derivatives expressed 2) downstream enhancer 
region was identified (NB-4; ChIP-seq data not shown). 
 
Figure 18: Epigenetic profiling of rearranged regions involving TERT. 
Input normalized read counts of histone marks H3K4me3 and H3K27ac within the rearranged 
genomic regions of NB primary tumors NB-1 (A), NB-2 (B) and NB-3 (C).  
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Individual ranking of histone mark H3K27ac signal according to SE definition (1.2.3) revealed 
that strong SE regions juxtaposed the TERT gene in all three tumors investigated (Figure 19A, B 
and C).  
 
 
Figure 19: Ranking of histone mark H3K27ac signal. 
Ranking of histone mark H3K27ac signal (enhancer elements) in tumors NB-3 (A), NB-1 (B) and 
NB-2 (C). Enhancers close to the breakpoint of TERT rearrangements are marked red and 
encircled. SE definition was applied according to (1.2.3; Figure 7). H3K27ac ChIP-seq peaks 
within 12.5 kb distance were stitched and defined as one single enhancer entity. All enhancers 
and combined enhancer entities were ranked according to their H3K27ac signal within the 
genomic region. Enhancers with H3K27ac signal above the point where the curve slope exceeds 
one were considered as SEs. Adapted from (Peifer et al. 2015). 
 
450K analysis identified DNA methylation status 
of CpG islands at TERT locus in primary NB tumors 
 
DNA methylation analysis of CpG islands at the TERT locus of 39 NB primary tumors were 
compared in TERT-rearranged samples (TERT), MYCN-amplified samples (MYCN) and tumors 
without TERT or MYCN events (Figure 20). MYCN tumors harbored highest CpG islands 
methylation across the TERT gene locus, followed by TERT-rearranged cases. Strongly enriched 
methylation was observed at a CpG site close to the TERT promoter of MYCN and TERT samples 
as compared to the others. 
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Figure 20: DNA methylation of CpG islands at TERT locus in NB. 
DNA methylation of CpG islands at the TERT locus in 39 primary NB tumors 
(HumanMethylation450K arrays). Samples were classified in TERT-rearranged (TERT, n = 6), 
MYCN-amplified (MYCN, n = 9) and cases without TERT or MYCN events (others, n = 24). 
Adapted from (Peifer et al. 2015). 
 
Taken together, a recurrent rearrangement affecting the TERT gene was identified in up to 24% 
of high-risk NB cases using integrated data from WGS and FISH analyses of primary tumors. 
TERT rearrangements upstream of the TSS caused high TERT expression and were associated 
with poor clinical outcome. 
In both, tumors and cell lines, ChIP-seq data identified highly active SE regions juxtaposed to the 
TERT gene, which led to activated chromatin state and likely drove high TERT expression 
observed in these cases. In NB cell lines, physical interactions of juxtaposed enhancer elements 
with the TERT promoter were confirmed by 4C-seq studies. 
 
3.1.2 Further rearrangements affecting oncogenes 
The principle of oncogene activation by chromosomal rearrangements bringing together active 
enhancers and oncogenes has been described for several cancer entities and is referred to as the 
phenomenon of “enhancer hijacking”. With the discovery of recurrent rearrangements of SE 
elements activating the TERT gene, we provided the first evidence for “enhancer hijacking” in 
NB. Due to the absence of coding mutations or amplifications, extraordinary high expression 
levels for several oncogenes including MYCN, MYC (summarized as MYC(N)) in NB remained 
unexplained for a long period and will be elucidated in this study using primary tumor and cell 
line data sets including FISH, WGS, RNA-seq, ChIP-seq, ATAC-seq and interaction data like 4C 
and HiChIP.  
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mRNA expression of MYC(N) in NB tumors and cell lines 
 
As a first step, the mRNA expression level of NB tumors and cell lines was evaluated using RNA-
seq data (Figure 21). Therefore, 498 cases with RNA seq data were included consisting of stage 1  
(n = 121, 24.3%), stage 2 (n = 78, 15.7%), stage 3 (n = 63, 12.7%), stage 4 (n=183, 36.7%), 
stage 4S (n = 53, 10.6%) and MYCN-amplified (92, 18.5%) samples (Zhang et al. 2015)) (Figure 
21A). In tumors classified as MYCN non-amplified (MNA), no elevated MYCN expression was 
detected (Figure 21A). Within the RNA-seq dataset of 32 NB cell lines, 18 harbored amplified 
MYCN while 14 were defined as MNA (Figure21B). All 18 cases of amplified MYCN were 
accompanied by high MYCN expression (FPKM of 258.1 for SIMA - 1534.1 for SMS-KCNR). In 
contrast, for all MNA cell lines, with the exception of NBL-S and SK-N-FI (FPKM of 118.6 and 
33.6), a relatively low MYCN expression was observed (FPKM of 0.17 for GI-ME-N). 
 
Figure 21: MYCN mRNA expression in NB. 
(A) MYCN mRNA expression according to stage and MYCN status in NB tumors by RNA-seq  
(n = 498; log2 scaling). (B) MYCN mRNA expression in NB cell lines by RNA-seq (n = 32; Sample 
MNA (blue) or MYCN-amplified (red)). 
 
MYC gene expression was highest in stage 4 patients followed by stage 1-3 and 4S within the 
RNA-seq cohort of 498 NB primary tumors (Figure 22A). Patients harboring amplified MYCN 
revealed the lowest MYC expression, which was in line in NB cell lines (Figure22B). While 
MYCN-amplified cell lines like CHP126 with the high MYCN expression harbored lowest MYC 
expression levels, MNA cell lines like GI-ME-N were among the top MYC expressing cell lines. 
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Figure 22: MYC mRNA expression in NB. 
(A) MYC mRNA expression according to stage and MYCN status in NB tumors by RNA-seq (n = 
498; log2 scaling). (B) MYC mRNA expression in NB cell lines by RNA-seq (n = 32; Sample MNA 
(blue) or MYCN-amplified (red)). 
 
Protein quantification of MYC(N) in NB cell lines 
 
The MYCN mRNA expression pattern of MNA cell lines (n = 7) was translated to the protein level 
as determined by western blotting. While no MYCN protein was detectable in most MNA cell 
lines (SK-N-AS, SH-SY5Y, CHLA20, CHLA15 and NB69) SK-N-FI and especially NBL-S cells 
displayed high MYCN protein signals (Figure 23) 
 
Figure 23: MYCN protein expression in NB cell lines.  
MYCN protein expression was quantified by western blotting using ß-actin as a loading control 
in a set of MYCN-non amplified (MNA) NB cell lines (n = 7). 
 
Western blot analysis of MYC expression in MNA NB cell lines (n = 7) revealed highest MYC 
protein levels in cell lines NB69 and CHLA20, followed by SH-SY5Y and SK-N-AS (Figure 24). 
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MYC protein expression was undetectable in the top MYCN expressing MNA cell lines NBL-S and 
SK-N-FI.  
 
Figure 24: MYC protein expression in NB cell lines. 
MYC protein expression was quantified by western blotting using ß-actin as a loading control in 
a set of MYCN-non amplified (MNA) NB cell lines (n = 7). 
 
High MYC(N) expression was associated with poor survival of NB patients 
 
Increased MYCN expression levels significantly correlated with poor event free (EFS) as well as 
overall survival (OS) in a cohort of 498 primary NBs (Figure 25). EFS probability (Figure 25A) in 
MYCN high cases accounted roughly 0.3 in contrast to less than 0.7 in patients with low MYCN 
expression while OS probability (Figure 25B) resulted in 0.4 and 0.85, respectively.  
  
Figure 25: High MYCN is associated with poor survival in NB. 
Kaplan-Meier analyses for event-free survival (EFS) (A) and overall survival (OS) (B) in respect 
to MYCN expression in a set of 498 NB primary tumors. Uncorrected (raw p) and Bonferroni-
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corrected (bonf p) p-values are shown. Cut-off values for dichotomization of MYCN expression 
were estimated by maximally selected log-rank statistics. 
 
FISH identified structural aberrations involving MYC(N) 
 
To trace the cause for high expression levels of MYCN and MYC in several NB cell lines, 
chromosome painting, which allows to visualize numerical and structural chromosomal 
aberrations, was performed (Ried et al. 1998) (data not shown). For identification of a more 
specific focus on the rearranged location, FISH analysis, which helps to spot structurally 
rearranged chromosomes using locus specific BAC probes (100 – 200 kb) was performed in 
NBL-S cells (Figure 26). Labeling the MYCN region (green) and a genomic region on 
chromosome 4 (red), close to the HAND2 gene (hereinafter referred to as HAND2), revealed two 
derivatives (der) including the MYCN gene (Figure 26). The two translocation events t(2;4) 
corresponded to the rearrangements of chromosome 2 and 4 (top-down) while the breakpoint 
was in close proximity to the MYCN  (chromosome 2) and HAND2 (chromosome 4) gene (Figure 
26).  
 
Figure 26: Structural aberrations involving MYCN. 
Fluorescence in situ hybridization (FISH) (A) and karyogram (B) of NB cell line NBL-S. Specific 
probes for MYCN and a genomic region on chromosome 4 (hereinafter referred to as HAND2) 
close to the HAND2 gene were labelled in green and red, respectively. Analyses were performed 
by Olga Sepman and Larissa Savelyeva. 
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Similar to MYCN, multicolor FISH using MYC locus-specific probes was performed to identify 
structural aberration events in cell lines with extraordinary high MYC expression levels. We 
focused on the composition of derivatives (der), which describe structurally rearranged 
chromosomes indicating the chromosome with an intact centromere. Fusion chromosomes on 
chromosome 8 with the MYC locus (green), chromosome 4 with HAND2 (red) and further 
chromosomal translocation partners were examined. In cell line NB69, we identified that all 
three derivatives ((der(4), der(8) and der(19)) containing MYC in chromosome 8 segments 
were flanked by chromosome 4 sections containing the HAND2 locus (Figure 27A). These 
translocation events (t(4;4), t(4;8;8)) and t(4;8;19)) included complex rearrangements and 
duplications. Cell line SH-SY-5Y harbored one translocation event on der(8) including the MYC 
gene (Figure 27B). We identified that der(8) was joined to chromosome segments close to the 
EXOC4 gene on chromosome 7 (t(7;8)) in SH-SY5Y cells. 
Two derivatives (der(8) and der(18)) containing the MYC gene that was joined to chromosome 
segments close to the HAND2 locus on chromosome 4 were identified in the isogenic cell lines 
CHLA15 and CHLA20, which derived from the same patient (CHLA15 was isolated prior to 
treatment; CHLA20 was isolated after treatment) (Figure 27C and D). Der(8) comprised the 
translocation event of chromosome 4 and 8 (t(4;8)), while in der(18) large chromosomal 
fragments of chromosome 18 (t(4;8;18)) were involved. The duplications of these fragments 
were found in cell line CHLA20, but not in CHLA15. Finally, one derivative (der(8)) was 
discovered containing translocated segments of chromosome 4 with HAND2 locus flanking the 
MYC locus (t(4;8)) in SK-N-AS cells (Figure 27E). Derivate (der(9)) explained rearrangement of 
MYC locus with chromosome 9.  
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Figure 27: Structural aberrations involving MYC. 
Fluorescence in situ hybridization (FISH) image of NB cell line NB69 (A), SH-SY-5Y (B), CHLA15 
(C), CHLA20 (D) and SK-N-AS (E). MYC and HAND2 locus-specific probes were labelled in red 
and green, respectively. In SH-SY5Y, EXOC4 locus-specific probe was labelled in blue. Analyses 
were performed by Olga Sepman and Larissa Savelyeva. 
 
Combined 4C-seq and ChIP-seq of histone marks identified interactions of active enhancers with 
MYC(N) promoter in rearranged cell lines 
 
4C-seq was used to validate the FISH defined MYC(N) rearrangements by detecting functional 
and genome wide physical interactions of a specific region, named viewpoint (Figure 28 - Figure 
30). Such a viewpoint, matching the MYC and MYCN promoter was designed and used in MYC- 
and MYCN-rearranged cell lines, respectively. For a reciprocal assay, three different viewpoints, 
using P300 ChIP-seq peaks as enhancer surrogates, were designed, which were close to the 
breakpoint on chromosome 4. 
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In NBL-S cells the trans-interaction of MYCN promoter on chromosome 2 and SEs on 
chromosome 4 were the only observed interactions (Figure 28). The reciprocal assays starting 
from the SE peaks confirmed this trans-interaction.  
 
 
Figure 28: Genome-wide interactions involving MYCN promoter. 
Genome-wide interaction profile of regulatory elements on chromosome 4 with the MYCN 
promoter in NB cell line NBL-S as determined via 4C-seq. Different viewpoints were applied 
(pink = MYCN TSS; green = HAND2 P300 position 1; yellow = HAND2 P300 position 2; grey = 
HAND2 P300 position 3) 
 
Trans-interactions of MYC promoter with the enhancer regions on chromosome 4 (NB69, SK-N-
AS and CHLA20; Figure 29 and Figure 30B) or chromosome 7 (SH-SY5Y; Figure 30A) were 
identified in all MYC-rearranged cells. A reciprocal assay including three different viewpoints 
was designed as previously described, applied to cell lines NB69 and SK-N-AS and confirmed 
these trans-interactions (Figure 29A and B).  
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Figure 29: Genome-wide interactions involving MYC promoter. 
Genome-wide interaction profile of regulatory elements on chromosome 4 with the MYC 
promoter in NB69 (A) and SK-N-AS (B) cells as determined via 4C-seq. Different viewpoints 
were applied in NB69 and SK-N-AS cells, respectively (orange = MYC TSS; green = HAND2 P300 
position 1; yellow = HAND2 P300 position 2; grey = HAND2 P300 position 3) 
 
 
Figure 30: Genome-wide interactions of MYCN promoter. 
Genome-wide interaction profile of regulatory elements on chromosome 7 and chromosome 4 in 
SH-SY5Y (A) cells and regulatory elements on chromosome 4 in CHLA20 (B) cells with the MYC 
promoter as determined via 4C-seq. MYC promoter viewpoint was applied (orange and purple = 
MYC TSS in SH-SY5Y and CHLA20, respectively). 
 
 
A B 
A B 
 Results 62 
For a more detailed view on the donor- and acceptor regions of MYC(N)-rearranged cells, all 4C-
seq interactions were examined further at the loci and complemented with ChIP-seq profiles 
(Figure 31 - Figure 35).   
In NBL-S cells, two histone modifications, H3K4me3, associated with active transcription at the 
transcription start sites (TSS) and H3K36me3, associated with transcriptional elongation at the 
gene body, were enriched at MYCN on chromosome 2 as well as CEP44 (centrosomal protein 44) 
and FBXO8 (F-box protein 8) on chromosome 4 indicating active transcription (Figure 31). 
Repressive marks including K27me3 and K9me3 showed only minor enrichment on 
chromosome 4 fragment. Patterns for H3K27ac and H3K4me1, in the absence of H3K4me3, 
generally used as surrogates for active regulatory enhancer elements, were significantly 
enriched downstream of the FBXO8 gene on chromosome 4 fragment. This region of multiple 
enhancer clusters was located directly adjacent to the breakpoint and therefore to the MYCN 
gene.  
 
Figure 31: Epigenetic profiling of rearranged regions involving MYCN. 
Input normalized read counts of histone marks H3K4me3, H3K4me1, H3K27ac, H3K36me3, 
H3K27me3 and H3K9me3 within the rearranged genomic regions in NBL-S cells. Interaction 
profiles of potential enhancer elements (VP1 on chr. 4) with the MYCN promoter (VP2 on chr. 2) 
were determined via circular chromatin conformation capturing with subsequent sequencing 
(4C-seq). 
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A large cluster of H3K27ac and H3K4me1 peaks was detected upstream of FBXO8 on 
chromosome 4 In NB69 cells (Figure 32). In general, the absence of concurrent H3K4me3 
promoter mark is considered as evidence that this cluster was a strong SE. The strong peak of 
H3K4me3 on chromosome 8 marked the active promoter of the MYC gene. In addition, 
enrichment of the transcriptional elongation mark H3K36me3 in the absence of repressive 
marks, H3K27me3 or H3K9me3, revealed active MYC transcription. 4C-seq analyses of the 
enhancer viewpoints on chromosome 4 (vp1-vp3) revealed cis-interactions close to the chosen 
viewpoint, which were decreasing with distance to the promoter from vp1 to vp3. This decrease 
of cis-interactions was accompanied by increased trans-interactions with the MYC promoter. 
The reciprocal assay with a viewpoint at the MYC promoter confirmed interactions with several 
enhancers of the chromosome 4 segment.  
Figure 32: Epigenetic profiling of rearranged regions involving MYC. 
Input normalized read counts of histone marks H3K4me3, H3K4me1, H3K27ac, H3K36me3, 
H3K27me3 and H3K9me3 at the junction between chromosome 4 and chromosome 8 in NB69 
cells. Interaction profile peaks of potential enhancer elements (VP1-3 on chr. 4) with the MYC 
promoter (VP4 on chr. 8) were determined via circular chromatin conformation capturing with 
subsequent sequencing (4C-seq). 
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In SK-N-AS cells, the distance between MYC and the downstream breakpoint on chromosome 8 
was more than 1 Mb compared to NB69 cells (Figure 33; compare Figure 77 in appendix and 
Figure 51). Besides the H3K27ac- and H3K4me1-marked SE region of the translocation partner 
on chromosome 4, several enhancer regions were identified within the PVT1 gene close to MYC. 
This was confirmed by ATAC-seq, which revealed an open chromatin region matching the 
potential SE cluster area identified by ChIP-seq. The 4C-seq viewpoint at the MYC promoter 
(vp4) confirmed strong cis-interactions of SE region located close to the PVT gene on 
chromosome 8 and the MYC promoter. Additional trans-interactions were observed with the SEs 
on the chromosome 4 segment, which decreased with inverse correlation to the distance  
(vp1-3). 
 
Figure 33: Epigenetic profiling of rearranged regions involving MYC. 
Input normalized read counts of histone marks H3K4me3, H3K4me1, H3K27ac, H3K36me3, 
H3K27me3 and H3K9me3 and ATACseq peaks at the junction between chromosome 4 and 
chromosome 8 in SK-N-AS cells. Interaction profile peaks of potential enhancer elements (VP1-3 
on chr. 4) with the MYC promoter (VP4 on chr. 8) were determined via circular chromatin 
conformation capturing with subsequent sequencing (4C-seq). 
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The rearrangement in cell line SH-SY-5Y revealed that MYC gene was joined with chromosome 
segments close to the EXOC4 gene on chromosome 7 (Figure 27). These chromosome segments 
harbored strong enrichment of SE associated histone marks (H3K27ac, H3K4me1 without 
H3K4me3) and additional minor enrichments of histone marks associated with repressive 
functions (H3K27me3 and H3K9me3) (Figure 34). The MYC locus was enriched for H3K4me3 
and RNA polymerase II (RPB1), indicating transcriptional activation. On the other hand, the 
repressive H3K27me3 mark was enriched at the MYC locus. 4C-seq using a viewpoint at the MYC 
promoter identified weak cis-interactions and strong trans-interactions with SE elements on 
chromosome 7. 
 
Figure 34: Epigenetic profiling of rearranged regions involving MYC. 
Input normalized read counts of histone marks H3K4me3, H3K4me1, H3K27ac, H3K36me3, 
H3K27me3 and H3K9me3 and RNA PolII peaks at the junction between chromosome 7 and 
chromosome 8 in SH-SY5Y cells. Interaction profile peaks of the MYC promoter (VP1 on chr. 8) 
with potential enhancer elements on chr. 7 were determined via circular chromatin 
conformation capturing with subsequent sequencing (4C-seq).  
 
A large cluster of SE associated histone marks (H3K27ac and H3K4me1 in the absence of 
H3K4m3) was detected upstream of the FBXO8 gene on chromosome 4 in CHLA20 cells (Figure 
35). This chromosomal segment was joined with chromosome 8 including the MYC gene. ChIP-
seq peaks of the architectural protein CTCF (CCCTC-Binding Factor) could indicate TAD borders 
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that prevent interactions between neighboring domains. Even though there were several CTCF 
peaks at chromosome 4, potentially disrupting the interaction of MYC promoter and SE 
elements, 4C-seq using MYC promoter viewpoints revealed significant trans-interactions with 
the SE elements on chromosome 4. 
 
Figure 35: Epigenetic profiling of rearranged regions involving MYC. 
Input normalized read counts of histone marks H3K4me3, H3K4me1, H3K27ac, H3K36me3, 
H3K27me3 and H3K9me3 and CTCF peaks at the junction between chromosome 4 and 
chromosome 8 in CHLA20 cells. Interaction profile peaks of the MYC promoter (VP1 on chr. 8) 
with potential enhancer elements on chr. 4 were determined via circular chromatin 
conformation capturing with subsequent sequencing (4C-seq). 
 
The H3K27ac enhancer profiles of the MYC(N)-rearranged cell lines were analyzed towards SEs 
ranking according to the strategy proposed by Hnisz and colleagues (Hnisz et al. 2013) (Figure 
36 and Figure 37).  
The analysis and ranking revealed that the enhancer cluster from Chr. 4 juxtaposed to MYCN in 
NBL-S cells was a SE (Figure 36). HAND2 associated SE region was defined as SE, which was 
outperformed by the SE with the highest signal of H3K27ac assigned to CAMTA1. 
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Figure 36: Ranking of histone mark H3K27ac signal. 
Ranking of histone mark H3K27ac signal (enhancer elements) of NB cell line NBL-S according to 
Hnisz and colleagues (Hnisz et al. 2013). Therefore, enhancer above the cut-off considered as 
SEs are marked as blue circles. HAND2 enhancer close to the breakpoint of MYCN 
rearrangements is highlighted (enlarged letters). SE assignment to HAND2 was supported by 
HAND2 4C-seq interaction data. 
 
The analysis and ranking revealed strong SE clusters which were juxtaposed to MYC in all MYC-
rearranged cell lines (Figure 37). 
The enhancer region downstream of HAND2 in NB69 cells, was ranked third after first ranked SE 
assigned to MAML3 (Figure 37A). The HAND2 SE region juxtaposed to MYC  in SK-N-AS cells was 
defined as a SE although the H3K27ac signal was moderate as compared to other SE regions 
including MYC itself in these cells (Figure 37B). ZMIZ1 was the highest ranked SE. Also the 
HAND2 associated enhancer region in CHLA20 cells was defined as SE. The SE with the highest 
signal of H3K27ac was assigned to GLIS1 (Figure 37C). The highest ranked SE in SH-SY-5Y 
genome-wide was the EXOC4 enhancer which was juxtaposed to the MYC gene (Figure 37D). 
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Figure 37: Ranking of histone mark H3K27ac signal. 
Ranking of histone mark H3K27ac signal (enhancer elements) of NB cell line NB69 (A), SK-N-AS 
(B), CHLA20 (C) and SH-SY5Y (D) according to Hnisz and colleagues (Hnisz et al. 2013). 
Therefore, enhancer above the cut-off considered as SEs are marked as blue circles. HAND2 
enhancer close to the breakpoint of MYC rearrangements is highlighted (enlarged letters). SE 
assignment to HAND2 was supported by HAND2 4C-seq interaction data.  
 
RNAi-mediated knockdown of MYC and its impact on cell viability 
 
Two different siRNAs were used for RNAi-mediated knockdown in four NB cell lines (SK-N-AS, 
SH-EP and GI-ME-N = MNA, NMB = MYCN-amplified). The knockdown experiments and 
subsequent analysis using two different assays were performed in two replicates (Figure 38). 
A B
  A 
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The Celltiter Blue (CTB) viability assay measures the metabolic activity, while the colony 
formation assay after GIEMSA staining was used to assess colony formation capacity (2.2.5 and 
2.2.6). SK-N-AS cells were most sensitive to RNAi-mediated knockdown of MYC using siRNA#2 
in both assays with remaining colonies or viability of 57% and 82%, respectively (Figure 38) 
(74% remaining colonies and 87% remaining viability using siRNA#1). All other tested cell lines 
(SH-EP, GI-ME-N and NMB) persisted almost unaffected with remaining colonies or viability of 
more than 95%. 
  
Figure 38: Impact of RNAi-mediated knockdown targeting MYC. 
Impact of RNAi-mediated knockdown using two different siRNA targeting MYC on colony 
formation capacity (A) and cell viability (B) analyzed using colony formation assay after GIEMSA 
staining or CTB assay, respectively. RNAi-mediated knockdown was performed in four NB cell 
lines (SH-EP, GI-ME-N and SK-N-FI = MNA, NMB = MYCN-amplified). 
 
Taken together, FISH data, of NB cell line NBL-S without MYCN copy number changes and high 
MYCN expression at mRNA and protein level, revealed a rearrangement affecting the MYCN 
gene. Likewise, FISH data of highly MYC expressing (MYC-non amplified) NB cell lines NB69, SK-
N-AS, CHLA20/15 and SH-SY5Y revealed rearrangements affecting chromosome 8 in the vicinity 
of MYC in all cases. In tumors, high MYCN expression was associated with poor clinical outcome. 
ChIP-seq data revealed that highly active SE regions juxtaposed to MYC(N), likely led to 
activated chromatin state and increased MYC(N) expression in these cells. Physical interaction 
of rearranged enhancer elements with the MYC(N) promoter was confirmed by 4C-seq analyses. 
RNAi-induced silencing of MYC revealed increased vulnerability in MYC-rearranged SK-N-AS 
cells as compared to MYC high expressing GI-ME-N and MYCN-amplified NMB, both without MYC 
rearrangement. 
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3.1.3 WGS identified rearrangements affecting oncogenes 
Further on in this study, due to recurring events of rearrangements, a combined comprehensive 
set of WGS (n = 111) and RNA-seq data was screened with the support of EPISTEME analysis for 
further enhancer hijacking events including IGF2BP1 (insulin-like growth factor 2 mRNA-
binding protein 1) and ATOH1 (atonal bHLH transcription factor 1). EPISTEME is a structural 
variation (SV) algorithm similar to the published DELLY, which identifies SVs by integrating 
paired-end and split-reads (Rausch et al. 2012). Further on, IGF2BP1 and ATOH1 
rearrangements, identified in NB tumors via WGS data, were functionally validated in NB cell 
lines or tumors, respectively. 
 
mRNA expression of IGF2BP1 in NB tumors and cell lines 
 
The expression of IGF2BP1 was compared between stage 1-3, stage 4, stage 4s (all MNA) and 
MYCN-amplified NB subgroups (Figure 39A). Stage 4s patients revealed a moderate higher 
expression of IGF2BP1 compared to the other groups. With the exception of several outlier 
cases, IGF2PB1 expression was low in all clinical subgroups. In NB cell lines, there were only few 
cell lines including CHLA90, SK-N-AS or SH-N-SH with almost undetectable IGF2BP1 expression 
(Figure39B). Most cell lines showed an elevated expression starting from an FPKM of 4.5 for SK-
N-BE2(C), FPKM of 29 for IMR32 up to an FPKM of 35 and 45 for LS and NMB, respectively. The 
IGF2BP1 top expressing cell line CLB-GA (FPKM of 86.8) displayed outlier expression of almost 
twice the IGF2BP1 expression levels observed for second ranked NMB cells. In contrast to the 
moderate correlation of higher IGF2BP1 expression with stage 4s MNA tumors, the 12 top 
expressing cell lines had amplified MYCN with the exception of CLB-GA.  
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Figure 39: IGF2BP1 mRNA expression in NB. 
(A)IGF2BP1 mRNA expression according to stage and MYCN status in NB tumors by RNA-seq 
(n=498; log2 scaling). (B) IGF2BP1 mRNA expression in NB cell lines by RNA-seq (n = 32; 
Sample MNA (blue) or MYCN-amplified (red)). 
 
Protein quantification of IGF2BP1 in NB cell lines 
 
Western blot analysis was used to validate IGF2BP1 protein expression in a set of three selected 
NB cell lines representing the complete spectrum of IGF2BP1 gene expression. There was no 
IGF2BP1 protein detectable in MNA cell line SK-N-FI while MYCN-amplified cell line IMR32 
revealed elevated IGF2BP1 protein. The highest gene expression level of MNA cell line CLB-GA 
was validated on the protein level via western blot (Figure 40). 
 
Figure 40: IGF2BP1 protein expression in NB cell lines. 
IGF2BP1 protein expression was quantified by western blotting using ß-actin as a loading 
control in three NB cell lines (CLB-GA and SK-N-FI = MNA, IMR32 = MYCN-amplified)    
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High IGF2BP1 expression was associated with poor survival of NB patients 
 
Increased IGF2BP1 levels significantly correlated with poor EFS as well as OS in a cohort of 498 
primary NBs (Figure 41). EFS probability in IGF2BP1 high expressing cases accounted roughly 
0.6 in contrast to less than 0.85 in patients with low IGF2BP1 expression while OS probability 
resulted in 0.7 and 0.9, respectively.  
 
Figure 41: High IGF2BP1 is associated with poor survival. 
Kaplan-Meier survival probability diagram indicates event-free survival (EFS) (A) and overall 
survival (OS) (B) in respect to IGF2BP1 expression in a set of 498 NB primary tumors. An 
uncorrected (raw p) and corrected (bonf p) p-value for multiple testing according to the 
Bonferroni method is shown. Cut-off values for dichotomization of IGF2BP1 expression were 
estimated by maximally selected log-rank statistics. 
 
FISH identified structural aberrations involving IGF2BP1 
 
The top IGF2BP1 expressing cell line CLB-GA was examined for chromosomal rearrangements 
by FISH using IGF2BP1 locus-specific probes (Figure 42). The composition of derivative (der) of 
chromosome 17, close to the IGF2BP1 locus (pink), was examined for joined segments including 
the genomic region on chromosome 4 close to HAND2 enhancers (green). Two derivatives 
((der(4) and der(3)) containing joined elements of chromosome 17 segments including 
Low (n=74)
High (n=424)
Low (n=110)
High (n=388)
A B 
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IGF2BP1 and chromosome 4 segments including HAND2 were identified. They consisted of one 
translocation event involving only two chromosome partners (t(4;17) and in the case of der(3) a 
complex rearrangement containing parts of chromosome 3, 4, 16 and 17 (t(3;4;16;18)).  
 
Figure 42: Structural aberrations involving IGF2BP1. 
Fluorescence in situ hybridization (FISH) image of NB cell line CLBGA. IGF2BP1 or HAND2 
specific probes were labelled in pink or green, respectively. Analyses were performed by Larissa 
Savelyeva. 
 
Combined ChIP-seq of histone marks, 4C-seq and HiChIP identified interactions of active 
enhancers with IGF2BP1 promoter in rearranged cell line 
 
4C-seq was used to validate the FISH defined IGF2BP1 rearrangements by identifying functional 
and genome wide physical interaction of enhancer regions on chromosome 4, downstream of 
HAND2. Strong trans-interaction signals of enhancer regions at chromosome 4 and the IGF2BP1 
promoter were detected in cell line CLG-GA (Figure 43). 
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Figure 43: Genome-wide interactions involving IGF2BP1. 
Genome-wide interaction profile of regulatory elements on chromosome 4 with the IGF2BP1 
promoter in NB cell line CLB-GA as determined via 4C-seq. Different viewpoints were applied  
(green = HAND2 P300 position 1; orange = HAND2 P300 position 2; grey = HAND2 P300 
position 3) 
 
In addition to the 4C-seq-based validation of trans-interactions, which depends on a viewpoint 
and therefore has a limited capacity, we performed HiChIP allowing all possible interactions in 
CLB-GA cells (Figure 44). Antibodies targeting H3K27ac and SMC1A were used for enrichment. 
Three trans-interactions between chromosome 4 and 17 were detected in CLB-GA, while there 
was no interaction observed in SK-N-AS (Figure 44). The strongest trans-interaction (read count 
of 11 versus 6 and 7) confirmed the by 4C-seq identified interaction of the IGF2BP1 promoter 
and the SE region downstream of HAND2 with a defined breakpoint on chromosome 4 position 
174.455.247-174.460.067 bps (hg19) and on chromosome 17 position 47.072.951-47.075.129 
bps (hg19). 
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Figure 44: Genome-wide interactions involving IGF2BP1. 
Genome-wide circos plot interaction profile of regulatory elements on chromosome 4 with 
chromosome 17 and the IGF2BP1 promoter in NB cell line CLB-GA as determined via HiChIP. 
(H3K27ac and SMC1A antibodies were used for enrichment). 
 
For a more detailed view on the donor- and acceptor regions of IGF2BP1-rearranged cells, all 4C-
seq interactions were examined further at the loci and complemented with ChIP-  and ATAC-seq 
profiles (Figure 45). The acceptor region of IGF2BP1 on chromosome 17 consisted of open 
chromatin and was marked by active histone modifications (H3K4me, H3K4m1, H3K27ac and 
H3K36me). In addition, there was H3K27me3 enrichment at the IGF2BP1 locus and the 
surrounding region, which is associated with repressive functions. A large cluster of H3K27ac 
and H3K4me1 histone marks peaks was detected downstream of the HAND2 locus on 
chromosome 4. Since a H3K4me3 mark was absent, this region could be considered as an 
enhancer. Enhancer viewpoints on chromosome 4 (vp1-vp3) showed cis-interactions close to 
the chosen viewpoint of the HAND2 promoter. The strongest trans-interactions with the 
IGF2BP1 promoter occurred with vp2 and vp1 and the least interaction happened with vp3, 
which was closest to the breakpoint. Using the HAND2 promoter as a viewpoint (vp5), cis-
interactions were identified with the enhancer elements downstream as well as trans-
interactions with the IGF2BP1 promoter on chromosome 17. The 4C-seq tracks of the reciprocal 
assay starting from the IGF2BP promoter (vp4) confirmed trans-interactions with the region of 
interest on chromosome 4. 
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Figure 45: Epigenetic profiling of rearranged regions involving IGF2BP1 locus. 
Input normalized read counts of histone marks (H3K4me3, H3K4me1, H3K27ac, H3K36me3, 
H3K27me3 and H3K9me3) and ATAC-seq peaks at the junction between chromosome 4 and 
chromosome 17 in SK-N-AS cells. Interaction profile peaks of potential enhancer elements (VP1-
3 on chr. 4) as well as the HAND2 promoter (VP 5 on chr. 4) with the IGF2BP1 promoter (VP4 on 
chr. 17) were determined via circular chromatin conformation capturing with subsequent 
sequencing (4C-seq). 
 
The H3K27ac enhancer profile of the IGF2BP1-rearranged cell line CLB-GA was analyzed 
towards SEs ranking according to the strategy proposed by Hnisz and colleagues (Hnisz et al. 
2013). The analysis and ranking revealed that the enhancer cluster assigned to HAND2 from 
Chr.4 juxtaposed to IGF2BP1 indeed was a SE in CLB-GA cells (Figure 46). The SE with the 
highest signal of H3K27ac was assigned to MVK (mevalonate kinase) gene. 
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Figure 46: Ranking of histone mark H3K27ac signal. 
Ranking of histone mark H3K27ac signal (enhancer elements) of NB cell line CLB-GA according 
to Hnisz and colleagues (Hnisz et al. 2013). Therefore, enhancer above the cut-off considered as 
SEs are marked as blue circles. HAND2 enhancer close to the breakpoint of IGF2BP1 
rearrangements is highlighted (enlarged letters). SE assignment to HAND2 was supported by 
HAND2 4C-seq interaction data. 
 
Taken together, using a combined approach of WGS (n = 111) and RNA-seq data including a 
downstream SV algorithm called EPISTEME, an IGF2BP1 rearrangement in one tumor and one 
cell lines was identified. Functionally, high IGF2BP1 expression was associated with poor clinical 
outcome in NB tumors. In addition, FISH data of NB cell line CLB-GA with high IGF2BP1 
expression at mRNA and protein level, revealed a rearrangement affecting the IGF2BP1 gene. 
ChIP-seq data in CLB-GA cell line, revealed highly active SE regions juxtaposed to the IGF2BP1 
gene, likely leading to activated chromatin state and increased IGF2BP1 expression. Physical 
interactions of rearranged enhancer elements with the IGF2BP1 gene promoter were confirmed 
by 4C-seq and genome wide HiChIP studies.  
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mRNA expression of ATOH1 in NB tumors and cell lines 
 
The gene expression of ATOH1 was compared between stage 1-3, stage 4, stage 4s (all MNA) and 
MYCN-amplified NB subgroups (Figure 47A). With the exception of some outlier expressers, 
present in all but the 4S subgroup, no subtype-specific increased gene expression for ATOH1 
was detectable. In NB cell lines, only SK-N-FI (FPKM = 3.9) showed increased ATOH1 expression 
(Figure 47B). Most NB cell lines had an expression level below FPKM of 1 or no ATOH1 
expression at all.  
 
Figure 47: ATOH1 mRNA expression in NB. 
ATOH1 mRNA expression according to stage and MYCN status in NB tumors by RNA-seq (n = 
498; log2 scaling). (B) ATOH1 mRNA expression in NB cell lines by RNA-seq (n = 32). 
 
High ATOH1 expression was associated with poor survival of NB patients 
 
Increased ATOH1 levels significantly correlated with poor EFS as well as OS in a cohort of 498 
primary NBs (Figure 48). EFS probability in ATOH1 high cases accounted roughly 0.55 in 
contrast to less than 0.80 in patients with low ATOH1 expression while OS probability resulted 
in 0.65 and 0.9, respectively.  
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Figure 48: High ATOH1 is associated with poor survival. 
Kaplan-Meier survival probability diagram indicates event-free survival (EFS) (A) and overall 
survival (OS) (B) in respect to ATOH1 expression in a set of 498 NB primary tumors. An 
uncorrected (raw p) and corrected (bonf p) p-value for multiple testing according to the 
Bonferroni method is shown. Cut-off values for dichotomization of ATOH1 expression were 
estimated by maximally selected log-rank statistics. 
 
ChIP-seq of histone marks identified active enhancers  
close to the junctions in rearranged tumor  
 
An intra-chromosomal (chromosome 4) rearrangement of HAND2 to ATOH1 was identified in 
two NB tumors via WGS data. For a more detailed view on the donor- and acceptor region, 
epigenetic profiling was examined performing H3K4me3 and H3K27ac ChIP-seq analysis in one 
of the two NB tumors (Figure 49). The acceptor-side breakpoint on chromosome 4 was located 
approximately 50 kB downstream of the ATOH1 gene locus, which was fused to the donor site at 
the CEP44 and FBXO8 locus on chromosome 4. Upstream of FBXO8 there was a cluster of 
H3K27ac histone modification marks without any active TSS, which would be considered as 
enhancer and stretches towards the HAND2 gene (Figure 49). 
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Figure 49: Epigenetic profiling of rearranged regions involving ATOH1 locus. 
Input normalized read counts of histone marks H3K4me3 and H3K27ac within the rearranged 
genomic regions of NB primary tumor NB-5.  
 
The H3K27ac enhancer profile of the ATOH1-rearranged tumor NB-5 was analyzed towards SE 
ranking according to the strategy proposed by Hnisz and colleagues (Hnisz et al. 2013). The 
ranking revealed strong enhancer regions that were joined to the ATOH1 gene segment (Figure 
37). The donor region of HAND2 associated enhancer was ranked higher than the ATOH1 
assigned enhancer. The SE with the highest signal of H3K27ac was assigned to CELF4 (CUGBP 
elav-like family member 4). 
 
Figure 50: Ranking of histone mark H3K27ac signal. 
Ranking of histone mark H3K27ac signal (enhancer elements) of NB primary tumor NB-5 
according to Hnisz and colleagues (Hnisz et al. 2013). Therefore, enhancer above the cut-off 
considered as SEs are marked as blue circles. HAND2 enhancer close to the breakpoint of ATOH1 
NB-5
 
 NB-  
 Results 81 
rearrangements is highlighted (enlarged letters). SE assignment to HAND2 was supported by 
HAND2 4C-seq interaction data. 
 
Taken together, using a combined approach of WGS (n = 111) and RNA-seq data including a 
downstream SV algorithm called EPISTEME, an ATOH1 rearrangement in two tumors was 
identified. Functionally, high ATOH1 expression was associated with poor clinical outcome in NB 
tumors. In one of the two identified primary tumors, ChIP-seq data revealed highly ranked 
enhancer regions juxtaposing the ATOH1 gene, which likely leads to activated chromatin state 
and increased ATOH1 expression.  
 
3.1.4 HAND2 SE cluster is recurrent donor-region in rearrangement events 
The SE cluster downstream of HAND2 and upstream of the FBXO8 gene locus was described in 
this study as a recurrent donor-region juxtaposing to oncogenes in NB cell lines and tumors, 
likely leading to increased expression of enhancer targets (Figure 51). HAND2 SE 
rearrangements were discovered as enhancer hijacking events joining to the MYCN locus (NB 
cell line NBL-S), MYC locus (NB cell lines NB69, SK-N-AS and CHLA20), IGF2BP1 locus (NB cell 
line CLB-GA), ATOH1 locus (NB primary tumor NB-5) and TERT locus (NB primary tumor NB-4). 
In all cases, ranking of histone mark H3K27ac signal for SE definition (according to Figure 7) 
determined the region between HAND2 and FBXO8 as a strong enhancer region juxtaposed to 
the described oncogenes. Intriguingly, the HAND2 enhancer stretch was ranked as the third 
strongest SE region genome-wide in NB69 cells. 
 
ChIP-seq of histone marks and RNA-seq identified active enhancers 
resulting in increased gene expression in rearranged cell lines 
 
Figure 51 shows the fusion junction of the MYC and HAND2 SE rearrangement in NB cell lines 
CHLA20, NB69 and SK-N-AS. In CHLA20 and NB69 the breakpoint is located 100 and 50 kbps 
apart the MYC gene locus, respectively, while in SK-N-AS it is localized approximately one Mb 
downstream. The mRNA expression of MYC and nearby genes was evaluated in the context of a 
NB cell line set (n = 32) highlighting five cell lines with a rearrangement event (NB69, CHLA29 
and SK-N-AS = MYC rearrangement; CLB-GA = IGF2BP1 rearrangement, NBL-S = MYCN 
rearrangement) (Figure 51 – lower panel). The genes upstream of MYC displayed overall low 
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expression in the cell line cohort. Exceptions were observed for PCAT2 (prostate cancer 
associated transcript 2), CCAT1 (colon cancer associated transcript 1) and POU5F1B (POU class 
5 homeobox 1B) (FPKM = 2.7; 0.4; 0.7) or CASC8 and CASC11 (cancer susceptibility 8 and 11) 
(FPKM = 0.4; 0.5) displaying outlier expression in NGP cells or MHH-NB-11 cells, respectively 
(Figure 51 - lower panel). CHLA20 and NB69 cells, harboring breakpoints close to MYC, 
expressed high levels of MYC in contrast to lower MYC expression in SK-N-AS cells. Expression of 
genes was decreasing, downstream of the MYC locus on chromosome 8, from PVT1 to TMEM75 
and further from CCDC26 to GSDMC (Gasdermin C), which were both excluded on the 
translocated allele by the three MYC-rearranged cell lines. Outlier expression was observed for 
PVT1 (FPKM = 7.6) in MHH-NB-11 cells, for TMEM75 (FPKM = 3.3) in SMS-KCNR cells and for 
CCDC26 and GSDMC (FPKM = 0.7; 0.6) in TR14 cells. Comparing PVT1 expression in the MYC-
rearranged cell lines, identified highest gene expression in CHLA20, which is truncated, followed 
by SK-N-AS cells (FPKM = 4.4; 2.5). In cell line NB69 PVT1 was not included in the translocated 
region and PVT1 displayed the lowest expression (FPKM = 2.1) as compared to the other MYC-
rearranged cell lines (Figure 51). A similar trend was observed for TMEM75, which is located 
further downstream on chromosome 8.  TMEM75 was solely included in the rearrangement of 
SK-N-AS cells (breakpoint on chromosome 8 position 129.902.921 bps; hg19) and displayed a 
slightly increased expression in SK-N-AS (FPKM = 0.6) as compared to CHLA20 and NB69 cells 
(FPKM = both 0.1) (Figure 51).  
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Figure 51: Epigenetic profiling and mRNA expression of genes within rearranged regions. 
Input normalized read counts of histone marks H3K4me3 and H3K27ac at the junction between 
chromosome 4 and chromosome 8 in NB cell lines CHLA20, NB69 and SK-N-AS and mRNA 
expression values (FPKM) of set of NB cell lines (n = 32; highlighted with colors). The area 
shown greyed out is excluded by the newly formed cell line-specific junction between 
chromosome 4 and chromosome 8. In addition mRNA expression of HAND2 and FBXO8 of NB 
cell lines CLB-GA (t(4;17)) and NBL-S (t(2;4)) was colored.  
 
The genes HAND2 and FBXO8, flanking the SE cluster on chromosome 4, were highly expressed 
in the whole set of NB cell lines (Figure 51 – upper panel). Extraordinary high HAND2 
expression was observed in IGF2BP1-rearranged cell line CLB-GA (Figure 51 – lower part). 
According to the CLB-GA 4C-seq interaction data (Figure 45), the HAND2 gene retained in 
contact with the downstream enhancer cluster and joined upstream with chromosome 17 
segment containing the IGF2BP1 gene. In MYCN-rearranged NBL-S cells, HAND2 interacted with 
the strong MYCN enhancer downstream of MYCN (Figure 31). In MYC-rearranged cell lines 
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CHLA20, NB69 and SK-N-AS, HAND2 expression was just average or below with an FPKM 
between 72 up to 87 within the panel of NB cells (Figure 51 – lower panel). 
 
Protein quantification of HAND2 in NB cell lines 
 
HAND2 protein expression was analyzed via western blotting in HAND2-rearranged cell lines 
NB69 and SK-N-AS (MYC-rearranged), NBL-S (MYCN-rearranged) and CLB-GA (IGF2BP1-
rearranged) (Figure 52). Non-rearranged SK-N-FI cells served as a control. NBL-S expressed 
highest levels of HAND2 protein, followed by SK-N-FI. In cell lines CLB-GA, SK-N-AS and NB69 
almost no HAND2 protein was detected. 
 
Figure 52: HAND2 protein expression of NB cells. 
HAND2 protein expression was quantified by western blotting using ß-actin as a loading control 
in a set of MYCN-non amplified (MNA) NB cell lines. 
 
RNAi-mediated knockdown of HAND2 and its impact on cell viability 
 
RNAi-mediated knockdown of HAND2 was performed in two replicates using two different 
siRNAs in HAND2-rearranged NB cell lines SK-N-AS (MNA) and NBL-S (MYCN-amplified). The 
impact on cell growth was analyzed via colony formation assay of GIEMSA stained cells. Both 
siRNAs decreased cell growth in both cell lines (Figure 53). However, HAND2 siRNA#1 had 
stronger impact on reduction of colony formation capacity with less than 70% in NBL-S and 
almost 80% in SK-N-AS cells. In contrast, siRNA#2 decreased colony formation capacity to 90% 
in the case of SK-N-AS and down to 85% in NBL-S cells. 
 
HAND2
ß-Actin
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Figure 53: Impact of RNAi-mediated knockdown targeting HAND2. 
Impact of RNAi-mediated knockdown using two different siRNA targeting HAND2 by subsequent 
colony formation assay analyzed after GIEMSA staining in SK-N-AS and NBL-S cells (both MNA). 
 
Taken together, these data indicated that SE regions between HAND2 and FBXO8 genes were 
recurrently translocated into the proximity of oncogenes like TERT, MYCN, MYC, IGF2BP1 and 
ATOH1 in NB cell lines and primary tumors. Rearrangements of HAND2 SE elements caused 
massive chromatin remodeling and upregulation of adjacent genes. The data indicated that the 
characteristic expression gains of genes in the acquired genomic context and expression losses 
of the genes in the old genomic context were breakpoint dependent (Figure 51).  
 
3.2 Global super enhancer landscape analysis in NB 
To get deeper insights into NB epigenetics and to define the NB SE landscape in vivo, a protocol 
for ChIP-seq of primary tissues was established in the course of the present study. Continuous 
optimization and streamlining of this protocol allowed the analysis of 60 tumor ChIP-seq 
profiles of histone mark H3K27ac. All bioinformatic work of this study was performed in 
collaboration with the department of cancer regulatory genomics at the DKFZ headed by Carl 
Herrmann. 
SEs were defined using the ROSE tool, based on H3K27ac peaks called by MACS2 and only peaks 
lacking H3K4me3 signal or those that are at least 2.5 kbs away from any H3K4me3 peak were 
considered. A tumor-specific SEs consensus list was generated containing all SEs identified in at 
least two samples (n = 1959).  
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3.2.1 Epigenetic profiling defines NB SE landscape 
The ChIP-seq-analyzed cohort consisted of 60 samples of which 49 were primary NBs (including 
3 matched relapsed cases), eight were relapsed cases and three were metastases (all from one 
relapsed case) (Figure 54). The NB primary cohort consisted of 20 MYCN-amplified and 40 MNA 
tumors. According to INSS staging 25 cases were considered as 1-3 and 4s stage, which were 
referred to hereinafter as low- to intermediate-risk due to missing risk information within this 
study. Likewise, 35 stage 4 cases were also referred to as high-risk patients. 52 patients were 
older and 8 patients were younger than 18 months at diagnosis. The NB primary tumor ChIP-seq 
cohort was complemented with ChIP-seq profiles from 26 NB cell lines (MYCN amplified = 10; 
MNA = 14) including two neural crest-derived cell lines provided by Hauser and colleagues 
(Hauser et al. 2012). 
 
Figure 54: NB tumor cohort composition of SE landscape.  
Composition of the NB tumor ChIP-seq cohort (n = 60) in respect MYCN status (MYCN-amplified 
and MNA), stage (INSS), age (age at diagnosis) and relapsed case.  
 
To estimate the expected total amount of SE regions in NB tumors and their coverage in the 60 
tumor cohort, saturation analysis revealed that 130 Mbs of predicted 200 Mbs SE regions (65%) 
were covered (Figure 55A). The model estimated a sample size of more than 900 primary tumor 
samples to cover all expected SE regions. To evaluate the specificity of our NB SE cohort, 
comparison analyses with public available profiles from 24 human primary tissues and 15 cell 
lines were performed (Hnisz et al. 2013). Therefore, the Jaccard index was calculated, which is a 
statistic tool to demonstrate the overlap of sample sets in terms of similarities.  Cross-tissue 
comparison of NB-specific SE regions revealed a maximum overlap of 11% with SEs (Figure 
55B). The tissues overlapping most with NB-specific SE regions were lung, osteoblasts and brain 
tissues. Comparing median expression of the predicted NB-specific SE target genes with public 
available expression profiles from 53 normal and 34 tumor tissues (GTex 
(https://gtexportal.org/home/), TCGA (http://cancergenome.nih.gov/) and TARGET 
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(https://ocg.cancer.gov/programs/target)) identified highest overlap with an external NB data 
set followed by brain and nerve tissue (Figure 55C).  
 
 
Figure 55: Tissue specificity of NB SE cohort. 
(A) SE regions in Mbs covered by the NB tumor ChIP-seq cohort (n = 60) and predicted 
saturation of region coverage computed by Michaelis-Menten model fit. (B) Cross-tissue 
comparison of the NB SE regions with SE regions of other human tissues and cell lines. (C) 
Median expression of the predicted SE target gene cohort compared to publicly available profiles 
from 53 normal (GTex - https://gtexportal.org/home/) and 34 tumor tissues including NB 
(TCGA - http://cancergenome.nih.gov/ and TARGET- https://ocg.cancer.gov/programs/target). 
 
The median cohort-wide signal intensity of the enhancer mark H3K27ac was calculated for all 
primary NB SEs and was used for a genome-wide ranking of NB SEs and their assigned target 
genes (n = 1424 SE target genes) (Figure 57). The identification of SE target genes was 
performed hierarchically, starting by prioritizing physical chromatin interactions that were 
confirmed by experimental HiChIP data in SK-N-AS and KELLY NB cells (hichip; green). 
Assignment of SE target genes was followed by public available HiC profiles (hic; dark purple) 
(Rao et al. 2014), correlation of the H3K27ac signal intensity with gene expression within the 
tumor samples (correlation; orange) and finally, proximity of SE to target gene (Figure 57). 
The SE to target gene assignment strategy was exemplified for CCND1 and MAML3, two top 
ranked candidates, in SK-N-AS and KELLY NB cells and NB primary tumor consensus H3K27ac 
and consensus SEs tracks (Figure 56). In both cell lines, H3K27ac-defined SE regions harbored 
open chromatin as indicated by enrichment of ATAC-seq peaks in these regions. HiChIP 
chromatin interaction data, using H3K27ac and SMC1A for enrichment, confirmed physical 
interactions between the SEs and the CCND1 (cyclin D1) or MAML3 TSS, as indicated by the 
arches (Figure 56). It is of note, that similar enrichment peaks were observed in consensus 
H3K27ac and SE data of primary NB tumors at these locations, further confirming the results 
obtained here. 
A B C 
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Figure 56: Validation of SE to target gene assignment using chromatin conformation data. 
Epigenetic landscape using ATAC-seq and H3K27ac ChIP-seq (H3K27ac) profiles, MACS2-called 
SEs (horizontal bars) and physical interactions (HiChIP chromatin interactions (HiChIP; 
arches)) of two top ranked SE regions (CCND1 and MAML3) in NB cell lines SK-N-AS (purple) 
and CLB-GA (green). A consensus H3K27ac track (turquoise) and consensus SEs (grey 
horizontal bars) including predicted target genes are depicted at the bottom. Promoter regions 
of CCND1 and MAML3 are shaded in grey and gene orientation is given by black arrows. 
 
Among the top ranked SE assigned target genes several previously published and well described 
NB-specific genes like MYCN, ALK, CAMTA1 and CCND1 were identified (Figure 57) (Schwab et 
al. 1983; Molenaar et al. 2003; Caren et al. 2008; Chen et al. 2008; George et al. 2008; Janoueix-
Lerosey et al. 2008; Mosse et al. 2008; Henrich et al. 2011). Further genes previously associated 
with NB SEs, including MAML3, GATA3, LMO1, HAND2 and PHOX2B were highly ranked on the 
extended SE list, which further confirms the robustness and reproducibility of the underlying 
epigenetic data (Figure 57 - upper panel) (Oldridge et al. 2015; Boeva et al. 2017; van Groningen 
et al. 2017). 
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Figure 57: Ranking of target gene assigned SEs in NB tumor cohort. 
Ranked boxplots of top 50 SEs in NB primary tumors derived from H3K27ac ChIP-seq profiles  
(n = 60; bottom panel). Whiskers denote the interval within 1.5 times the interquartile range 
(box edges) of the median (center line). Target genes were predicted hierarchically by (i) 
HiChIP interactions (hichip; green), (ii) public Hi-C profiles (hic; purple) (Rao et al. 2014) (iii) 
H3K27ac signal versus expression correlation (correlation; orange) or (iv) SE target gene 
proximity (closest). An activity map of the whole set of 1424 SEs is given in the top panel, 
highlighting genes previously assigned to NB SEs. 
 
3.2.2 SE defined NB epigenetic subtypes 
H3K4me3-substracted H3K27ac ChIP-seq profiles of primary tumors were further used to 
define the SE landscape of NB by applying non-negative matrix factorization (NMF) analysis 
(Figure 58). NMF was described by Huebschmann and colleagues in 2017 and can be used to 
subdivide higher-dimensional datasets into several lower-dimensional signatures 
(Huebschmann et al. 2017). Each individual sample (tumor or cell line H3K27ac ChIP-seq 
profiles) that was included in the data set, received an exposure value of each signature. Samples 
with similar exposure patterns composed a subset of samples. For the tumor NMF, four 
signatures produced the most stable factorization and subdivision of the tumor cohort (Figure 
58). According to the clinical annotation (Figure 54; MYCN status, INSS stage, age and relapse) 
MYCN signature defined a subset of MYCN-amplified samples (MYCN). MNA-LR and MNA-HR 
were both composed of MNA samples, which were associated with low-risk disease (MNA-LR) 
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or high-risk disease (MNA-HR), respectively. Many samples showed exposure to more than one 
signature, which impeded a clear signature assignment for some cases. The remaining signature 
revealed no clear enrichment for one of the clinical annotations. Due to missing clinico-biological 
parameters describing the subgroup that was formed by the remaining signature, gene set 
enrichment analysis (GSEA) for gene sets defined by all four signatures SEs was performed 
(Figure 58). The GSEA revealed significant enrichment of epithelial mesenchymal transition 
(EMT) terms and cell migration for this mesenchymal (Mes) signature, which was not the case 
for all other signatures. MNA-HR signature was enriched for gene sets associated with 
transcriptional regulation and signaling while MNA-LR and MYCN signatures showed no 
significant enrichment. 
 
Figure 58: NMF analysis of NB tumors.  
Non-negative matrix factorization (NMF) analysis of NB tumors (n = 60) based on H3K27ac 
histone mark ChIP-seq signal at NB SEs leading to four signatures (MYCN, Mes, MNA-LR and 
MNA-HR). Degree of exposure from high to low is depicted by a color gradient from yellow to 
blue. Information on clinico-biological parameters of the tumors is given as previously described 
(Figure 54) regarding MYCN status (MYCN amplified = black; MNA = grey), stage (INSS stage 1-
3 and 4s (grey) or 4 (black)), age (age at diagnosis or 18 months (black) or younger 18 months 
(grey)) and relapsed case (yes (black) or no (grey)). Gene set enrichment analysis (GSEA) of the 
predicted SE target genes defining the NMF signatures are given on the right. GSEA was 
performed using the MSigDB (https://software.broadinstitute.org/gsea/msigdb/). 
 
For the cell lines, three NMF signatures produced the most stable factorization and subdivision 
of the cohort (Figure 59). With the exception of MYCN-amplified SMS-KCNR, which was assigned 
 Results 91 
to MNA signature, all MYCN-amplified cell lines were assigned to MYCN signature, defining this 
signature as MYCN-amplified (MYCN). The Mes signature revealed high exposure values for all 
contained samples and consisted exclusively of MNA samples. With the exception of SMS-KCNR, 
MNA signature displayed highest exposure values for MNA samples. NB cell lines are exclusively 
derived from high-risk tumors so that, in analogy to tumor MNA-HR, signature was termed cell 
line MNA signature. To identify specific subtype characteristics of the three cell line NMF 
signatures, GSEA was performed (Figure 59). Similar to GSEA of tumor NMF, the non-clinico-
biologically defined Mes cell line signature was significantly enriched for terms associated with 
EMT and cell migration and minor enrichment for the two other gene sets. Both signatures, 
MYCN and MNA were enriched for terms linked to transcriptional regulation and signalling 
while MNA showed additionally enrichment for gene sets associated with neuronal and 
developmental processes. 
 
Figure 59: NMF analysis of NB cell lines. 
Non-negative matrix factorization (NMF) analysis of the NB cell lines (n = 25) based on 
H3K27ac histone mark ChIP-seq signal at NB SEs leading to three signatures (MYCN, Mes and 
MNA). Information is given on the MYCN status (MYCN amplified (black) and MNA (grey)). Gene 
set enrichment analysis (GSEA) of the predicted SE target genes defining the NMF signatures are 
given on the right. GSEA was performed using the MSigDB 
(https://software.broadinstitute.org/gsea/msigdb/). 
 
Tumor and cell line H3K27ac histone mark ChIP-seq data were combined and analyzed by t-
distributed stochastic neighbor embedding (t-SNE) to validate NMF-defined subgrouping 
(Figure 60). Another aspect was to assay for stable subgroups, which would be reflected by 
defined clusters made up of tumors and cell lines. Intriguingly, tumors and cell lines previously 
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assigned to a Mes signature by NMF and GSEA (Mes in Figure 58 and Figure 59) were arranged 
together in a cluster and distinct from all other samples. The mesenchymal tumor and cell line 
samples mixed cluster was the only intermixed cluster in the t-SNE analysis. Cell line samples of 
MYCN and MNA NMF signature (Figure 58) grouped close together and did not mix with tumor 
samples. Similarly, tumor samples of MYCN, MNA-HR and MNA-LR NMF signature were 
arranged without obvious pattern and without mixing with cell line samples. 
 
 
Figure 60: t-SNE analysis of NB tumors and cell lines. 
T-distributed stochastic neighbor embedding (t-SNE) analysis of NB primary tumors (n = 60; 
triangles) and NB cell lines (n = 26; squares) based on H3K27ac histone mark ChIP-seq signal. 
NB tumor and cell line samples were separated in MYCN-amplified (MYCN) and MNA cases and 
colored to NMF signature two exposures (Mesenchymal Score). 
 
60 NB tumors of the ChIP-seq cohort allowed the identification of a novel epigenetically-defined 
four NB subtypes including a new one with mesenchymal characteristics (Figure 58). To further 
extent the cohort, the set of assigned NB SE target genes (as described for Figure 56 and Figure 
58) was used to perform NMF analysis based on expression in an available RNA-seq cohort of 
598 NB tumors (Figure 61). For both tumor NMFs based on ChIP-seq and RNA-seq data, four 
signatures produced the most stable factorization and subdivision of the tumor cohort. 
According to the clinical annotation (Figure 54; MYCN status, INSS stage, age and relapse) the 
MYCN RNA-seq NMF signature defined a subset of MYCN-amplified samples. The Mes signature 
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revealed enrichment for relapsed cases, while MNA-LR signature defined almost exclusively 
MNA cases with low-risk features. In contrast to this, MNA-HR signature was enriched for high-
risk samples and contained only 2 (of 107) MYCN amplified-samples. As described for the 
results of tumor ChIP-seq NMF (Figure 58), many samples in the tumor RNA-seq NMF were 
exposed to more than one signature. Similar to GSEA of tumor and cell line ChIP-seq NMF, the 
non-clinico-biologically defined Mes RNA-seq signature was significantly enriched for terms 
associated with EMT and cell migration and for transcriptional regulation and signaling in the 
RNA-seq cohort (Figure 61). MNA-LR signature was significantly enriched for gene sets 
associated with transcriptional regulation and signaling as well as neuronal and developmental 
processes while MNA-HR and MYCN signatures showed no significant enrichment. 
 
Figure 61: Extended NMF analysis of NB tumors based on RNA-seq data. 
Non-negative matrix factorization (NMF) analysis of NB tumors (n = 589) based on predicted 
NB primary tumor SE target gene expression defined by RNA-seq leading to four signatures 
(MYCN, Mes, MNA-LR and MNA-HR). Information on clinico-biological parameters of the tumors 
is given as previously described (Figure 54) regarding MYCN status (MYCN amplified (black) 
and MNA (grey)), stage (INSS stage 1-3 and 4s (grey) or 4 (black)), age (age at diagnosis or 18 
months (black) or younger 18 months (grey)) and relapsed case (yes (black) or no (grey)). Gene 
set enrichment analysis (GSEA) of the predicted SE target genes defining the NMF signatures are 
given on the right. GSEA was performed using the MSigDB 
(https://software.broadinstitute.org/gsea/msigdb/). 
 
To compare ChIP-seq- and RNA-seq-defined NMF signatures, signature exposure values of 
tumors represented in both cohorts were plotted in scatter plots (Figure 62). Samples with high 
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exposure to MYCN signature and Mes in the ChIP-seq NMF also displayed high exposure to the 
respective signature in the RNA-seq NMF, thus confirming the robustness of these signatures. In 
contrast to this, LR-MNA signature and HR-MNA showed discrepancies between the two 
datasets when samples with high exposure in the ChIP-seq based NMF had low exposure in the 
RNA-seq based NMF and vice versa. 
 
 
Figure 62: Scatterplots of NMF-based signatures for NB tumors. 
Scatterplots of NMF-based signature exposure values for NB primary tumors present in both, the 
ChIP-seq (SE signal signatures, from Figure 58) and the RNA-seq cohort (SE target genes 
expression signatures, from Figure 61).   
 
All four NB subtypes defined by NMF of NB tumors SEs were analyzed for association with the 
clinical characteristics high-risk and relapsed disease (Figure 63). Therefore, Recovery analyses 
were performed, revealing strong association of relapse disease with tumors highly exposed to 
the Mes as well as the MYCN signature and strong association of the MYCN signature with high-
risk disease. 
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Figure 63: Recovery analysis of clinical variables of NMF-based signatures for NB tumors. 
Recovery analysis of clinical variables of relapse (A) and high-risk disease (B) in the SE-defined 
subgroups. The x-axis depicts the samples of the extended NB RNA-seq NMF cohort (n = 589) 
sorted by descending exposure to the respective signature. On the y-axis the percent recovery of 
the considered clinical variable is given within the respective fraction of samples. Curve 
progression above or below the diagonal represent positive or negative association of the 
particular signature with the clinical variable, respectively (Sig = signature). 
 
3.2.3 Core regulatory circuitries of NB subtypes 
NMF analysis of the NB tumor SE landscape revealed distinct epigenetically defined NB 
subtypes, which were also manifested through the expression of the SE assigned target genes. 
We hypothesized that specific sets of master regulator or a core regulatory circuitry (CRC) is 
driving and regulating each individual subtype and making it distinct from one another. NB 
subtype-specific CRCs were explored by a bioinformatic approach. 
For the reconstruction of NB-specific gene regulatory network of transcription factors (TFs) and 
their target genes, the ARACNE (Algorithm for the Reconstruction of Accurate Cellular 
Networks) algorithm was used. The ARACNE or improved ARACNE-AP (Adaptive Partitioning 
strategy) algorithm requires gene expression data as an input and omits interactions due to co-
expression (Margolin et al. 2006; Lachmann et al. 2016). The method estimated an NB regulome 
consisting of 239,499 significant TF-gene interactions using expression profiles of the extended 
NB RNA-seq cohort (n = 589) and a list of human specific TFs (n = 1471) from the FANTOM5 
(Functional ANnoTation Of the Mammalian genome) project (Forrest et al. 2014) 
(http://fantom.gsc.riken.jp/). 
As regulatory elements, like SEs that recruit and build up transcription factor networks and are 
thereby involved in aberrant gene regulation in human cancers we tried to identify these 
relevant regulators, using the concept of CRCs (Saint-Andre et al. 2016). CRCs are defined as 
regulating their own and the expression of other CRC TFs and consequently forming an 
interconnected auto-regulatory loop. Therefore, NB subtype-specific CRCs were determined by 
A B 
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integrating the NB regulome data and the subtype-specific transcription factor activities defined 
by VIPER as well as the previously published CRCmapper (Saint-Andre et al. 2016). VIPER infers 
transcription factor activity by analysing RNA-seq gene expression data of the transcription 
factors target genes (Alvarez et al. 2016). 
The CRC TFs in the network were established and displayed colour coded and clustered 
according to their observed frequency of CRCs in tumors (n = 60) and cell lines (n = 25) 
assigned to each per sample and per signature as well as TF activity analyzed by VIPER 
algorithm, which was assigned to the respective CRC (Figure 64).  A set of 75 NB CRC TFs was 
identified, based on the criteria of being present in at least 5% of tumor samples as well as in the 
ARACNE defined NB regulome. All 24 cluster one CRC TFs were observed in the Mes cell line 
subtype but only 14 of them in the Mes tumor subtype. Some of the CRC TFs including RARB 
(retinoic acid receptor beta), KLF4 (kruppel like factor 4) and RUNX2 (runt related transcription 
factor 2) were exclusively observed in the Mes subtype of cell lines and tumors. All 24 cluster 
one CRC TFs were significantly enriched for mesenchymal (Mes) TF activity. 
 
Figure 64: Definition of NB-specific CRCs. 
Definition of NB-specific core regulatory circuitry (CRC) clusters by integration of ARACNE 
regulome analysis and identification of subtype-specific transcription factor activity via VIPER’s 
regulon analysis. CRC TF abundance in the networks of the respective samples is colour coded 
ascending from white (not present) to purple (observed in up to 100%) for NB cell lines (n = 
24) and NB tumors (n = 60). NB cell line and tumor cohorts were subdivided in three or four 
subgroups, respectively based on the signatures derived from NMF (Huebschmann et al. 2017). 
MNA, mesenchymal (Mes) and MYCN-amplified high-risk (HR) and low-risk (LR) (MNA in NB 
cell lines) as previously defined by NMF. 
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Cluster two CRC TFs were mainly observed in both MNA subtypes of tumors and Mes cell line 
signature, while MYCN signature for both and Mes subtype exclusively in tumor revealed low 
and no presents at all, respectively (Figure 64). TF activities of the 13 CRC TFs within cluster 
two were enriched for Mes and both MNA (HR and LR) tumor subtypes, while TF activity for 
MYCN subtypes was low. In cluster three and five neither any increased abundance of CRC TFs of 
any subtype nor obvious enrichment for TF activity were observed. Cluster four CRC TF MYCN 
was increased and almost exclusively observed within MYCN subtype of cell lines and tumors. 
CRC TFs were enriched for MYCN TF activity in tumors.  
Validation of the CRC networks of SE-driven TFs was exemplified in SK-N-AS cells (mes subtype) 
by exploring the epigenetic status of three CRC candidates loci FOSL2 (FOS like 2), MYC and 
SMAD3 (Figure 65). The chromatin status at these loci was analyzed by ATAC-seq, SE 
identification by H3K27ac ChIP-seq and predicted CRC TF binding by PIQ algorithm, which uses 
DNase I hypersensitivity profiles for TF binding site prediction (Sherwood et al. 2014). SE 
regions assigned to FOSL2, MYC and SMAD3 harbored open chromatin structure and revealed 
binding motifs for their own and the respective two other CRC TFs. 
 
Figure 65: Validation of exemplar CRC TFs using chromatin conformation data. 
Chromatin status and conformation at SE elements (FOSL2 - SE1028, MYC - SE1838 and SMAD3 
- SE642) assigned to the three active CRC transcription factors FOSL2 (A), MYC (B) and SMAD3 
(C) in SK-N-AS cells. H3K27ac ChIP-seq (top lane), ATAC-seq (second lane) and motif prediction 
analysis by protein interaction quantitation (PIQ) were performed for validation of innate and 
reciprocal transcription factor binding. 
 
RNAi-induced knockdown of CRC TFs and its impact on viability and gene expression 
 
For functional validation of the NB CRCs, RNAi-induced knockdown of a set of CRC TFs (n = 28) 
was performed in GI-ME-N (Mes subtype) and NMB (MYCN subtype) cells (Figure 66A). 
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Knockdown (KD) sensitivity was evaluated by a colony formation assay using GIEMSA staining 
and transcription factor activity of the CRC TFs in the Mes subtypes was displayed. RNAi-
induced knockdown of CRC TFs NFKB2 (nuclear factor kappa B subunit 2), RUNX1 or RARB 
from cluster one, which was enriched for the Mes subtype and Mes TF activity (Figure 64), had 
strong effect on KD sensitivity in mesenchymal GI-ME-N cells. In contrast, RNAi-induced 
knockdown of CRC TFs from other clusters, including GATA2 (cluster two), PHOX2B (cluster 
five) or SOX11 (cluster four) revealed a higher impact on KD sensitivity in NMB cells. To identify 
the impact of RNAi-induced knockdown of a set of CRC TFs, the expression profiles after Mes-
specific RARB, ETS1 or SMAD3 RNAi were resolved by RNA-seq in Mes SH-EP cells (Figure 66B). 
RNAi-induced knockdown of RARB led to downregulation of EMT, KRAS signalling as well as 
TNF signalling via NFKB2. In contrast, MYC target genes were upregulated. ETS1 knockdown 
caused downregulation of gene sets involved in cell cycle regulation (i.e. mitotic spindle 
regulators, E2F targets as well as G2M checkpoint genes). Finally, RNAi-induced knockdown of 
SMAD3 decreased the expression of oxidative phosphorylation and fatty acid metabolism gene 
sets and furthermore, TNF signalling via NFKB2 was significantly upregulated. 
 
Figure 66: Functional validation via RNAi-induced knockdown of exemplar CRC TFs. 
(A) Log2 ratio of RNAi-induced knockdown (KD) sensitivity (x-axis) in GI-ME-N versus NMB for 
a subset of CRC TFs (n = 28) in dependence of Mes transcription factor activity (y-axis). KD 
sensitivity was defined by colony formation assay using GIEMSA staining and subsequent colony 
count via ImageJ version 1.47 using the ColonyArea plugin. In addition, KD sensitivity was 
depicted by colour code (light yellow = high sensitivity in NMB; dark red = high sensitivity in 
GI-ME-N). (B) Expression changes (red = decrease; blue = increase) of GSEA after RNAi-induced 
knockdown of RARB, ETS1 or SMAD3 in SH-EP (Mes subtype) cells defined by RNA-seq. GSEA 
was performed using the MSigDB (https://software.broadinstitute.org/gsea/msigdb/). 
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For validation of RNAi-induced knockdown efficiency prior to RNA-seq, protein levels of the 
respective genes were quantified using western blotting (Figure 67). RNAi-induced knockdown 
of ETS1 caused protein reduction down to 9.6% and 5.7% remaining protein for siRNA one and 
two, respectively. After SMAD3 knockdown 6.7% (siRNA#1) and 2.6% (siRNA#2) protein was 
left and RNAi-induced knockdown of RARB reduced the protein level to 32.5% (siRNA#1) and 
93.8% (siRNA#2). For each of the targets, the siRNA causing the most efficient gene knockdown 
and protein reduction was used for subsequent functional experiments.  
 
Figure 67: Validation of RNAi-induced knockdown of exemplar CRC TFs. 
Validation of RNAi-induced knockdown of (A) ETS1 (#1 = 9.6% and #2 = 5.7% protein left) , 
(B) SMAD3 (#1 = 6.7% and #2 = 2.6% protein left) and (C) RARB (#1 = 32.5% and #2 = 93.8% 
protein left) in SH-EP (Mes subtype) cells by protein quantification (Western blotting). Protein 
quantification after RNAi-induced knockdown was performed via ImageJ by normalization using 
the loading control and the untreated control. 
 
The four NMF-defined NB subtypes exposed clear differences in SEs and their predicted target 
gene activities, which allowed the identification of a network of master transcription factors that 
likely drive expression programs associated with distinct clinical associations. 
To further define the epigenetic regulation, the genome-wide physical interactions of CLB-GA 
(MNA subtype) and SK-N-AS (Mes subtype) cells were analyzed by HiChIP chromatin capturing 
assay (Figure 68A). In SK-N-AS cells, the fraction of interactions with SEs assigned to the Mes 
signature was three times higher as compared to CLB-GA cells (SK-N-AS = 64%; CLB-GA = 
20.3%). In contrast, CLB-GA cells harbored more than twice the amount of interactions with SEs 
associated with the non-mesenchymal (nonMes) signature as compared to SK-N-AS (CLB-GA = 
79.7%; SK-N-AS = 36%). Comparing the chromatin status and accessibility in KELLY (MYCN 
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subtype) and SK-N-AS (Mes subtype) via ATAC-seq in a foot-printing analysis revealed mainly 
subtype-specific assigned CRC TFs in the corresponding cell line (Figure 68B). This foot-printing 
analysis was positively correlated with VIPER defined TF activity within 498 NB primary 
tumors. CRC TFs with a Mes TF activity like JUN, FOSL2 or MAFK (MAF BZIP transcription factor 
K) were associated with highly accessible chromatin in mesenchymal SK-N-AS cells, while TBX2 
(T-box transcription factor 2), MEIS2 (Meis homeobox 2) or ZEB1 (zinc finger E-Box binding 
homeobox 1) revealed higher accessibility in non-mesenchymal KELLY cells (Figure 68B). One 
exception from this trend was observed for CRC TF SMAD3 with high Mes TF activity and higher 
chromatin accessibility in KELLY cells as compared to SK-N-AS. 
 
 
Figure 68: Interactions and chromatin conformation of NB subgroup and specific CRC TFs. 
 (A) Chromatin interaction plot depicting fractions of interactions with SE regions identified as 
Mes or nonMes in CLB-CA (green; MNA subtype) and SK-N-AS (purple; Mes subtype) cells as 
determined by genome wide HiChIP analysis using H3K27ac and SMC1A antibodies for 
enrichment. (B) Foot-printing analysis of chromatin accessibility was performed by ATAC-seq in 
KELLY (MYCN subtype) and SK-N-AS (Mes subtype) cells. Coloring of the samples was done 
according to VIPER defined Mes TF activity (green – high in Mes; purple – high in nonMes). 
 
3.2.4 Functional and clinical relevance of NB epigenetic subtypes 
Distinct master transcription factors and their networks driving each individual of the four NMF-
defined NB subtypes were identified. In the following section, the aim was to analyze the 
epigenetic subtype signatures using functional models to evaluate their applicability for 
potential therapy targets. 
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Retinoic acid (RA) receptor RARB, identified as a mesenchymal CRC TF in this work, was 
reported to reduce RA signaling and suppresses EMT-transition in basal-like breast cancer in 
mice (Liu and Giguere 2014). Since RA receptors, including RARB, are the downstream 
mediators of RA, the effect of all-trans retinoic acid (ATRA) on Mes signature was analyzed. 
ATRA is known as an inducer of differentiation of malignant cells, used in therapy for patients 
with low- and intermediate-risk NB (Matthay et al. 1999). ChIP-seq of the enhancer associated 
histone mark H3K27ac was performed at two time points of ATRA treatment in BE(2)-C and 
KELLY cells (both MYCN subtype). Exposure values to each NMF signature obtained from cell 
line ChIP-seq were computed for these experiments (Figure 69). These analyses, called radar 
plots, visualize exposure of different samples to the NMF-defined subtypes representing highest 
exposure (100% of indicated signature) on the outer and lowest (0% of indicated signature) on 
the inner circle (Figure 69).  
In BE(2)-C cells, a clear shift towards increasing exposure values of Mes signature was observed 
upon ATRA treatment as compared to controls (Figure 69A). Mes exposure values, starting from 
44 in the control, increased upon treatment in a time-dependent manner to 1081 after 24 h up 
to almost 2231 after 144 h of ATRA treatment. BE(2)-C exposure values for MNA were slightly 
increased (4847 (EtOH control) to 5006) or for MYCN signature highly decreased (3506 (EtOH 
control) to 113) after 144 h of ATRA treatment. In KELLY cells no shift of exposure values was 
observed for the Mes or MYCN signature (Figure 69B). At the 24 h time point of ATRA treatment 
MNA signature was slightly increased (1243 (EtOH control) to 1935)) but decreased again after 
144 h compared to the EtOH control (1243 (EtOH control) to 818). 
 
Figure 69: ATRA-induced shifts of NB subtype exposure values of ChIP-seq data. 
Radar plots visualizing exposure changes to the NMF-defined subtypes MYCN, Mes, MNA (red 
lines) obtained from cell line RNA-seq upon ATRA treatment in BE(2)-C (A) and KELLY (B) 
(both MYCN subtype) cells based on ChIP-seq H3K27ac data. ATRA- or EtOH- (pink) treated 
cells were harvested at the indicated time points as replicates for ChIP-seq 24 h (purple) and 
144 h (green) after ATRA treatment. 
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In analogy to the ChIP-seq analysis, RNA-seq time course data of ATRA-treated BE(2)-C and 
KELLY cells were used to compute exposure values to each NMF signature obtained from cell 
line RNA-seq data (Figure 70). ATRA treatment resulted in decreased MYCN signature exposure 
and increased Mes signature exposure in BE(2)-C cells, while exposure to the MNA signature 
remained unchanged compared to the EtOH control (Figure 70A). Both changes in signature 
exposure occurred in a time-dependent manner up to 144 h upon ATRA treatment. In KELLY 
cells no apparent changes in any of the three signature exposures were detected (Figure 70B). 
Since NB cell lines are exclusively derived from high-risk tumors, ChIP-seq NMF of cell lines is 
incapable of resolving high-risk and low-risk MNA tumor signatures. To circumvent this 
limitation, the RNA-seq time course data of ATRA-treated BE(2)-C and KELLY cells was used to 
compute exposure values for the tumor derived LR- and HR-MNA NMF signature (Figure 70C). 
BE(2)-C cells showed an increase of LR-MNA tumor signature exposure in a time-dependent 
manner as compared to the EtOH control while no changes were observed in the exposure to the 
HR-MNA tumor signature. The replicates for KELLY showed no consistent or directed exposure 
shift of any type. 
 
 
Figure 70: ATRA-induced shifts of NB subtype exposure values of RNA-seq data. 
RNA-seq data of ATRA-treated BE(2)-C (A) and KELLY (B (both MYCN subtype) cells was used 
to compute exposure values to each NMF signature (MYCN, Mes and MNA) obtained from cell 
line RNA-seq. (C) RNA-seq data of ATRA-treated BE(2)-C and KELLY (both MYCN subtype) cells 
was used to compute exposure values to tumor MNA-LR and MNA-HR NMF signatures obtained 
from tumor RNA-seq. ATRA (continuous line) or EtOH- control (dotted line) treated cells were 
harvested at the indicated time points (0 h, 1 h, 3 h, 6 h, 12 h, 24 h, 48 h, 96 h and 144 h after 
ATRA treatment) as replicates for RNA-seq analysis. 
 
As strong clinical association of relapsed disease with tumors exposed to the Mes signature was 
revealed already (Figure 63), RNA-seq data of three primary tumors and matching relapsed 
samples was used to compute exposure values to each NMF signature obtained from tumor 
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RNA-seq. All three patient samples revealed a shift towards a stronger Mes signature exposure 
in the relapsed as compared to the primary tumor sample (Figure 71). Furthermore, slight 
decrease of exposure to the HR-MNA signature and minor increase of exposure to the MYCN 
signature was observed after relapse in all three cases. Exposure to the LR-MNA signature was 
slightly decreased upon relapse in the first patient while an increase of exposure to this 
signature was observed upon relapse in patients two and three. The sample from a metastasis 
during second relapse (pink) of patient one revealed the same but less pronounced trend in 
shifting signature exposure values.  
 
Figure 71: NB subtype exposure values of relapsed patients. 
Radar plots visualizing exposure changes to the NMF-defined subtypes MYCN, Mes, MNA-LR and 
MNA-HR obtained from tumor RNA-seq of primary tumors (purple) to matched relapsed 
samples (primary site = green; metastatic site = pink) based on RNA-seq data. 
 
Taken together, these data indicate that samples from relapsed tumors showed higher exposure 
to the tumor ChIP-seq NMF-derived Mes signature as compared to matched primary samples, 
regardless of whether the primary or metastatic site at relapse was analyzed. In addition, ATRA 
treatment caused a time-dependent shift towards the Mes signature. Given this dynamic shifts of 
the Mes signature, we wanted to search for an involved pathway or underlying mechanism of 
this Mes signature. First evidence of JUN and FOSL2 being associated with highly accessible 
chromatin in mesenchymal SK-N-AS cells (Figure 68B) suggested involvement of JUN/FOS 
associated genes with the Mes signature. An enrichment of activating RAS-MAPK pathway gene 
mutations in relapsed NBs was already described (Eleveld et al. 2015). Our results pointed 
towards a possible involvement of RAS associated genes with the Mes signature. Therefore, the 
Mes signature was analyzed for enrichment of JUN/FOS or RAS pathway signature or target 
genes. A strong positive correlation was identified for the RAS signature (ρ=0.83) and JUN/FOS 
target genes ((ρ=0.72) (Figure 72). 
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Figure 72: Pathway gene correlation of Mes signature. 
Correlation analysis of (A) RAS signature (public available gene expression signature of RAS 
pathway (Loboda et al. 2010)) or (B) JUN/FOS (based on previously defined ARACNE regulom 
including AP-1 transcription factor subunits: FOS, FOSB, FOSL1, FOSL2, JUN, JUNB, JUND). 
Median expression (log2FPKM) of a set of genes (signature) representing RAS or JUN/FOS 
activation (x-axis) versus patients’ mesenchymal exposure derived from ChIP-seq NMF. 
 
Intriguingly, gene expression of RAS signature genes was strongly increased in relapsed samples 
as RAS signature genes were enriched in the top 25% of expressed genes in relapsed samples 
(Figure 73A). In primary samples, only a few RAS signature genes showed increased expression. 
Similarly, JUN/FOS target genes with high expression were enriched in relapsed samples, 
particularly in the top 25% of expressed genes (Figure 73B). In contrast, in the top 25% 
expressed genes in primary tumors the JUN/FOS target genes were represented to a much lesser 
extent.  
 
Figure 73: Pathway gene enrichment in primary and relapsed cases. 
Enrichment analysis of (A) RAS signature target genes (public available gene expression 
signature of RAS pathway (Loboda et al. 2010)) or (B) JUN/FOS target genes (based on 
previously defined ARACNE regulom including FOS, FOSB, FOSL1, FOSL2, JUN, JUNB, JUND) in 
differentially expressed genes between primary and relapsed tumor samples. 
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NB relapsed samples showed increase in Mes signature exposure as well as increased 
expression of RAS signature genes and JUN/FOS target genes in contrast to matched primary 
samples. To deepen the insight into regulatory networks governing gene expression of primary 
and relapsed tumors, the enrichment of NB-specific CRC TF target genes defined in the present 
study (3.2.3) in primary versus relapsed NB samples was analyzed (Figure 74). In line with 
previously described results of the present study, target genes of CRC TFs that harbored a high 
Mes TF activity were accumulated and highly expressed in relapsed samples. Among those CRC 
TFs IRF8 (interferon regulatory factor 8), RUNX1, FOXL1 (forkhead box L1) and NFKB2 
displayed highest expression and normalized enrichment score in relapsed cases in contrast to 
primary samples. On the other hand, target genes of CRC TFs that occupied a high nonMes TF 
activity were accumulated and highly expressed in primary samples. Here, PBX1 (PBX 
homeobox 1) and SREBF2 (sterol regulatory element binding transcription factor 2) revealed 
highest expression and normalized enrichment score in primary in contrast to relapsed samples. 
It is of note, that most target genes of NB CRC TFs showed a clear assignment to either primary 
or relapsed samples according to enrichment score and expression level. Only a few genes 
including MYC or TCF4 (transcription factor 4) were expressed comparably low and showed low 
enrichment values. 
 
Figure 74: CRC TF enrichment in primary and relapsed cases. 
Normalized enrichment score of NB-specific core regulatory circuitry (CRC) transcription factor 
(TF) target genes in primary or relapsed NB samples arranged by their gene expression  
(-log10FDR). Each CRC TF is coloured according to VIPER defined mesenchymal TF activity  
(green – high in Mes; purple – high in nonMes). 
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4. Discussion 
4.1 Global enhancer hijacking landscape in NB 
Shedding light on the global landscape of oncogene activating enhancer hijacking events in NB 
was a central task of this work. Regulatory elements, like SEs that recruit and build up 
transcription factor complexes and thereby regulate gene expression play an essential role in 
aberrant function of many human cancers. Several mechanisms of enhancer malfunction that 
lead to cancer development due to altered oncogene expression are known. These include 
mutations, insertions or deletions within enhancer elements that change transcription factor 
binding sites as well as their de novo formation (Demichelis et al. 2012; Huang et al. 2014; 
Mansour et al. 2014; Oldridge et al. 2015). The principle of alternative oncogene activation 
through translocation of enhancers in the proximity of oncogenes was described in several 
cancer types and is referred to as enhancer-hijacking (Taub et al. 1982; Bakhshi et al. 1987; 
Groschel et al. 2014; Northcott et al. 2014). The present study reports enhancer-hijacking for 
several NB-specific oncogenes including TERT, MYCN, MYC, IGF2BP1 and ATOH1 that play an 
essential role in NB tumorigenesis. Intriguingly, in NB cell lines and primary tumors, a strong, 
lineage-specific SE region downstream of HAND2 and upstream the FBXO8 gene locus was 
recurrently rearranged into the proximity of these oncogenes, thereby leading to increased 
expression. Given the predominant role of epigenetic deregulation in NB, high-frequency of 
enhancer-hijacking events, reported in the present study, emphasizes a strong epigenetic 
involvement in NB tumorigenesis (Henrich et al. 2016). A better understanding of the epigenetic 
landscape could pave the way towards more specific epigenetic drugs and novel therapies 
including epigenetic analyses as basic diagnostic methods for NB tumors.  
 
4.1.1 Telomerase activation by genomic rearrangements in high-risk NB 
WGS (n = 59) and FISH (n = 217) analysis of primary NB tumors revealed recurrent 
rearrangements affecting the TERT gene and leading to alternative telomere activation in up to 
24% of high-risk NB cases. Overcoming the Hayflick limit by escaping replicative senescence and 
gaining indefinite proliferation capacity is a well-known hallmark of cancer, which can be 
implemented by reactivation of telomerase activity (Hayflick 1965; Kim et al. 1994; Shay and 
Bacchetti 1997). Telomerase is the most important component of telomere maintenance in 
humans. It consists of the catalytic subunit TERT (telomerase reverse transcriptase) and TERC 
(telomerase RNA component), which is essential for template repeat elongation at gDNA 
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telomeres (Greider and Blackburn 1989; Lendvay et al. 1996; Lingner and Cech 1996). The 
protective function of telomere maintenance is usually inactive in somatic cells, while it is 
reactivated in germ cells, stem cells and 80 – 90% of malignant tumors where it is commonly 
associated with poor prognosis (Liu et al. 2004; Pestana et al. 2017). Increased telomere activity 
due to TERT promoter mutations is associated with metastasis and reduced survival in 
melanoma, thyroid carcinomas and gliomas (Melo et al. 2014; Populo et al. 2014; Heidenreich et 
al. 2015). In line with these observations, TERT rearrangements in the present study were 
associated with poor prognosis and poor clinical outcome in NB patients, comparable to that 
observed for patients harboring amplified MYCN. It has been previously shown that short 
telomeres were associated with favorable prognosis whereas maintained telomeres were 
accompanied with unfavorable outcome in a cohort of 51 NB primary tumors (Ohali et al. 2006). 
A recent study revealed that tumors with intact telomere maintenance mechanism in 
combination with RAS/p53 pathway mutations were associated with fatal outcome in a cohort 
of 416 untreated NB tumors.  In contrast, occurrence of spontaneous regression was restricted 
to tumors lacking RAS/p53 pathway mutations and simultaneous telomere maintenance 
(Ackermann et al., 2018, submitted). Genomic rearrangements, especially those upstream of the 
TERT gene, were already described as an alternative process of transcriptional activation of 
TERT and thereby telomerase activation (Zhao et al. 2009). This study from 2009 was 
conducted in genetically modified fibroblast cells to describe cellular immortalization and a 
novel mechanism to alter the epigenetic condensed chromatin landscape upstream the TERT 
locus.  
Besides the discovery of TERT rearrangements, WGS in this study confirmed established 
genomic aberrations including amplified MYCN, ATRX deletion and gain of chromosome 17 in 
NB tumors, which is in line with recently published studies (Maris et al. 2007; Molenaar et al. 
2012; Pugh et al. 2013). Inactivating ATRX mutations are common in several cancer entities like 
pancreatic neuroendocrine tumors (PanNETs) and are associated with alternative telomere 
maintenance and alternative lengthening of telomeres (ALT) (Heaphy et al. 2011). ATRX protein 
is involved in chromatin remodeling but ALT mechanism is not only restricted to ATRX-mutated 
tumors (Cheung et al. 2012). In the present study, ATRX mutations (n=7), amplified MYCN  
(n = 10) or TERT rearrangement (n = 12) were observed in a mutually exclusive fashion in a 
cohort of 56 primary NBs. Intriguingly, all of these three high-risk associated aberrations induce 
one of the two telomerase maintenance mechanisms. Either by increasing TERT expression 
through activating TERT rearrangements, transcriptional activation by amplified MYCN or by 
activating the homologous recombination-based ALT pathway through ATRX inactivation (Duan 
and Zhao 2018).  
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In the present study, no mutations of the TERT gene or promoter region were detected in 59 
analyzed primary NBs, whereas these aberrations are commonly activating TERT and telomere 
activity in various cancer entities. Recurrent somatic mutations within the TERT promoter were 
found in 44% (n = 225) of thyroid cancer types and 33% (n = 77) of primary melanomas 
(Landa et al. 2013). In melanomas it was shown that somatic mutations within the promoter 
region of TERT can establish ETS transcription factor binding motifs causing up to two fold 
upregulation of TERT (Horn et al. 2013; Huang et al. 2013). Recurrent TERT promoter 
mutations were detected in 6.4% of renal cell carcinomas (n = 188) and in more than 65% of 
bladder cancers  
(n = 327) (Hosen et al. 2015; Hosen et al. 2015). In addition, TERT promoter mutations were 
identified in 66% of gliomas (n = 303) with 80% in primary glioblastomas, 70% in 
oligodendrogliomas and 39% in astrocytomas (Heidenreich et al. 2015). On the DNA level, the 
present study determined a low overall mutation frequency of only 13.3 mutations per genome, 
which confirms previous NB sequencing studies (Pugh et al. 2013). In an analysis of 12 major 
cancer types lowest median mutation frequency of 0.28 mutations per megabase (Mb) was 
found in acute myeloid leukemia (AML) whereas highest mutation frequency was observed in 
lung squamous cell carcinoma with 8.15 mutations per Mb (Kandoth et al. 2013). A recent pan-
cancer study revealed that mutation frequencies across 24 non-adult cancer types (n = 961) 
were up to 14 times lower (0.02 – 0.49 mutations per Mb) compared to adult cancer entities. In 
this study, NB samples (n = 59), including three relapsed samples with increased mutation 
rates, harbored a median mutation frequency of 0.22 mutations per Mb (Grobner et al. 2018).  
In NB cells (n = 32), three of the six top TERT expressing lines (CLB-GA, GI-ME-N and KELLY) 
harbored a TERT rearrangement which was confirmed by FISH. Despite the fact that TERT 
expression was significantly higher in TERT-rearranged versus MYCN-amplified cases in NB 
tumors, MYCN-amplified and non-TERT-rearranged NGP cells exhibited the highest TERT 
expression of all NB cell lines. In NGP cells, as well as in two further MNA cell lines, among the 
six top TERT expressing cell lines, additional activating aberrations like TERT promoter 
mutations might be present, which should be analyzed by e.g. WGS and subsequent analyses. 
Particularly, in MYCN-amplified NGP cells a duplication event of TERT locus was identified but 
not further characterized in this study. If high expression of TERT in NGP cells is due to 
duplication or correlation with amplified MYCN has to be clarified. For all the three TERT-
rearranged tumors analyzed, ChIP-seq profiles of TSS associated H3K4me3 and enhancer 
surrogate H3K27ac histone marks revealed repositioning of enhancer elements into the 
proximity of the TERT gene. Genome wide enhancer ranking by H3K27ac signal identified all 
three translocated enhancers as SEs. The three TERT-rearranged cell lines with high TERT 
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expression harbored a heavily silenced region upstream of TERT with condensed chromatin 
represented by H3K27me3 and H3K9me3. However, TERT was enriched for activating histone 
modifications like H3K4me3, H3K4me1 and H3K27ac at the promoter and H3K36me3 at the 
gene body in all TERT-rearranged cell lines and were absent in the non-rearranged control cell 
lines. Such co-occurrence of activating and repressive marks at the same locus is termed as a 
bivalent state and is described in colon cancer and further tissues and cancers. Dysregulation of 
such bivalent genomic regions (promoters and gene bodies) through loss of the repressive 
marks can cause oncogene activation (Baylin and Jones 2011; Hahn et al. 2014). Changes in the 
epigenetic landscape, including transformation from repressive polycomb-mediated 
trimethylation of H3K27 to long-term silencing by DNA methylation (epigenetic switching), are 
reported in many cancer trypes and reduces epigenetic plasticity (Gal-Yam et al. 2008). In this 
study, DNA methylation analysis of CpG islands at the TERT locus of 39 NB primary tumors 
revealed highest methylation of CpG islands across the TERT gene in MYCN-amplified and TERT-
rearranged tumors. In contrast to this silenced region the CLPTM1L (cisplatin resistance-related 
protein 9) gene further upstream of TERT showed lack of repressive marks in all analyzed cell 
lines (TERT-rearranged and control). CLPTM1L was even enriched for ATAC-seq peaks, which 
marks open chromatin, as well as for histone marks associated with transcriptional elongation 
(H3K36me3) and active transcription (H3K4me1, H3K4me3 and H3K27ac). TERT 
rearrangements in NB cell lines CLB-GA, GI-ME-N and KELLY were validated using FISH, as 
described before. The principle of alternative oncogenes activation by enhancer rearrangements 
into the proximity of oncogenes and upregulating their expression was described for many 
cancer types (Taub et al. 1982; Bakhshi et al. 1987; Groschel et al. 2014; Northcott et al. 2014). 
As a proof of principle, 4C-seq using a viewpoint matching the TERT promoter was performed in 
NB cell line CLB-GA, GI-ME-N, KELLY. Using this validation of physical interaction with the TERT 
promoter, the location of the hijacked enhancer was identified. Likewise, enhancer elements 
assigned to GATA2 on chromosome 3 were replaced into the proximity of EVI1 as detected by 
4C-seq analysis in AML. This caused downregulation and upregulation of both genes, GATA2 and 
EVI1, respectively (Groschel et al. 2014). 
Finally, there are treatment opportunities by targeting tumor cells with uncontrolled telomerase 
maintenance through e.g. the activation of TERT as demonstrated in NB cells. Treatment 
approaches with telomestatin that inhibits telomere activity and results in telomere shortening, 
growth arrest and apoptosis in vitro are particularly promising (Binz et al. 2005). 
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4.1.2 Further rearrangements affecting oncogenes 
The principle of oncogene activation by chromosomal rearrangements bringing together active 
enhancers and oncogenes has been describe for several cancer entities and is referred to as 
“enhancer hijacking” (Taub et al. 1982; Bakhshi et al. 1987; Groschel et al. 2014; Northcott et al. 
2014). With the discovery of recurrent rearrangements of SE elements activating the TERT gene, 
we provided the first evidence for “enhancer hijacking” in NB. Due to the absence of coding 
mutations or amplifications, extraordinary high expression levels known for several oncogenes 
in NB remained unexplained for a long period. The present study followed the hypothesis that 
“enhancer hijacking” might be the driving force of activation for oncogenes including MYCN, 
MYC, IGF2BP1 and ATOH1, which will be discussed in the following section.  
MYCN and MYC  
Examining mRNA levels of NB cell lines (n = 32) using RNA-sequencing data, revealed 
extraordinary high MYCN expression levels in NBL-S despite the fact that they bear no changes 
in MYCN copy number. Similarly, outlier expression of MYC was observed in MYC single-copy 
cell lines NB69, SK-N-AS, CHLA20 and SH-SY5Y. High mRNA expression of either MYCN or MYC 
in the respective cell lines were mirrored by protein expression as could be confirmed by 
western blotting. MYC and MYCN expression is mutually exclusive, which is in accordance with 
previous studies that identified a lack of MYC expression in MYCN-amplified NB tumors, which is 
explained by regulatory interactions of both (Breit and Schwab 1989).  In another study, high 
expression of MYCN and MYC target genes was identified as marker for poor survival and was 
driven by MYC in stage 4 tumors lacking amplified MYCN (Westermann et al. 2008). In addition, 
immunohistochemistry (IHC) staining for MYCN and MYC protein appeared almost mutually 
exclusive in a cohort of 157 NB primary tumors. The tumors defined as MYC-positive (11%) in a 
subset of high-risk cases were associated with worse prognosis than MYCN-positive tumors or 
tumors negative for both (Wang et al. 2013). This fosters prognostic significance of MYC in 
addition to MYCN as described in a group of patients with undifferentiated NB (Wang et al. 
2015). In general, MYCN and MYC share several homolog regions and hold similar cellular 
functions especially during development since MYCN was discovered as MYC homolog that is 
subject to amplification in NB tumors (Gustafson and Weiss 2010). Both, ectopic MYCN and MYC 
expression can drive neuroblastoma tumorigenesis in vivo in mice or zebrafish (Althoff et al. 
2015; Zimmerman et al. 2018). To evaluate MYC dependency, RNAi-mediated MYC knockdown 
was performed in NB cell lines. Among the MNA cell lines, the strongest decrease of viability was 
observed in SK-N-AS, which harbored intermediate MYC expression as compared to GI-ME-N 
(higher MYC expression) and SHEP (lower MYC expression). MYCN-amplified NMB cells 
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displayed only marginal levels of MYC expression and viability remained unaffected by RNAi-
mediated MYC knockdown. This emphasizes a unique MYC dependency of MYC-rearranged cell 
line SK-N-AS, which is lower in GI-ME-N cells with a higher MYC expression. 
In contrast to MYCN, which is amplified in advanced stage disease in approximately half of the 
cases and in 20% of all NB, amplification of MYC is a very rare event (Brodeur et al. 1984). An 
exception was found by a WGS study in NB primary tumors (n = 87), identifying chromothripsis 
as causa for amplification and strong upregulation of MYC in one patient of the study (Molenaar 
et al. 2012). However, MYC amplification is not always associated with high MYC expression or 
increased protein level due to posttranscriptional modifications or due to a short half-life of MYC 
protein, as described in breast cancer (Mariani-Costantini et al. 1988). MYC itself is deregulated 
in many ways in many cancer entities and is described as the most frequently deregulated 
oncogene in cancer (Kalkat et al. 2017). Amplification of the MYC locus as well as co-
amplification of adjacent genes within the MYC surrounding “gene desert” is a well described 
phenomenon in many cancer entities, like ovarian and small cell lung cancer or prostate 
carcinoma (Sato et al. 1999; Kim et al. 2006; Haverty et al. 2009). Co-amplified genes 
downstream of MYC are the long non-coding RNA genes PVT1 and CCDC26 as well as the GSDMC 
gene (Gasdermin C), which regulates apoptosis of the gastric epithelium (Saeki et al. 2009). 
PVT1-MYC co-amplification was found in medulloblastoma group 3 as the first recurrent 
translocation involving PVT1 and MYC, due to chromosome 8 chromothripsis events (Northcott 
et al. 2012). Interestingly, high MYC expression was particularly depending on increased levels 
of PVT1, a long non-coding RNA gene downstream of MYC, through a positive feedback loop. 
Both genes are co-amplified and co-expressed in 98% of all MYC-amplified tumors (Tseng et al. 
2014). However, no correlation between MYC and PVT1 expression was observed in NB cell 
lines. On the contrary, NB69 cells that highly express MYC revealed low PVT1 expression, which 
was even lower expressed than the first quartile of 32 NB cells. Furthermore, highest PVT1 
expression co-occurred with low MYC expression in MHH-NB11 cells. According to this, MYC 
amplification is most probably not the reason for high MYC expression in NB cases and there will 
be another cause for MYC activation. Since there are hardly any genes within the MYC 
surrounding “gene desert”, most of the adjacent enhancer elements are assigned to regulate or 
deregulate MYC expression. Alterations including focal amplifications of MYC-interacting 
enhancer elements in these non-coding regions were reported for lung adenocarcinoma as well 
as for NB (Zhang et al. 2016; Zimmerman et al. 2018). Among four MYC-rearranged NB cell lines 
with highest MYC expression, only SK-N-AS and SH-SY5Y cells contained the PVT1 gene on the 
rearranged strand. In addition, all four cell lines lack PVT1, CCDC26 as well as GSDMC, 
downstream of MYC on the translocated allele. For CCDC26 and GSDMC only average expression 
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level was detected in MYC-rearranged cell lines. All MYC-rearranged NB cell lines exhibited only 
one chromosome 8 wild-type allele carrying MYC, PVT1, CCDC26 as well as GSDMC genes. Only a 
region-gain including MYC and three downstream genes was able to promote cancer in mice, 
which was impossible for amplified MYC gene alone (Tseng et al. 2014).  
In search for the reason for high MYCN expression at mRNA and protein level in NB NBL-S cells 
and extraordinary high MYC expression and protein level in NB69, SK-N-AS, CHLA20 and SH-
SY5Y cells these lines were studied via FISH in the present study. MYC and MYCN 
rearrangements were identified in all tested cell lines, while almost all translocated SE elements 
juxtaposed to MYC or MYCN originated from the same genomic location at chromosome 4 (Chr.4 
q34). The phenomenon of enhancer hijacking was first described in 1982 in Burkitt’s lymphoma, 
where structural rearrangements juxtapose immunoglobulin H (IgH) enhancers to MYC thereby 
driving increased MYC expression (Taub et al. 1982). As described for TERT rearrangements, 
4C-seq confirmed interactions of the MYCN or MYC promoter with translocated enhancer 
elements in NB cell lines NBL-S or, NB69, SK-N-AS, CHLA20 and SH-SY5Y, respectively. These 
experiments identified further the precise positions of the interacting enhancers. Genome wide 
enhancer ranking by H3K27ac signal identified all four MYC- as well as the MYCN-rearranged 
enhancers as SEs, which was directly associated with increased oncogene expression. In addition 
to this epigenetic profiling, MYC rearrangement with chromosome 7 segments in SH-SY5Y 
revealed enriched repressive H3K27me3 marks at the MYC locus. This bivalent state, with 
activating and repressive marks at the same locus is described in colon cancer and further 
entities. Dysregulation of such bivalent genomic regions by loss of the repressive marks can 
cause oncogene activation (Baylin and Jones 2011; Hahn et al. 2014). 
As the principle of alternative oncogene activation by enhancer rearrangements plays an 
important role in NB biology by regulating TERT, MYCN and MYC, we screened for further 
potential “enhancer hijacking” events in NB tumors and cells. Therefore, combination of WGS 
and supplemented RNA-seq data of primary tumors without amplified MYCN (n = 111) and a 
small set of NB cell lines were used as input for our EPISTEME analysis platform developed by 
Umut Toprak (Neuroblastoma Genomic, DKFZ).  EPISTEME  is a  structural variation (SV) 
algorithm similar to the published DELLY, which identifies SVs by integrating paired-end and 
split-reads (Rausch et al. 2012). Within this study, IGF2BP1 and ATOH1 two candidates for 
alternative activation by rearrangements were examined further. 
IGF2BP1 
The present study revealed cases of enhancer-hijacking involving IGF2BP1, in NB cell lines and 
tumors, providing evidence for recurrent targeting of this gene. IGF2BP1, which is located on 
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17q21.32, was first described in 2015 by Bell and colleagues to play a role in NB biology (Bell et 
al. 2015). IGF2BP1 family members including RNA-binding protein Vg1 RBP are involved in 
neural crest cell migration as well as neurite development (Yaniv et al. 2003; Bell et al. 2015). 
IGF2BP1 involvement in LIN28/Let-7 pathway, which is described to induce NB in mice, 
confirms prognostic significance for NB tumors independently of MYCN status (Molenaar et al. 
2012). In further cancer entities, like cutaneous squamous cell carcinoma (cSCC) increased 
IGF2BP1 is associated with higher staging, decreased cell differentiation and increased 
proliferation (Kim et al. 2017). In melanoma, IGF2BP1 expression was increased in metastatic 
disease and associated with chemotherapeutic resistance (Kim et al. 2018). IGF2BP1 was highly 
expressed throughout our NB cell line cohort (n = 32) revealing a strong positive correlation 
with amplified MYCN, which was less pronounced in NB tumors. However, in an external NB 
tumor cohort IGF2BP1 is associated with amplified MYCN and high MYCN expression (Bell et al. 
2015). Interestingly, the candidate cell line for IGF2BP1 rearrangement, CLB-GA, exhibited by far 
the highest IGF2BP1 gene expression, which was almost two fold increased as compared to the 
next in line. This finding of elevated IGF2BP1 in CLB-GA was confirmed on the protein level in a 
small set of NB cell lines. The RNA-binding protein IGF2BP1 was shown to be involved in 
supporting high MYC expression level by protecting its mRNA, which might explain correlation 
with MYCN or MYC (Lemm and Ross 2002). In a previous study of two NB tumor cohorts, 
IGF2BP1 was found to be expressed and increased expression was associated with poor patient 
survival, which was both confirmed in the NB tumor cohort of the present study (Bell et al. 
2015). It was described previously that NB tumors display elevated IGF2BP1 expression due to 
frequent gains of chromosome 17q21 in NB (Bell et al. 2015). 
In one tumor an IGF2BP1 rearrangement with chromosome 4 was predicted by WGS data and 
the EPISTEME SV algorithm that integrates paired-end and split-reads and finally RNA-seq 
analysis. Chromatin interaction analyses via 4C-seq confirmed physical interactions between the 
IGF2BP1 promoter and the HAND2 enhancer cluster on chromosome 4 in CLB-GA cells. This was 
validated independently using genome wide interactions identified by HiChIP in CLB-GA. 
IGF2BP1 resides on chromosome 17q, which is the most frequently gained region in NB. 
Furthermore, IGF2BP1 was identified as a MYCN transcriptional target. Despite this complex 
high-risk associated network of IGF2BP1 upregulation, we could resolve IGF2BP1 
rearrangement as an additional and novel mechanism of IGF2BP1 upregulation, in the present 
study. Analyzing the rearranged regions at the IGF2BP1 locus by ChIP-seq confirmed that strong 
enhancers reside on the chromosome 4 translocation partner region in CL-B-GA cells. In 
addition, the IGF2BP1 locus was enriched for repressive H3K27me3 marks and further marks 
associated with active transcription. Similar to TERT rearrangements or MYC rearrangement in 
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SH-SY5Y cells, this could be defined as a bivalent promoter as well as the repressed epigenetic 
status of wild-type allele. This should be clarified in further experiments choosing a monoallelic 
RNA-seq or allele-specific ChIP- or ATAC-seq approach using QuASAR (Quantitative Allele 
Specific Analysis of Reads), which recognizes allelic imbalance at heterozygous sites (Harvey et 
al. 2015). A tumor suppressive function of indirect reduction of IGF2BP1 via knockdown of 
regulator miR-506 was reported in glioblastoma (Luo et al. 2015). Taken together, IGF2BP1 has 
been identified as a promising candidate for a therapeutic approach in other entities, like 
glioblastoma. In terms of the epigenetic deregulation and novel mechanism of IGF2BP1 
upregulation by rearrangement as described in the present study, targeting IGF2BP1 would be 
also a promising approach for NB tumors. 
ATOH1 
The present study revealed cases of enhancer-hijacking involving ATOH1 in three NB tumors, 
providing evidence for recurrent targeting of this gene. This demonstrates that recurrence of 
enhancer hijacking events in vivo is not restricted to the TERT gene. The role of NOTCH pathway 
transcription factor ATOH1 is contradictory in different cancer entities. Dependent on the tumor 
type, ATOH1 is reported to exert oncogenic or tumor suppressive functions. ATOH1 is described 
to have a tumor suppressive role preventing transcriptional repression of ARID2 (AT-rich 
interaction domain 2) in hepatocellular carcinoma (Gao et al. 2017). In most colorectal cancers 
ATOH1 is silenced and high ATOH1 activity is associated with cell differentiation (Kazanjian and 
Shroyer 2011). In the NB cohort of the present study, increased ATOH1 expression (EFS n = 
366; OS n = 308) was associated with decreased EFS and OS probability, which is pointing 
towards an oncogenic function. This is in line with findings in another neuronal pediatric tumor, 
aggressive medulloblastomas, displaying high ATOH1 expression in recurrent and metastatic 
medulloblastoma (Grausam et al. 2017). Further adding to this, ATOH1 enhances oncogenic 
function via GLI2 (GLI family zinc finger 2) target genes and inhibits neuronal differentiation in 
medulloblastoma-initating cells (Ayrault et al. 2010). In the present study, ATOH1 dispalyed 
outlier expression for one MNA cell line SK-N-FI as well as for several tumors of different stages.  
Integrated analysis of structural rearrangements and expression data did not detect any ATOH1 
rearrangements in NB cell lines, which have not been confirmed by FISH or 4C-seq analysis yet. 
The epigenetic status was determined exemplary for one tumor with predicted ATOH1 
rearrangement and revealed strong enhancer elements within the recurrently translocated 
region coming into the proximity of ATOH1 gene locus and most likely driving the expression. In 
mouse NB and neural progenitor cells, ß-catenin increases ATOH1 expression by ATOH1 
enhancer binding and vice versa RNAi-mediated knockdown of ß-catenin decreased ATOH1 
expression (Shi et al. 2010). In medulloblastoma, Jak2 (janus kinase 2) inhibition reduced tumor 
 Discussion 115 
growth in vivo through reduction of tyrosine 78 phosphorylation of ATOH1. This effect on tumor 
growth caused protein destabilization and reduced ATOH1 activity presenting a promising way 
of targeting ATOH1 (Klisch et al. 2011; Klisch et al. 2017). Taken together, targeting ATOH1 has 
been a promising candidate for a therapeutic approach in other entities, like medulloblastoma. 
In terms of the epigenetic deregulation and novel mechanism of ATOH1 upregulation by 
rearrangement described in the present study, targeting ATOH1 would be a promising approach 
for NB tumors. 
 
4.1.3 HAND2 SE cluster is recurrent donor-region in rearrangement events 
The present study identified structural rearrangements, which recurrently juxtaposed a 
particular enhancer region in the proximity of different NB oncogenes including TERT, MYCN, 
MYC, IGF2BP1 and ATOH1. This enhancer region downstream of the HAND2 (referred to as 
HAND2 SE region in the following) and upstream of the FBXO8 gene was characterized by strong 
H3K27ac signal in NB cell lines and tumors. An increased H3K27ac signal, which is an 
established enhancer surrogate, was observed in the presence or absence of rearrangement 
events at this locus, which points towards an important regulatory role and also lineage 
specificity in wild-type NB.  
FBXO8 gene, a member of the F-box gene family mediates protein-protein interactions and is 
involved in developmental processes, even though its exact function is still unknown (Calcia et 
al. 2013). In contrast, the functions of DNA binding protein HAND2 are diverse and regulate 
development and cell specification in different tissues and cell types like heart, cardiac cushion, 
bone and noradrenergic sympathetic ganglion neurons. Hand2 inactivation is lethal in vivo in 
mice (Hendershot et al. 2008) and the present study showed that RNAi-mediated knockdown of 
HAND2 caused reduced viability in two HAND2 SE-rearranged NB cell lines, independent of 
amplified MYCN. Both genes, HAND2 and FBXO8, were highly expressed across NB cell lines, 
while expression of both genes was slightly increased in rearranged cases and revealed HAND2 
outlier expression in CLB-GA cells as well as FBXO8 outlier expression in NB69 and CHLA20 
cells. In addition, 4C-seq analysis of the HAND2 enhancer regions demonstrated physical 
interaction with the HAND2 as well as the FBXO8 transcription start site (TSS), which are likely 
driving the increased expression observed for both genes. Interestingly, CLB-GA with the highest 
HAND2 expression of the NB cell line cohort was the only rearranged cell line harboring both, 
the HAND2 gene and HAND2 enhancer region, on the translocated allele which indicates strong 
breakpoint dependency of expression. Surprisingly, high HAND2 mRNA expression did not 
result in increased HAND2 protein level. HAND2 protein levels were relatively low in CLB-GA 
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and undetectable in NB69 cells. In endometrial cancer, HAND2 is associated with potential 
tumor suppressive functions through HAND2-mediated proteasomal degradation of estrogen 
receptor α (ERα) protein by ubiquitination (Fukuda et al. 2015). Potential proteasomal 
degradation functions or self-degradation might be the cause of the discrepancy between 
HAND2 mRNA and HAND2 protein expression observed in NB and will be an interesting topic 
for future investigations. A reason for recurrent rearrangements of HAND2 enhancer region 
could be the presence of a “hot spot” like a fragile site with predisposition to breakage as 
described for subtypes of lymphomas and leukemia (Barski et al. 2007). Such common fragile 
sites (CFS) are defined as highly unstable genomic regions that are prone to non-random gaps, 
breaks or even rearrangements under replication stress (Fungtammasan et al. 2012). Many 
genomic and epigenetic markers for CFS prediction have been described, although several of 
those including gene density measures, TSS location and enrichment of certain histone 
modifications are under discussion. While Jiang and colleagues identified association of  CFSs 
with histone marks for condensed and repressive elements (Jiang et al. 2009), opposing findings 
revealed an open chromatin structure and DNase hypersensitive sites at the regions of recurrent 
breaks (Zhang and Rowley 2006). In line with the hypothesis that active chromatin sites, as the 
NB HAND2 enhancer region, might be prone to breakage, TSS or enhancer marks like H3K4me3, 
H3K4me1 and H3K27ac were associated with recurrent breakpoints cell type-specific in T-cell 
cancer (Barski et al. 2007).  
Taken together, these data indicate that recurrent rearrangements of the lineage-specific SE 
region downstream of HAND2 and upstream the FBXO8 gene locus has a predisposition to 
breakage leading to aberrant expression of oncogenes as described in this study for TERT, 
MYCN, MYC, IGF2BP1 and ATOH1. In case of targeting aberrant SE activity there are several 
treatment strategies existing as SE regulation and transcription is dependent on BRD4 and CDK-
containing (cyclin dependent kinase) complexes. 
 
4.2 Global super enhancer landscape analysis in NB 
Active enhancer elements are defined as DNA regulatory units bound by transcription factors 
that control cell type-specific gene expression and thereby cell identity in mammalian cells 
(Bulger and Groudine 2011; Thurman et al. 2012). In a cancer context, there is an urgent need to 
define entity-specific enhancer and SE profiles. These regulatory elements are often enriched at 
driving oncogenes essential for cancer cell survival, offering vulnerability for targeted therapy 
(Wong et al. 2017). Especially highly active SEs are described to regulate entity specific master 
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transcription factors composing a CRC. CRC TFs regulating their own expression and expression 
of other CRC TFs forming hierarchically an interconnected auto-regulatory loop are crucial 
elements of many epigenetic driven cancer types (Saint-Andre et al. 2016). 
 
4.2.1 Epigenetic profiling defines NB SE landscape 
For the identification of enhancer and super-enhancer (SE) profiles, histone mark H3K27ac 
profiles were generated by ChIP-seq for a representative cohort of 60 primary NB tumors 
including MYCN-amplified high-risk, low-risk as well as relapsed patient samples. The obtained 
data were used to generate the first comprehensive global NB tumor-specific enhancer and SE 
landscape map, which was aditionally supplemented with the data of 23 NB cell lines and two 
neural crest-derived human cells. Similar approaches identifying enhancer or SE profiles in 
primary tumor samples have been undertaken in cancer entities including ependymoma or 
colorectal cancer (Cohen et al. 2017; Mack et al. 2018). In primary gastric adenocarcinoma (GC) 
epigenetic SE profiles (n = 110) using GC and normal tissues as well as cell lines were used to 
generate an enhancer and SE landscape. In tumor tissues a large scale reprogramming of the 
epigenetic landscape was reported, which caused dysregulation and cancer gene expression (Ooi 
et al. 2016). Enhancer profiling in adult T-cell leukemia/lymphoma (ATL), revealed SE elements 
at cancer driving genes including CCR4 (C-C motif chemokine receptor 4) and TP73 (tumor 
protein P73), which were absent in normal T-cells (Wong et al. 2017). Identification of new 
subtypes was the result of an enhancer profiling study in 66 AML patients. The study defined six 
novel subtypes with distinct leukemic cell states and RARA (retinoic acid receptor alpha) as a 
new transcriptional driver gene that was functionally validated in further approaches 
(McKeown et al. 2017). In the present study, all tumor-derived SE regions as well as their 
predicted target genes were validated for tissue specificity in a cross-tissue comparison. High 
tissue specificity of the NB SE set was confirmed, with a maximum of 11% overlap with SE 
regions defined in other tissues and strongest overlap with an external NB data set of predicted 
SE target genes. The strategy to derive SEs and their targets in primary NB tumors from 
H3K27ac ChIP-seq profiles was based on the method described by Hnisz and colleagues and a 
hierarchical assignment approach, respectively (Hnisz et al. 2013). To generate a stringent list of 
NB consensus SEs, all H3K27ac peaks closer than 2.5 kb to H3K4me3 promoter peaks were 
omitted prior to calling. Stringency was further increased by considering only those SEs which 
were called in two or more samples. Target genes were predicted hierarchically based on i) 
physical HiChIP and Hi-C interactions, followed by ii) H3K27ac signal versus expression 
correlation and iii) SE target gene proximity. The strategy of inferring causal enhancer-gene 
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interaction has previously been proven to be valid in a pan-cancer enhancer analysis using 8928 
tumor samples of 33 cancer entities. Here, HiC data and co-expression of mRNA was used to 
predict physical enhancer-gene interaction, which was validated experimentally exemplified for 
PD-L1 (programmed death-ligand 1) enhancer interaction (Chen et al. 2018). The robustness 
and reproducibility of the underlying epigenetic data and subsequent gene assignment strategy 
was rendered by the huge overlap of the highly ranked genes and previously identified NB-
specific and SE associated genes. Similar to the study by Chen et al., the validity of the applied SE 
to target gene assignment strategy was demonstrated in the present study for CCND1 and 
MAML3, two top ranked candidates, in SK-N-AS and KELLY NB cell lines by ChIP-seq, ATAC-seq 
and HiChIP data. 
 
4.2.2 SE defined NB epigenetic subtypes 
The SE profiles of NB tumors were used as an input for NMF analysis to search for novel 
epigenetically defined NB subtypes. NMF computed four SE signatures as most suitable to 
represent the whole NB tumor cohort based on SE data of the ChIP-seq cohort. Three out of four 
signatures could be assigned to specific subgroups due to clinical parameters (MYCN-amplified, 
MNA low-risk and high-risk). Importantly, an additional, previously undefined NB tumor 
subtype was identified by NMF of SE data which could be defined as enriched for mesenchymal 
terms including “EMT” or “migratory potential” by gene set enrichment analysis (GSEA). NMF 
analysis of NB cell line SE profiles computed three stable signatures, namely MYCN-amplified, 
MNA and, similar to the tumors, a third group displaying strong enrichment for mesenchymal 
terms (hereinafter referred to as Mes subgroup). In parallel to the proceeding of the present 
study, a related study was published based solely on SE data from nine NB cell lines. This study 
identified two distinguishable cell line populations, described as undifferentiated mesenchymal 
and adrenergic cells (van Groningen et al. 2017). This dichotomy was further validated in a joint 
study in an extended cohort of 25 NB cell lines, which was subdivided in a sympathetic 
noradrenergic, a neural crest cell like and a mixed identity subgroup (Boeva et al. 2017). 
To further access the depth of information in the primary tumor SE cohort and the large cohort 
of cell lines, t-SNE analysis on joint tumor and cell line SE profiles was performed. These 
analyses revealed that most cell line and tumor samples grouped apart from each other, 
representing inherent and disclosed differences that are distinct for tumors and cell lines. This 
indicates the relevance of the NB tumor SE landscape to judge the actual in vivo situation in NB. 
Interestingly, only samples with the highest exposure to the Mes signature grouped intermixed 
between tumors and cell lines. This emphasizes the prominence of the mesenchymal character 
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and confirmed the stability of the Mes signature. Interestingly, NMF signature exposure values of 
cell lines compared to tumors reflects the selective nature of numerous passages of cell lines 
under cell culture conditions. For tumors, NMF signature exposures are more continuous with 
several intermediate samples, which reflects the situation in nature and the importance of a 
tumor based epigenetic approach.  
Despite the fact that the cohort with available ChIP-seq data has grown to a considerable size of 
60 tumors during the study, a cohort increase promised to gain even deeper insights in the NB 
regulatory networks. Therefore, the cohort size was extended by using predicted SE-target 
genes to perform NMF on RNA-seq data from 589 primary NBs. The four NMF signatures 
derived directly from SE profiles could be confirmed using gene expression data and robustness 
was validated in scatterplots and GSEA. Particularly, the MYCN-amplified- and the Mes signature 
displayed high congruence between the two underlying data sets. The extended RNA-seq based 
NMF analysis, which was based on the epigenetic profiling, was able to recapitulate the ChIP-seq 
NMF analysis. De novo RNA-seq based NMF analysis alone could not reflect the distinct and 
robust Mes signature.  Intriguingly, the robust Mes and MYCN-amplified signatures displayed a 
strong association with relapsed cases for tumors. The mesenchymal subtype of cells and EMT is 
associated with loss of cell adhesion, increased tumor invasion and metastatic initiation in 
different cancer entities including breast cancer or NB (Taube et al. 2010; Nozato et al. 2013). 
This goes along with poor patient outcome and drug resistance mechanisms as defined by the 
clinical association in the present study since metastasis in NB patients is still one of the main 
causes of death of the disease (Naiditch et al. 2015; Shao et al. 2017).  
Despite the identification of this distinct and robust Mes signature in NB tumors it remains still 
uncertain if the mesenchymal cells are an independent subgroup of the NB entity or rather a 
transferable population by changing the expression pattern as described by van Groningen and 
colleagues. Here, the mesenchymal SE associated TF PRRX1 (paired related homeobox 1) was 
overexpressed in an adrenergic NB cell line resulting in a more mesenchymal state (van 
Groningen et al. 2017).  
 
4.2.3 Core regulatory circuitries of NB subtypes 
With the SE NMF-based definition of four distinct and clinically relevant NB subtypes, the basis 
was proven for defining the transcriptional network driving and regulating these discrete 
subtypes. This SE based approach was used in combination with significant TF interactions 
using expression profiles to generate a set of the 75 most essential core regulatory circuitry TFs 
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within four distinct NB subtypes. The analysis identified regulatory networks which were 
exclusively present in the Mes signature (driven by CRC TFs including RARB and KLF4) of 
tumors and cell lines. Consistently, the comprised CRC TFs harbored high activity exclusively in 
samples with high exposure to the Mes signature. However, some exceptions were found among 
CRC TFs including POU2F2 in MNA-HR, which were present in particular signatures but did not 
show any TF activity in those. Activators of regulatory networks have been identified for further 
entities. The pioneer factor FOXF1 (forkhead box F1), regulates the two master transcription 
factors KIT (KIT proto-oncogene receptor tyrosine kinase) and ETV1 providing evidence that 
FOXF1 is essential for in vivo tumor growth and maintenance in gastrointestinal stromal tumors 
(Ran et al. 2018). Another study presented the overlap of regulatory circuitries of glioblastoma 
and neural stem cells, which proofed to be extensive. The study focused mainly on the 
transcriptional network of KLF4 that have both populations in common (Riddick et al. 2017). 
KLF4 is part of the 75 NB CRC TFs identified in this study and was observed in the Mes cell line 
and tumor subtype. An interesting finding of the present study was the discovery of a group of 
TFs that were observed as CRC in the Mes subtype exclusively in cell lines but displayed a high 
Mes TF activity which was derived from tumor RNA-seq (e.g. TEAD4 (TEA domain transcription 
factor 4), FOSL2 and ETS1/2 among others). This shows the strength of combining both 
analyses, TF activity and observed CRC TFs, since all of those TFs lacking CRC classification in 
tumors might have still essential functions in Mes tumors. In this case the function might be 
irrespective of an auto regulatory feedback-loop, which is the requirement for CRC classification. 
The combination of TF activity and CRC analysis confirmed consistency of the Mes signature. 
This is in line of MYC TF, which was observed only in the Mes cell line subtype but was heavily 
enriched for Mes TF activity in tumors. Missing the requirements for CRC classification in 
tumors does not change the MYC assignment as a Mes TF. Involvement of MYC in EMT and a 
relevance in the Mes subtype was observed and confirmed in breast cancer where high MYC 
expression induces EMT (Cho et al. 2010). 
Despite the fact that the definition of an entity-specific regulatory network solely by CRCs might 
ignore important TFs that do not fulfil CRC criteria, the auto-regulatory aspect of defined CRC 
networks could be confirmed via ATAC-seq as exemplified for the network of FOSL2, MYC and 
SMAD3. The present study revealed that RNAi-induced knockdown of Mes or nonMes TFs had a 
greater impact on viability in a mesenchymal or non-mesenchymal cell line, respectively. This 
confirms that targeting a core component of a subtype-specific regulatory network has impact 
on the cells of the corresponding subtype and their function is essential for NB subtype 
maintenance. RNAi-induced knockdown or overexpression of one or more TFs central for a 
specific subtype might have the power to collapse the whole regulatory network, which might 
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pave the way for high-risk subtype-specific targeted therapy. A subtype-specific network 
collapse was demonstrated by RNAi-induced knockdown of three Mes TFs in Mes SH-EP cells. 
While RNAi-induced knockdown of RARB is in line with reduction of EMT processes targeting, 
ETS1 and SMAD3 revealed the opposite. It is of note that defining a subtype-specific list of a 
regulatory network is only an approximation as ETS1 and SMAD3 were defined as Mes CRC TF 
but have different function in Mes SH-EP cells. This emphasizes sample-specific CRC TF 
definition for experiments and potential therapies. 
A similar functional validation of central TF of regulatory networks was performed in 
ependymoma and decreased survival upon RNAi-induced knockdown of central factors 
including SOX2/9 and RFX2 (regulatory factor X2) in contrast to control shRNA constructs 
(Mack et al. 2018). In glioblastoma stem cells, knockdown of regulatory core component KLF4 
by shRNA, caused downregulation of HRAS and increased abundance of differentiated cells. On 
the other hand, overexpression of KLF4 blocked differentiation and was negatively correlated 
with patient’s survival, indicating a cellular context dependent role in tumor progression for this 
master TF (Rowland and Peeper 2006; Riddick et al. 2017). This emphasizes the entity- and also 
cell type-specific role of an identified core component and confirms results from the present 
study. As described previously, the identified Mes CRC components ETS1 and SMAD3 revealed 
an opposing effect after RNAi-induced knockdown in Mes SH-EP cells. 
 
4.2.4 Functional and clinical relevance of NB epigenetic subtypes 
In the final part of the present study, epigenetic subtype signatures were analyzed for novel 
clinical implications or vulnerabilities in view of potential specific treatment options. Finding a 
therapeutic window for a Mes subgroup is crucial as Mes cells of several entities revealed 
increased chemo-resistance (Arumugam et al. 2009). For the Mes CRC TF and RA receptor 
RARB, which was tested after RNAi-induced knockdown in Mes SH-EP cells in this study, it is 
reported that reduced RA signaling through RARB suppresses EMT-transition in basal-like 
breast cancer in mice (Liu and Giguere 2014). As RA receptors, including RARB, are the 
downstream mediators of RA signalling, the effect of all-trans retinoic acid (ATRA) was 
analyzed. ChIP- and RNA-seq profiles of ATRA-treated sensitive or resistant NB cells were used 
to compute exposure to each of the four NB tumor NMF signatures. Intriguingly, ATRA treatment 
caused a reduction of exposure to the MYCN-amplified signature and an increased exposure to 
the Mes signature in ATRA sensitive BE(2)-C cell line in both, RNA-seq  and ChIP-seq based 
analyses. In contrast, no such effect was observed in the ATRA-resistant KELLY cell line. The 
reduction of MYCN expression in NB cell lines upon ATRA-treatment is a well described 
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phenomenon (Reynolds et al. 1991). RA, an inducer of differentiation of malignant cells, is used 
as therapy for patients with low- and intermediate-risk, while it is ineffective for many patients 
with high-risk neuroblastoma (Matthay et al. 1999; Reynolds et al. 2003). The reason for an 
unsuccessful therapy of many high-risk patients was previously explained by MYCN-induced 
resistance as high MYCN prevents neuronal differentiation (Duffy et al. 2017). The present data 
provides the basis for an alternative explanation of RA resistance for many high-risk patients 
that might initially respond to this therapy approach but finally establish a population of 
resistant, mesenchymal tumor cells. The fact, that NB tumors are a heterogeneous cell 
population with mesenchymal cells was already described previously. Within this recent study a 
mesenchymal SE associated TF PRRX1 was overexpressed in an adrenergic NB cell line, resulting 
in a time dependent increasing mesenchymal state (van Groningen et al. 2017). 
Further dissecting the MNA cell line signature, which remained unaffected by ATRA treatment, 
into the LR- and HR-MNA tumor signature revealed increased exposure to the LR-MNA signature 
in BE(2)-Ceffect of RA on differentiation, which is phenotypically detectable by neurite-like 
outgrowth, cell cycle arrest and expression of neuronal differentiation marker like TrkA 
(tropomyosin receptor kinase A) and CDH5 (Sidell et al. 1986; Higashi et al. 2015). Further on, 
clinical association analysis of the Mes NB subtype revealed strong association with relapsed 
disease, which is in line with the radar plot results and the shift of exposure towards a Mes cell 
type of primary tumors samples compared to matching relapsed samples. This might be due to 
resistance mechanisms of a cellular subpopulation of the tumor with mesenchymal character, 
which was described previously. Chemotherapeutic treatment using drugs including 
doxorubicin or cisplatin in Mes cells revealed higher resistance compared to nonMes cells 
(Boeva et al. 2017; van Groningen et al. 2017). This is supported by the finding that Mes 
subtype-specific CRC TFs in the present study were enriched and highly expressed in relapsed 
samples compared to primary tumors that rather showed enrichment for the non-mes 
regulatory networks. First evidence for JUN and FOSL2 association with highly accessible 
chromatin in Mes SK-N-AS cells suggested involvement of JUN/FOS associated genes with the 
Mes signature. A WGS study of NB relapsed patients (n = 32) identified an enrichment of 
activating RAS-MAPK pathway gene mutation in relapsed NBs, which points towards a possible 
involvement of RAS associated genes with the Mes signature (Eleveld et al. 2015). Our study 
follows this hypothesis further and provides evidence for a strong correlation of exposure to the 
Mes signature with activation of the RAS pathway and JUN/FOS target genes. This suggests 
involvement of RAS and JUN/FOS pathway genes in the Mes component and EMT in NB tumor 
pathways which showed enrichment in relapsed samples. Aberrant activation of EMT has been 
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already described for oncogenic RAS signaling and RAS effectors like AP-1 (activator protein-1) 
family members FOS (Reichmann et al. 1992; Shao et al. 2014).  
In concert, this data emphasizes the robustness of the defined Mes subgroup including their core 
regulatory component, which is in line with characterized cancer pathways and clinical 
correlations in NB. Involvement of RAS and JUN/FOS pathway genes in the Mes component 
might open a therapeutic window targeting this distinct subgroup of NB tumors. 
 
4.3 Conclusion and perspective 
A central finding of the first part of the present study is the discovery of recurrent chromosomal 
rearrangements juxtaposing SE elements in the proximity of the oncogene TERT. These 
rearrangements are associated with telomerase activation and occur in up to 24% of high-risk 
NB cases providing the first evidence for “enhancer hijacking” in NB tumors. Further omics 
analyses, integrating genome-wide expression, enhancer signal and chromatin interaction data, 
reveal that enhancer hijacking is not restricted to TERT but also affects other oncogenes 
including MYCN, MYC, IGF2BP1 and ATOH1 in NB cell lines and tumors sporadically and in a 
recurrent manner. Intriguingly, a strong lineage-specific SE region, assigned to the HAND2 gene 
in the wild-type situation, is recurrently involved in enhancer hijacking events with all the above 
mentioned oncogenes, implicating the relevance of strong lineage-specific enhancers in 
tumorigenesis. 
As a proof of principle, the present study provides evidence that NB cells are “addicted” to 
enhancer hijacking activated MYC via RNAi experiments in NB cell lines. However, the relevance 
of other enhancer hijacking candidate genes, identified in this study, remains to be determined. 
A strong focus should be placed on the identification of further candidates using the established 
EPISTEM structural variant algorithm approach coupled with RNA-seq data. At the moment, 
functional validation of physical SE-promoter interactions is still restricted to cell culture 
material. Enhancer hijacking validation approaches for primary material have to be optimized 
and can be based on chromatin interaction assays (e.g. 4C-seq), monoallelic RNA expression or 
allele-specific ChIP-seq and should be object for future investigations. A bidirectional approach 
should be undertaken to further elucidate the contribution of SE hijacking events as NB drivers. 
First, CRISPR/Cas9-based deletion of hijacked SE elements in NB model cell lines should be 
conducted. A particular focus should be placed on the lineage-specific HAND2-associated SE 
involved in various NB hijacking events. Such experiments would directly verify the causal link 
of SE regulation and targeted gene expression. A reciprocal approach to determine the 
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tumorigenic impact of a SE proto-oncogene interaction would be the introduction of a highly 
active SE element into the proximity of a candidate oncogene in non-tumor neural crest-derived 
cell lines. Neural crest-derived cells are missing a tumorigenic background, thereby reflecting 
the full impact of genome editing approach by CRISPR/Cas9. To elaborate on this aspect further, 
the described genome editing approach should be conducted in genetic mouse models. 
Reasonable treatment options for enhancer hijacking-activated genes include targeting (i) the 
gene directly, (ii) its downstream networks indirectly or (iii) driving SE. The enhancer hijacking 
candidate IGF2BP1 is a potentially druggable target and can be selectively inhibited by the 
recently identified small molecule BTYNB (Kim et al. 2018). Also, several therapeutic targeting 
strategies are available for TERT, which should be examined for efficiency in the available TERT 
rearrangement model systems. The most promising approaches of telomerase inhibition are G-
quadruplex stabilizer including telomestatin or guanine-rich oligonucleotides (GROs). In case of 
targeting aberrant SE activity, several treatment options exist, as SE regulation and transcription 
is dependent on BRD4 and CDK-containing complexes. The most commonly used small-molecule 
inhibitor targeting SE complexes is a BET bromodomain inhibitor. Several bromodomain 
inhibitors targeting BRD2, BRD3 and BRD4 (iBET726) combined or BRD4 (OTX015) alone are 
currently tested in clinical studies including NB in a MYCN-dependent context. Functional 
studies should include CDK7 (THZ1) and CDK 4/6 (Lee011) inhibitors in order to identify to 
potential synergy. Promising results towards this direction were recently published for a 
covalent CDK7 inhibitor, which reduced SE-associated MYCN expression in MYCN-amplified NB 
while CDK4/6 inhibitors reduced cyclin D1-associated SE and their target genes (Chipumuro et 
al. 2014).   
The second part of the present study defines the first NB- and NB subgroup-specific SE 
landscape of primary tumors and cell lines with assigned target genes and their inherent 
downstream core transcription factor networks. In depth analysis of tumor ChIP-seq data 
resolves three SE signatures underlying distinct clinico-biologically-defined NB subtypes of 
MYCN-amplified, MNA high-risk and MNA low-risk cases. Intriguingly, a forth signature is 
discovered harboring mesenchymal (Mes) features, which is stably validated also in NB cells, 
indicating a profound role of the underlying signature in the biology of affected NBs. The Mes 
signature shows an ATRA-inducible dynamic, association with clinical features of relapsed cases 
as well as correlation with RAS and JUN/FOS signature genes.  
In view of the indicated clinical implications and pathway associations of the newly defined Mes 
subgroup, the cohort size has to be extended. Therefore, an applicable screening method for 
detection, probably H3K27ac ChIP- or RNA-seq based, as well as bioinformatic processing are 
needed. The impact of entity- as well as subgroup-specific SE regulated genes should be clarified 
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in further functional studies. From the NB entity perspective, the potential of assigned genes 
including CCND1 or MAML3, of the cohort-wide top ranked SE in terms of H3K27ac activity, 
should be assessed. The dependency on subgroup-specific key player genes should be elucidated 
by further RNAi-induced knockdown experiments with subsequent viability measurement. This 
has been successfully applied for three Mes-specific transcription factors (TF) ETS1, RARB and 
SMAD3 in in the present study. Here, the choice of the NB cell line is crucial as the expression of 
subgroup specific genes is assumed to be indispensable for cell survival. A subgroup-specific 
core TF is not necessarily active in every cell line assigned to this subgroup. As already stated in 
the enhancer hijacking part, selective inhibition of dysregulated key genes within the networks 
would be a promising venue towards identifying therapeutical approaches. Targeting enhancer-
mediated transcription, e.g. by epigenetic drugs including bromodomain or CDK7 inhibitors, 
might be another promising strategy. The implication of RAS and JUN/FOS signaling in the Mes 
subgroup of NB tumors demands a better understanding of the pathways in the subgroup. Since 
gain-of-function mutations of RAS are relatively common in human cancers and frequently 
detected in NB relapsed tumors, it should be clarified whether there is any connection of RAS 
mutations and the Mes subgroup in NB. Targeting RAS, either directly or indirectly, with recently 
developed pan-RAS inhibitors (e.g. compound 3144) or downstream pathway inhibitors might 
be a promising approach for the treatment of Mes subgroup NBs.  
In conclusion, the present study identifies a major involvement of epigenetic deregulation on the 
chromatin and enhancer level in the pathogenesis of NB. A better understanding of aberrant 
enhancer functions leading to patient-specific targeting could pave the way towards an 
individualized and more efficient therapy for this deadly disease. 
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5. Appendix 
5.1 ChIP-seq step-by-step protocol 
Cells in a 15 cm dish should have a confluency of approximately 70-80% before fixation. 
(~1x106 cells for histone marks and at least 10x106 cells for transcription factors) 
Formaldehyde fixation and harvesting of cells 
1. Crosslink by adding 1.7 ml of a fresh 16% formaldehyde (FA) ampulla to ~25 ml media  
(1% FA final conc.). 
2. Shake for 10 min (Polymax 2040 shaker, Heidolph). 
3. Add 2.6 ml of 1.25 M fresh glycine solution. 
4. Shake for 5 min (Polymax 2040 shaker, Heidolph). 
5. Scrape cells and collect medium into 50 ml tubes (working on ice!). 
6. Centrifuge at 1250 rpm for 7 min and remove supernatant. 
7. Resuspend pellet with 1x PBS with proteinase inhibitor and transfer into 1.5 ml tubes. 
8. Centrifuge at 2000 rpm at 4°C for 7min and remove supernatant. 
9. Repeat the washing step 4 times. 
- Pellets can be snap-frozen in liquid nitrogen and stored at -80°C. 
Cell lysis and sonication 
1. Resuspend pellet with 900 µl RIPA I lysis buffer and incubate on ice for 30 min. 
2. Aliquot 300 µl into Bioruptor Pico 1.5 ml microtubes with caps. 
3. For sonication with a Bioruptor Pico cool down the system to 4°C. Use 30 – 60 cycles of 
each 30 sec ON and 30 sec OFF intervals. 
4. After sonication spin for 15 min at 13300 rpm and 4°C and pool the samples arising from 
one experiment into a new tube. 
5. Take a 15 µl aliquot of the sample as the input control and store at 4°C until next step 6 
of the “Immunoprecipitation (IP) and reverse cross-linking” chapter. 
Antibody coupling with magnetic beads (prepare during sonication) 
1. Wash 75 µl magnetic protein G beads per IP twice with 300 µl binding/blocking buffer 
using a magnetic device. 
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2. Resuspend the magnetic beads in 100 µl binding/blocking buffer per IP and add the 
desired antibody (10 µg for TF and 3 µg for histone modifications). 
3. Add 300 µl of binding/blocking buffer und mix by flicking. 
4. Collect beads using a magnetic device and discard supernatant. 
5. Wash twice with 300 µl of binding/blocking buffer and proceed immediately with the 
next step. 
Immunoprecipitation (IP) and reverse cross-linking 
1. Combine sonicated material for one IP with specific antibodies coupled to beads and 
tumble the tubes over night at 4°C. 
2. Collect beads on a magnetic device and discard supernatant. 
3. Transfer magnetic beads in 180 µl ice cold RIPA buffer to a 96-well plate. 
4. Wash beads five times with 200 µl ice cold RIPA, twice with 200 µl RIPA-500, twice with 
200 µl LiCl and finally with 200 µl TE-buffer (no aspirator for TE-buffer). 
5. Discard the supernatant and let the beads as dry as possible. 
6. Include 8 µl of input sample from step 5 of the cell lysis and sonication part. 
7. Add 50 µl direct elution buffer to each sample and 42 µl to each input control. 
8. Add per sample a mix of 3 µl direct elution buffer and 1 µl RNase A (10 mg/mL, DNase 
and protease-free) and incubate mix for 30 min at 37°C. 
9. Add per sample a mix of 2.5 µl Proteinase K (10 mg/ml), 1 µl glycogen (10901393001, 
Roche) and 1.5 µl direct elution buffer and incubate 1 h at 37°C. 
DNA purification of ChIP DNA 
1. Add 135 µl of SPRI beads to the sample and elute in 44 µl 10 mM Tris-HCL (pH 8.0). 
End repair of ChIP DNA (NEBNext) 
1. Add 5 µl of end repair reaction buffer and 2.5 µl end repair enzyme mix. 
2. Incubate reaction plate for 30 min at 20°C. 
3. Add 90 µl of SPRI beads to the sample and elute in 44 µl 10 mM Tris-HCL (pH 8.0) 
A-tailing of end repaired DNA 
1. Add 5 µl of A-tailing reaction buffer and 3 µl Klenow Fragment. 
2. Incubate reaction plate for 30 min at 37°C. 
3. Add 90 µl of SPRI beads to the sample and elute in 21 µl 10 mM Tris-HCL (pH 8.0). 
Adaptor ligation of A-Tailed DNA 
1. Add 6 µl of Quick ligation reaction buffer, 1 µl of diluted Adaptor (1.5 µM) and 5 µl of 
Quick T4 DNA Ligase. 
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2. Incubate reaction plate for 15 min at 20°C. 
3. Add 54 µl of SPRI beads to the sample and elute in 25 µl 10 mM Tris-HCL (pH 8.0). 
PCR enrichment of adaptor ligated DNA and small size selection 
1. Add 25 µl of High-Fidelity PCR Master Mix, 1 µl Universal PCR Primer (25 µM) and 2.5 µl 
individual Index primer (25 µm) to each sample. 
2. Incubate reaction plate: 
2.1. 98°C– 0:30 min,  
2.2. 98°C– 0:10 min  
2.3. 65°C – 0:30 min  
2.4. 72°C – 0:30 min (repeat step 2.2. – 2.4. for 10 cycles), 
2.5. 72°C – 5:00 min  
2.6. 4°C forever 
3. Add 37 µl of SPRI beads to the sample and elute in 25 µl 10mM Tris-HCL (pH 8.0) 
QC of fragment size distribution and concentration using a Bioanalyzer and Qubit assay  
1. Determine the mean peak size and fragment size distribution (e.g. primer dimer). Pool size 
cutoff as needed. 
 
Figure 75: Fragment distribution of ChIP-seq library. 
Fragment distribution of ChIP-seq library using a chip of the Bioanalyser Agilent High Sensitivity 
DNA Kit. 
2. Measure the PCR-enriched DNA concentration using the Qubit dsDNA HS kit. 
3. Pool equimolar amounts of each sample and sequence multiplexed libraries (50 bases 
single-end) on the Illumina sequencing platform (German Cancer Research Center Core 
facility). 
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5.2 Tumor ChIP-seq step-by-step protocol 
Hereinafter, only the different parts to the previous ChIP-seq protocol like cutting, fixation and 
sonication of the tumor material are described. All downstream procedure has to be performed 
according to the “ChIP-seq step-by-step protocol (5.1)”. 
Preparation of tumor material and formaldehyde fixation 
1. Add 500 µl of 1% formaldehyde in PBS solution with proteinase inhibitor. Vortex 5 sec and 
incubate 10 min at RT. 
2. Add 57 µl of 1.25 M fresh glycine solution and incubate 5 minutes. 
3. Centrifuge 10 min at 2000 rpm and 4°C and remove supernatant. 
4. Add 500 µl ice-cold PBS with proteinase inhibitor and mix. 
5. Centrifuge 10 min at 2000 rpm and 4°C and remove supernatant except for 10 µl. Store at  
-80°C.  
Cell lysis and sonication 
1. Resuspend pellet with 120 µl lysis buffer and use a homogenizer until solution is cloudy. 
Subsequently incubate on ice for 5 min. 
2. For sonication with a Bioruptor Pico cool down the system to 4°C. Use 5 cycles of each 30 
sec ON and 30 sec OFF intervals. 
3. Centrifuge 10 min at 11200 rpm and 4°C and transfer supernatant into Bioruptor Pico 
1.5 ml microtubes with caps. 
4. Add 30 µl lysis buffer to the pellet and mix. Subsequently, centrifuge 10 min at 11200 
rpm and 4°C and transfer supernatant into the same Bioruptor Pico 1.5 ml microtubes 
with caps from step 3. 
5. Add 150 µl RIPA (without SDS) and use Bioruptor Pico for 40 cycles of each 30 sec ON 
and 30 sec OFF intervals. 
6. Add 220 µl RIPA I (without SDS), centrifuge 10 min at 11200 rpm and 4°C and transfer 
500µl of supernatant into a new tube. 
7. Add 220 µl RIPA I (without SDS) to the pellet, mix and centrifuge 10 min at 11200 rpm 
and 4°C. 
8. Transfer 400 µl of the supernatant with the supernatant from step 6. 
9. Store 50 µl of the supernatant for the input at -20°C. 
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5.3 ChIPmentation step-by-step protocol 
Hereinafter, only the different parts to the previous ChIP-seq protocol like reduced sonication 
time and the whole library preparation of cells or tumor material are described. All downstream 
procedure has to be performed according to the “ChIP-seq step-by-step protocol” (5.1). 
Sonication 
1. Resuspend pellet with 900 µl RIPA I lysis buffer and incubate on ice for 30 min. 
2. Aliquot 300 µl into Bioruptor Pico 1.5 ml microtubes with caps. 
3. For sonication with a Bioruptor Pico cool down the system to 4°C. Use 20 cycles of each 
30 sec ON and 30 sec OFF intervals. 
4. After sonication, spin for 15 min at 13300rpm and 4°C and pool the samples arising from 
one experiment into a new tube. 
5. Take a 15 µl aliquot of the samples as the input control and store it at 4°C until step 6 of 
the “Immunoprecipitation (IP) and reverse cross-linking” chapter in (5.1). 
Immunoprecipitation (IP) and tagmentation reaction 
1. Combine sonicated material for one IP with specific antibodies coupled to beads and 
tumble the tubes over night at 4°C. 
2. Collect beads on a magnetic device and discard supernatant. 
3. Transfer magnetic beads in 180 µl ice cold RIPA buffer to a 96-well plate. 
4. Wash beads five times with 200 µl ice cold RIPA, twice with 200 µl RIPA-500, twice with 
200 µl LiCl buffer. 
5. Wash beads twice with 10 nM Tris-Cl pH 8.0 and transfer the beads-Tris-HCl solution 
during the second wash into a new tube. 
6. Collect beads on a magnetic device. 
7. Resuspend beads in 25 µl of 1x Tagment DNA buffer (Illumina, Nextera DNA Library 
Prep Kit) and add 1 µl Tagment DNA Enzyme. Mix and incubate for 1 min at 37°C. 
8. Collect beads on an ice-cold magnetic device and discard supernatant. 
9. Wash beads twice with 200 µl ice cold RIPA- and twice with 200 µl TE-buffer and 
transfer the beads-TE-solution during the second wash into a new tube. 
10. Discard the supernatant and let the beads as dry as possible. 
11. Include 8 µl of input sample from step 5 of the cell lysis and sonication part. 
12. Add 50 µl direct elution buffer to each sample and 42 µl to each input control. 
13. Add per sample a mix of 3 µl direct elution buffer and 1 µl RNase A (10 mg/mL, DNase 
and protease-free) and incubate mix for 30 min at 37°C. 
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14. Add per sample a mix of 2.5 µl Proteinase K (10mg/ml), 1 µl glycogen (10901393001, 
Roche) and 1.5 µl direct elution buffer and incubate 1 h at 37°C. 
DNA purification of ChIP and input DNA 
1. Add 135 µl of SPRI beads to the CHIP and input DNA sample and elute in 25 µl 10 mM 
Tris-HCL (pH 8.0) 
Input sample preparation 
1. Concentration of purified input DNA was measured and diluted in 10 nM Tris-HCl to 2.5 
ng/µl. 
2. Add 0.5 µl of 1:10-diluted Tagment DNA enzyme and 2.5 µl 2x Tagment DNA buffer. 
3. Mix and incubate for 5 min at 55°C. 
4. Clean up the reaction mix by using the Qiagen MinElute kit according to manufacturers’ 
protocol and elute in 25 µl Tris-HCl. 
PCR Enrichment of ChIP and input DNA and small size selection 
1. The 25 µl ChIP- and input samples were PCR amplified using 25 µl Illumina or KAPA 
Biosystems PCR Master Mix, 5 µl of Illumina or KAPA Biosystems PCR Primer Cocktail and 
each 5 µl of compatible Illumina index primer i7 and i5. 
2. Incubate reaction plate: 
1. 72°C– 3:00 min,  
2. 98°C– 0:30 min  
3. 98°C– 0:10 min  
4. 63°C – 0:30 min  
5. 72°C – 0:30 min (repeat step 2. – 5. for 12 cycles), 
6. 72°C – 3:00 min  
7. 4°C forever 
4. Add 91 µl of SPRI beads to the sample and elute in 25 µl 10 mM Tris-HCL (pH 8.0). 
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5.4 4C-seq step-by-step protocol 
Protocol for cell culture material and approximately 107 loose cells. 
Harvesting cells 
1. Remove media completely and wash cells briefly with 5 ml versene. 
2. Add 3 ml trypsin (0.25 mg/ml; Lonza) per plate and incubate 5 min at 37°C. 
3. Detach cells gently and inactivate trypsin by adding 9 ml media with 10% FCS. 
4. Collect cell solution in 50 ml falcon. 
5. Count cells (10 µl trypan blue (TB) + 10 µl cells) Luna - automated cell counter) and 
prepare aliquots of 107 cells in 50 ml reaction tubes. 
6. Centrifuge 5 min at 1100 rpm and RT in swing out centrifuge. 
7. Discard supernatant by pouring and resuspend pellet in 5 ml PBS with 10% FCS. 
Formaldehyde fixation  
1. Add 5 ml 4% formaldehyde to the cell suspension in PBS with 10% FCS. 
2. Incubate 10 min at RT while tumbling. 
3. Add 1.425 ml 1M glycine, mix and put tubes immediately on ice. 
4. Continue immediately and centrifuge 8 min at 1300 rpm and RT and remove 
supernatant. 
Cell lysis 
1. Resuspend pellet in 1 ml freshly prepared 4C lysis buffer and incubate 5 min at RT, then 
5 min in 65°C waterbath and transfer on ice. 
2. Perform verification of successful cell lysis by mixing 2 µl TB with 3 µl cells and 
microscopic evaluation. 
- In the case of insufficient cell lysis repeat step lysis at 65°C or try to homogenize cells 
mechanically. 
3. Centrifuge 8 min at 1800 rpm and RT and remove supernatant. 
4. Resuspend pellets in 1 ml PBS and transfer to 1.5 ml tube. 
5. Centrifuge 2 min at 2400 rpm and 4°C and remove supernatant. 
- Pellets could be snap frozen in liquid nitrogen and stored at -80°C. 
First digestion (Restriction enzyme (RE) DpnII; NEB) 
1. Resuspend cell pellet in 440 µl and 60 µl 10x RE-buffer. 
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2. Add 15 µl 10% SDS and incubate at 37°C for 1 h while shaking at 900 rpm. 
3. Add 75 µl 20% Triton X-100 and incubate at 37°C for 1 h while shaking at 900 rpm. 
4. Take a 5 µl aliquot of the sample as the “undigested control”. 
5. Add 200 U RE DpnII, incubate 4 h at 37°C while shaking at 900 rpm. 
6. Add 200 U RE DpnII, incubate o/n at 37°C while shaking at 900 rpm. 
7. Add 200 U RE DpnII, incubate 4 h at 37°C while shaking at 900 rpm. 
8. Take 5 µl aliquot of the sample as the “digested control”. 
9. Verification of digestion efficiency: 
Add 2.5 µl Prot K (20 mg/ml) and incubate for 1 h at 65°C. Compare 20 µl of digested and 
undigested control sample on a 0.6% agarose gel. 
- In case of insufficient digestion efficiency repeat step 5-7. 
First ligation 
1. Inactivate enzyme (DpnII) by incubating 20 min at 65°C. 
2. For diluted ligation, transfer each sample to a 50 ml reaction tube. 
3. Add 700 µl 10X 4C ligation buffer and H2O up to 7 ml. 
4. Add 10 µl T4 Ligase (Roche 5U/µl) and incubate o/n at 16°C. 
5. Take a 100 µl aliquot of the sample as the “ligated control”. 
6. Verification of ligation efficiency: 
Add 2.5µl Prot K (20 mg/ml) and incubate for 1 h at 65°C. Compare 20 µl of digested and 
undigested control sample on a 0.6% agarose gel. 
- In case of insufficient ligation efficiency repeat step 5-7 and add fresh ATP to ligation 
buffer. 
Reverse crosslinking and precipitation 
1. In case of sufficient ligation efficiency add Prot K (20 mg/ml) to the samples and de-
crosslink o/n at 65°C (waterbath). 
2. Add 30 µl RNAse A (10 mg/ml) and incubate 45 min at 37°C. 
3. Add 7 ml phenol-chloroform, mix vigorously. 
4. Centrifuge at 3750 rpm for 15 min at RT and transfer water phase carefully to a new 50 
ml reaction tube. 
5. Add 7 ml H2O, 7 µl Glycogen, 1.5 ml 2M NaAC (pH 5.6) and 35 ml 100% ethanol. 
6. Mix and place at –80°C until the sample is completely frozen (o/n). 
7. Centrifuge at 4500 rpm for 45 min at 4°C and remove the supernatant. 
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8. Add 10 ml ice cold 70% ethanol and centrifuge 15 min at 4500 rpm and 4°C. 
9. Remove the supernatant and briefly dry the pellet at RT. 
10. Resuspend and dissolve the pellet in 150 µl pre-warmed Tris (10 mM, pH 7.5, 37°C). 
11. Samples can be stored at this point at -20 °C. 
Second digestion (RE Csp6I (NEB) /BfaI (Thermo Fisher Scientific) 
1. To 150 µl 4C sample add 50 µl 10X RE buffer, 50 U RE Csp6I or BfaI, fill up with water to 
500 µl and incubate o/n at 37°C. 
2. Take a 5 µl aliquot of the sample as the “second digested control”.  
3. Verification of digestion efficiency: 
Add 95 µl 10 mM Tris pH 7.5 to the 5 µl sample second digested control. Compare 20 µl 
of “undigested” and “second digested” control sample on a 0.6% agarose gel. 
In case of insufficient digestion efficiency repeat step 1-3. 
Second ligation 
1. Inactivate enzyme (DpnII) by incubating 20 min at 65°C. 
2. For diluted ligation, transfer each sample to a 50 ml reaction tube. 
3. Add 1.4 ml 10X 4C ligation buffer and H2O up to 14 ml. 
4. Add 20 µl T4 Ligase (Roche 5 U/µl) and incubate o/n at 16°C. 
Precipitation 
1. Add 1.4 ml 2M NaAC (pH 5.6), 14 µl glycogen and 35 ml 100% ethanol. 
2. Mix and place at –80°C until the sample is completely frozen (o/n). 
3. Centrifuge at 3750 rpm for 45 min at 4°C and remove the supernatant. 
4. Remove supernatant and add 15 ml cold 70% ethanol. 
5. Centrifuge at 3750 rpm for 15 min at 20°C, remove the supernatant and briefly dry the 
pellet at RT. 
6. Resuspend and dissolve the pellet in 150 µl pre-warmed Tris (10 mM, pH 7.5, 37°C). 
Purification of 4C samples 
1. Use 3 columns of the QIAquick PCR purification kit per 4C sample according to the 
manufacturer’s protocol. 
2. Elute columns in total 50 µl of 10 mM Tris (pH 7.5) and measure the concentration. 
3. Samples can be stored at this point at -20°C. 
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Primer design and preliminary amplification 
1. Forward and reverse primer for each viewpoint were designed according to the 
published protocol (van de Werken et al. 2012). 
2. A preliminary PCR was performed for each sample to assess the quality of primers and 
the best amount of 4C material for the final preparative amplification step.  
Preparative amplification 
1. For preparative PCR the Expand Long Template PCR System (Roche) was used. 
2. A master mix sufficient for 16 PCR reactions with a volume of 50 µl each was prepared. 
for each viewpoint and sample. 
Prepare and mix (single reaction): 
5 µl 10X PCR buffer 1.1 µl dNTPs (10 mM), 1.5 µl forward primer (1 µg/µl), 1 µl reverse 
primer (1 µg/µl), 0.7 µl Polymerase ELT and 50 – 200 ng 4C-PCR template. 
3. Run the following PCR program: 
1. 94°C– 2:00 min,  
2. 94°C– 00:15 min  
3. 55°C– 1:00 min 
4. 68°C – 3:00 min (repeat step 2. – 4. for 35 cycles), 
5. 68°C – 7:00 min 
6. 4°C forever 
Purification of PCR products 
1. Pooling of all samples per 4C-PCR and purification to get rid of primer dimer by using 2 
columns of the high pure PCR template preparation kit (Roche) according to the 
manufacturer’s protocol. 
2. Elute each column in 50 µl of 10 mM Tris (pH 7.5) - of each 4C-PCR.  
3. As a last purification step, use 2 columns of the QIAquick PCR purification kit (Qiagen) 
per 4C sample according to the manufacturer’s protocol. 
4. Elute each column in 50 µl of 10 mM Tris (pH 7.5) and measure the concentration using 
a Nanodrop ND-1000. 
5. Check fragment size of each 4C-PCR sample on a 1% agarose gel. 
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Sample preparation of sequencing 
1. Prepare a 1:3 (sample 4-6) and 1:6 (sample 7-9) dilution of the pooled 4C libraries and 
measure fragment distribution by loading triplicates on a chip of the Bioanalyser Agilent 
DNA 12000 Kit according to the manufacturer’s protocol. 
2. Determine the mean peak size and the overall molarity of the pooled 4C libraries and 
adjust to a final concentration of 10 nM for submission. 
 
Figure 76: Fragment distribution of 4C-seq library. 
Fragment distribution using a chip of the Bioanalyser Agilent DNA 12000 Kit of undiluted 
(sample 1-3), 1:3 (sample 4-6) and 1:6 (sample 7-9) diluted pooled 4C libraries. 
 
3. Libraries were sequenced (50 bases single-end) on the Illumina sequencing platform 
(German Cancer Research Center Core facility). 
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5.5 Further figures and tables 
 
Figure 77: Summary of rearrangements in NB cell lines (hg19) including genomic position and 
assigned gene of acceptor and donor region. 
cell line Acceptor region Genomic position Donor region Genomic position associated gene
GI-ME-N TERT / Chr. 19 / /
LAN2 TERT / Chr. X / /
KELLY TERT / Chr. 2 / ALK
CLB-GA TERT / Chr. 20 / /
NBL-S MYCN chr2:16,023,867 Chr. 4 chr4:174,964,065 HAND2
NB69 MYC chr8:128,803,002 Chr. 4 chr4:174,487,645 HAND2
SK-N-AS MYC chr8:129,902,921 Chr. 4 chr4:174,820,996 HAND2
SH-SY-5Y MYC chr8:129,065,737 Chr. 7 chr7:134,080,765 EXOC4
CHLA15/20 MYC chr8:128,855,087 Chr. 4 chr4:174,661,821 HAND2
CLB-GA IGF2BP1 chr17:47,031,746 Chr. 4 chr4:175,024,980 HAND2
Enjancer hijacking events in NB cell lines
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